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 i 
Abstract 
Congenital heart disease (CHD) is the most common congenital malformation, affecting 8 
out of 1000 lives births, yet its aetiology remains largely unresolved. The rapidly growing 
number of point mutations implicated in isolated CHD suggests that single mutations may 
contribute significantly to CHD risk. This thesis presents an investigation of the genetic 
underpinnings of various types of CHD following different study designs. 
First, I designed a new approach to variant calling which I implemented as the variant 
caller BAMily. My aim was to develop a method of uncovering putative variants in next-
generation sequencing data, shared by a subset of individuals and absent in another 
subset. I tested the variant caller’s performance against other known variant callers and 
demonstrated that it provides comparable; and often better, results. This novel variant 
caller was applied to a study of 8 families in which a disease trait was segregating; along 
with the variant caller SAMtools, leading to the discovery of likely disease-causing 
variants in 5 families. 
Second, I studied de novo mutation in 32 sporadic cases of transposition of the great 
arteries (TGA) in an attempt to identify genes that, when mutated, lead to TGA. The 32 
patients with TGA were sequenced with their parents; as well as one unaffected sibling. 
To achieve this aim, three variant callers were used: SAMtools, GATK Unified 
Genotyper and BAMily, the latter acting as a filter. Potential de novo variants were found 
in GREB1, RBP5, SNX13. Results suggested a complex genetic etiology underlying TGA. 
Finally, I studied a large series of cases of tetralogy of Fallot (ToF). The study involved 
824 patients which ToF and a comparator set of 490 patients with neurodevelopmental 
disorders lifted from the UK10K project. The aim of the study was to identify genes that, 
when mutated, play a role in the manifestation of ToF might cluster. For this, I first 
categorised variants according to their potential to disrupt protein function. I then 
compared genes in which potentially disease-causing rare variants occurred to lists of 
genes previously implicated in CHD in the literature. Following this, I identified the 
clustering of potentially deleterious rare variants across the coding region of genes and 
exons in ToF patients, hypothesising that variants influencing ToF would cluster in ToF 
patients. This study led to the discovery of candidate variants in FLT4 and NOTCH1 for 
non-syndromic ToF. As with TGA, the results I have obtained suggested a complex 
etiology for ToF. 
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Chapter 1. Introduction
 2 
 
1.1. Summary 
This thesis presents multiple whole-exome sequencing and capture (WES) studies 
performed on patients with congenital heart disease (CHD). It also describes a new 
approach to variant calling, a key step of sequence analysis. This introductory chapter 
provides an overview of CHD and its causes, paying particular attention to the 
contribution of genetic factors, including results of previous WES studies. This chapter 
also describes the steps involved in a sequencing study, with a particular emphasis on 
WES studies. The last section provides an overview of different sequencing study designs. 
1.2.  Congenital Heart Disease Overview 
1.2.1. Definition and incidence 
Congenital heart disease (CHD) in its broadest sense refers to heart malformations arising 
during cardiogenesis (Bruneau and Srivastava, 2014). Disruption of regulatory 
mechanisms acting on specific cell lineages in the maturing heart can lead to structural 
deviations from the heart’s typical morphology, resulting in varying degrees of morbidity 
at birth and later in life (Bruneau, 2008).  
A recurring figure given for the incidence of CHD is 8 per 1000 live births (Bernier et al., 
2010). As such, CHD accounts for close to a third of all major congenital defects (van der 
Linde et al., 2011). However, this figure is based on the aggregation of the results from 
epidemiological studies using different criteria as to what constitutes CHD. One early 
study of CHD by Mitchell et al. (1971) set the requirement that a heart defect should be 
“actually or potentially of functional significance” to be considered a CHD. This 
definition excludes defects largely considered benign such as persistent left superior vena 
cava (Hoffman and Kaplan, 2002). One notable heart defect that is consequently largely 
excluded from most epidemiological studies is bicuspid aortic valve (BAV) as clinical 
symptoms typically do not manifest before 40 years of age (Hoffman and Kaplan, 2002). 
Factoring BAV in the incidence of CHD would put the total CHD incidence at 21 per 
1000 live births (Hoffman and Kaplan, 2002). Other limiting factors in estimating CHD 
are regional variations in incidence and the effectiveness of diagnosis (Bernier et al., 
2010). 
CHD can take on many distinct forms. The 8 most common forms of CHD among modest 
to severe cases are shown in Figure 1 with their reported birth prevalence by continent. 
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They are as follows: ventricular septal defect (VSD), atrial septal defect (ASD), tetralogy 
of Fallot (ToF), pulmonary stenosis (PS), aortic stenosis (AoS), patent ductus arteriosus 
(PDA), coarctation of the aorta (CoA) and transposition of the great arteries (TGA) (van 
der Linde et al., 2011). 
 
Figure 1. Birth prevalence of the 8 most common subtypes of modest to severe forms of CHD as measured on 
different continents. This bar chart is from van der Linde (2011) and is based on their meta-analysis of 
worldwide birth prevalence of CHD. Above each CHD subtype, the average prevalence is given. *Prevalence 
rate significantly higher than in Europe and North America. †Prevalence rate significantly lower than in Europe. 
‡ Prevalence rate significantly lower than in Europe, North America and Oceania. § No data available. 
Among CHD subtypes, VSD is the most common form of CHD. As an isolated cardiac 
defect, VSD accounts for nearly 40% of all diagnosed CHD (Penny and Vick, 2011). 
VSD also appears in complex forms of CHD, either as an integral part of a more complex 
condition; such as ToF, or as a secondary consequence; as in TGA. A VSD is a defect in 
the wall separating the heart’s ventricles (Kung and Wong, 2014). The main outcome of 
VSD is the redirection of some of the heart’s blood flow from one chamber directly into 
another (Penny and Vick, 2011). This bypassing of the circulatory system is referred to as 
‘shunting’ and can occur in either or both directions, with varying levels of intensity, 
depending on the size and location of the defect. In some cases, the direction in which 
shunting occurs changes over time. Patients described as having Eisenmenger syndrome 
originally experience left-to-right shunting which, left untreated, turns into right-to-left 
shunting in young adult life owing to the development of pulmonary hypertension (Gamss 
and Haramati, 2014). In general, right-to-left shunting reduces blood flow to the lungs, 
thus limiting blood oxygenation (Penny and Vick, 2011). The mixing of deoxygenated 
blood with oxygenated blood manifests in patients as cyanosis, a bluish coloration of the 
skin (Bruneau, 2008). VSDs can also subsequently cause aortic valve prolapse or 
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pulmonary valve obstruction (Penny and Vick, 2011). Most VSDs detected at birth are 
asymptomatic muscular defects that close within the first year of life (Penny and Vick, 
2011). VSDs presenting a risk for a patient’s health can be closed through surgery or the 
implantation of a catheter device (Kung and Wong, 2014). 
 
Figure 2. There are different types of ventricular septal defect (VSD) including conoventricular (1), 
perimembranous (2), inlet (3) and Muscular (4) VSD. The arrows represent the redirection of blood flow; also 
known as shunting. Abbreviations: RA: right atrium, RV: right ventricle, LA: left atrium, LV: left ventricle, 
SVC: superior vena cava, IVC: inferior vena cava, MPA: main pulmonary artery, Ao: aorta, TV: tricuspid valve, 
MV: mitral valve, PV: pulmonary valve, AoV: aortic valve. Image from the Centers for Disease Control and 
Prevention, National Center on Birth Defects and Developmental Disabilities available at:  
http://www.cdc.gov/ncbddd/heartdefects/ventricularseptaldefect.html  
Defects in the septum may also arise at the level of the atria. ASDs are the second most 
common form of CHD totalling nearly 13% of all CHDs (Kendall et al., 2014). ASD are 
further classified according to the atrial structure affected: the septum primum or the 
septum secundum (Kendall et al., 2014). Septal defects in this latter structure, termed 
ostium secundum, are the most common, representing 80% of all ASDs (Kendall et al., 
2014). As with VSD, shunting occurs and its intensity is dependent on the location and 
size of the defect. Most ASDs requiring intervention are closed through the use of a 
catheter device with only extreme cases requiring surgery (Kendall et al., 2014). An 
illustration of ASD is shown in Figure 3. 
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Figure 3. Atrial septal defect (ASD). The arrow crossing the septal defect represents the redirection of 
oxygenated blood flow from the left atrium to the right atrium. Abbreviations: RA: right atrium, RV: right 
ventricle, LA: left atrium, LV: left ventricle, SVC: superior vena cava, IVC: inferior vena cava, MPA: main 
pulmonary artery, Ao : aorta, TV: tricuspid valve, MV: mitral valve. Image from the Centers for Disease 
Control and Prevention, National Center on Birth Defects and Developmental Disabilities available at: 
http://www.cdc.gov/ncbddd/heartdefects/atrialseptaldefect.html  
Another common type of cardiac abnormality involves the narrowing of structures of the 
heart, impeding blood flow. The three most common subtypes of CHD that fit this 
description are CoA, AoS and PS. According to Lee et al. (2014a), CoA is estimated to 
amount to 7% of all CHD cases, with a slight bias towards male cases. Individuals with 
CoA are likely to be diagnosed with other cardiac defects, particularly BAV (Lee et al., 
2014a). CoA describes the constriction of the stretch of aortic arch found between the left 
subclavian artery and the ductus arteriosus in the developing heart. Different levels of 
coarctation exist. Lee et al. (2014a) liken severe cases of CoA to cases of interrupted 
aortic arch as blood circulation through the aorta is blocked. On the other hand, some 
cases are asymptomatic. The latter are left mostly untreated (Lee et al., 2014a). Both 
surgery and transcatheter balloon angioplasty have been extensively used to repair CoA 
with extremely low levels of morbidity and mortality in either case (Vergales et al., 2013; 
Lee et al., 2014a). Despite this, neither technique is fully restorative and patients are at 
risk of recoarctation, developing aneurysm or hypertension (Vergales et al., 2013). As a 
result, lifelong follow-ups are necessary (Vergales et al., 2013). 
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Figure 4. Coarctation of the aorta (CoA). The arrows show the direction of regular blood flow. Blood flow is 
impeded towards the descending aorta. Abbreviations: RA: right atrium, RV: right ventricle, LA: left atrium, 
LV: left ventricle, SVC: superior vena cava, IVC: inferior vena cava, MPA: main pulmonary artery, Ao: aorta, 
TV: tricuspid valve, MV: mitral valve, PV: pulmonary valve, AoV: aortic valve. Image from the Centers for 
Disease Control and Prevention, National Center on Birth Defects and Developmental Disabilities available at: 
http://www.cdc.gov/ncbddd/heartdefects/coarctationofaorta.html 
AoS accounts for about 4% of all CHD cases (Hochstrasser et al., 2014). AoS takes on 
the form of a narrowing of the aortic valve, called stenosis, which hinders blood flow 
from the left ventricle to the aorta (Alizadehasl and Sadeghpour, 2014). The stenosis is 
the result of the joining; termed commissural fusion, of normally distinct heart valve 
leaflets. The aortic valve is thus described in many cases as uniscupid; in predominantly 
severe cases, or bicuspid, although in some cases remains tricuspid (Alizadehasl and 
Sadeghpour, 2014). The additional resistance created by the stenosis puts a strain on the 
muscles of the heart’s left chamber, leading to the development of an excessive, and 
eventually less efficient, left ventricle muscle mass. Balloon aortic valvuloplasty is 
performed on infants with the condition in order to widen the aortic valve with more 
invasive surgery taking place later in life (Ewert et al., 2011; Alizadehasl and Sadeghpour, 
2014). Long term treatment, particularly if stenosis reoccurs, includes aortic valve 
replacement either by inserting a mechanical aortic valve or grafting a donor’s aortic or 
pulmonary valve (Alizadehasl and Sadeghpour, 2014). 
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Figure 5. Aortic stenosis (Aos). The arrows represent blood flow. In AoS, the blood flow to the aorta is limited by 
the partial fusion of valve leaflets. AoS can lead ventricular hypertrophy as shown above. Abbreviations: RA: 
right atrium, RV: right ventricle, LA: left atrium, LV: left ventricle, Ao: aorta, PA: pulmonary artery. Image is 
from The Royal Childent's Hospital Melbourne and is available at: 
http://www.rch.org.au/cardiology/heart_defects/Aortic_Stenosis_AS/ 
PS occurs in 7-12% of patients with CHD (Warnes et al., 2008). PS is an obstructions 
similar to AoS, but located instead on the pulmonary valve (Sadeghpour and Alizadehasl, 
2014). In this instance, the stenosis limits blood outflow towards the lungs. As with AoS, 
PS is the result of varying levels of commissural fusion (Sadeghpour and Alizadehasl, 
2014). Depending on the severity of the PS, the right ventricle can display varying levels 
of hypertrophy and occasionally mild hypoplasia (Sadeghpour and Alizadehasl, 2014). 
 During foetal development, the aorta and the pulmonary artery are connected by the 
ductus arteriosus. This bridge usually disappears within two days of birth (Schneider and 
Moore, 2006). The ductus arteriosus is considered patent when the structure persists long 
after birth. For Schneider and Moore (2006), the structure can be considered patent if it 
persists beyond the first weeks after birth. However, Schneider and Moore (2006) 
acknowledge that other experts place the threshold for abnormality at 3 months. 
Excluding silent PDAs that are unintentionally discovered during echocardiography, PDA 
represents between 5 to 10% of all CHD cases (Schneider and Moore, 2006). PDAs lead 
to left-to-right shunting, some of the oxygenated blood returning to the pulmonary artery. 
The excess pulmonary blood flow results in an increase of pressure in the pulmonary 
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circulation and may result in difficulties breathing (Schneider and Moore, 2006). If 
shunting is substantial and uncorrected, the rise in pulmonary pressure may achieve levels 
greater than the systemic circulation and become permanent, leading to Eisenmenger 
syndrome (Schneider and Moore, 2006). There is an active debate as to whether PDAs 
should be treated in the early years of life, when the rate of spontaneous ductus arteriosus 
closure is high, and if so, what treatments are preferable (Bose and Laughon, 2007; 
Clyman and Chorne, 2007).  
ToF accounts for around 7-10% of CHD patients and is the most common cyanotic CHD 
(Bailliard and Anderson, 2009). The underlying abnormality in developmental anatomy 
resulting in ToF is typically considered to be an anterocephalad deviation of the outflow 
tract septum, which leads to an aggregation of four heart defects: a large VSD, a 
displacement of the aorta over the VSD, a PS causing the obstruction of the right 
ventricular outflow tract (RVOT), and hypertrophy of the right ventricle (Nelson et al., 
2014). This tetrad of abnormalities can be accompanied by other defects such as a right 
aortic arch or additional VSDs (Bailliard and Anderson, 2009). As such, ToF is one of the 
most complex forms of CHD. Surgery is performed in the first few months of life in order 
to close the VSD and mitigate the effect of the PS using the techniques usually associated 
with both these malformations in their isolated form (Mazur et al., 2013). A more detailed 
description of ToF is presented in chapter 5. 
TGA represents 5% of all CHD and is more prevalent in males (Unolt et al., 2013). It is 
considered one of the most severe forms of CHD, carrying a 95% mortality rate within 
the first year of life if left untreated (Saremi, 2014). Patients with the most common form 
of TGA, dextro-transposition of the great arteries (D-TGA), display a pulmonary artery 
and an aorta that are each connected to the wrong ventricle (Warnes, 2006). Warnes 
(2006) describes this severe malformation as ventriculoarterial discordance. This 
discordance results in a lack of oxygenation of the blood travelling through the body as 
the circulation consists of two parallel circuits. Most cases are accompanied by additional 
cardiac malformations such as VSD, PS and other valvular abnormalies (Warnes, 2006). 
In the absence of a communication between the right and left circulations, the condition is 
lethal; therefore, initial intervention in TGA, in the early hours to days of life, typically 
consists in creating communication between the circulations at atrial level using balloon 
septostomy until a definite repair can be performed (Warnes, 2006). Where a complete 
 9 
 
TGA is observed, an arterial switch operation is necessary (Warnes, 2006). A further 
description of TGA is given in chapter 4. 
1.2.2. Evolution of treatment 
While CHD remains the most prevalent cause of childhood morbidity in the Western 
world to this day, advances in medical and surgical care over the last few decades have 
made it possible for many of those afflicted to live beyond childhood (van der Linde et al., 
2011). Since the year 2000, more adults live with CHD than children (Guleserian, 2011). 
This has shifted some of the mortality from birth to adulthood. 
The first serious attempt to correct a heart defect, was undertaken by John Strieder in 
1937 (Kaemmerer et al., 2004). However, the operation, which consisted in the ligation of 
a PDA, ended in failure, with the patient dying from complications 4 days later. The 
following year brought two successful PDA ligations, independently performed by Robert 
Gross and Emil Karl Frey within months of each other (Kaemmerer et al., 2004). A few 
years later, in 1944, Clarence Crafoord performed the first successful CoA reparation 
(Guleserian, 2011). The same year, Blalock performed what was to be known as the 
Blalock-Taussig shunt operation (Guleserian, 2011). Designed to relieve the lack of blood 
oxygenation that characterises cyanotic heart disease, the operation redirects blood flow 
from the subclavian artery to the pulmonary artery. Many cardiac surgery firsts followed 
suit. 
One important milestone in the treatment of heart defects is the development of the 
cardiopulmonary bypass unit, which allowed for effective open heart surgery (Guleserian, 
2011). Previous surgeries of the same kind relied on hypothermia, presenting great risks 
for patients who did not receive blood to vital organs such as the brain (Guleserian, 2011). 
Cardiopulmonary bypass largely solved this issue. For Kendall et al. (2014), the first 
successful intracardial operation to correct ASD, performed by John Heysham Gibbon in 
1953, marks the birth of modern cardiac surgery. Intracardial repair of multiple cardiac 
pathologies soon followed, with the successful operation of patients with VSD and ToF 
occurring less than a year after the first pioneering ASD surgery (Geva et al., 2014). 
The further development of heart surgery over a period of half a century has dramatically 
reduced CHD-related child mortality. Hoffman et al. (2004) estimate that in the US alone, 
1.5 million patients will have been diagnosed with some form of CHD between 1940 and 
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2002. Conducting a large review of reports on various CHDs they concluded that, without 
surgery, we could expect 650,000 CHD patients to be alive in that time frame against 
more than 1.3 million, assuming equal access to available treatment. The actual number 
of CHD survivors is therefore somewhere in between these two estimates. 
The increasing prevalence of CHD results chiefly from the ever-increasing number of 
patients surviving into adulthood (Hoffman et al., 2004). This positive development 
comes with a caveat, that while heart surgery allows many CHD sufferers to survive 
beyond childhood, the surgery is rarely a fully restorative process. Operations on the heart 
leave behind what Perloff and Warnes (2001) describe as residua of the condition. In a 
patient with supravalvular aortic stenosis, systemic hypertension may persist even after 
surgical repair as some arterial abnormalities remain (Perloff and Warnes, 2001). 
Additionally, some surgical intervention, such as those which involve the grafting of 
cardiac structures, will inevitably inflict sequelae to the heart (Perloff and Warnes, 2001). 
For these reasons, adult survivors display a lower life expectancy when compared to that 
of the average population (Verheugt et al., 2010). It is crucial for adults with CHD to 
receive proper medical advice on potential complications of corrected heart defects 
throughout life. 
The shift in mortality rates caused by CHD from a primarily neonate population to 
adulthood also implies an additional disease burden on future generations where genetic 
variation plays a significant role in the disease (Fesslova et al., 2011). In this context, 
genetic counselling becomes a crucial part of patient care. For prospective parents with a 
history of CHD risk, knowing the recurrence risk of a specific type of CHD in offspring 
allows them to make informed family planning decisions (Deanfield et al., 2003). It also 
allows medical practitioners to better accompany at risk pregnancies (Deanfield et al., 
2003). Beyond recurrence risk, genetic testing, based on the rapidly evolving field of 
CHD genetics research, can provide a more targeted diagnosis for families (Pierpont et al., 
2007). Providing the most complete and up-to-date genetic counselling requires the 
identification of the whole range of genetic factors that contribute to CHD (Zaidi et al., 
2013).  
1.2.3.  Genetic contribution to CHD 
In a seminal paper on the etiology of CHD, James Nora (1968) formulated the hypothesis 
that CHD was largely the result of a multitude of gene-environment interactions. Through 
 11 
 
this hypothesis, Nora suggests that cases of CHD are predominantly isolated events, with 
no single leading environmental or genetic cause (Gelb and Chung, 2014). However, 
successive population studies of CHD lead to a different conclusion, namely that genetic 
factors play a much larger role in CHD than would be expected if CHD were mainly the 
result of combined polygenic inheritance and environmental factors (Gelb and Chung, 
2014). A case-control study of 2,102 infants with CHD in the Baltimore-Washington 
metropolitan area (Ferencz et al., 1989) revealed a higher frequency of extracardiac 
abnormalities in CHD patients compared to healthy controls in the same area. 17.5% of 
infants with CHD had extracardiac abnormalities with an identified genetic cause, 
compared to 0.7% of healthy controls. From the CHD history of first degree relatives of 
1893 cases, Ferencz et al. (1989) identified a significant excess of CHD in mothers and 
full siblings in cases compared with controls, further emphasizing the role inheritance can 
play in CHD. Burn et al. (1998) studied 727 adults with severe CHD, attempting a 
comprehensive nationwide ascertainment of the first cohort of CHD patients in the UK 
that had cardiac surgery in childhood and had at the time of the study started having 
families of their own. This study aimed to provide the recurrence risk in offspring for all 
CHD as well as distinct subtypes. Recurrence risk provides some insight into the fraction 
of a disease that is attributable to inherited risk. For adults with CHD, Burn et al. (1998) 
found a recurrence risk of CHD in offspring of 4.1%. This represents a fivefold higher 
prevalence than the 0.8% consensus estimate in an unselected population. However, this 
risk estimate conceals the strong variability that exists between CHD subtypes. Burn et al. 
(1998) report the disease recurrence risk in offspring of patient with ToF, anomalous 
pulmonary venous connection, abnormal connection and atrioventricular septal defect 
(AVSD) as 3.1%, 3.7%, 5.1% and 7.8% respectively, indicating very substantial genetic 
contributions to risk of these individually rare conditions. It is important to note here that 
“abnormal connection” refers to a category created for the study to include “abnormalities 
of situs, of atrioventricular concordance, and of the architecture of the atrioventricular and 
ventriculoarterial valves” (Burn et al., 1998). None of the offspring of patients with TGA 
had been diagnosed with the disease. Using the disease recurrence risks for different 
categories of relatives, Burn et al. (1998) attributed different models of inheritance to the 
CHD subtypes analysed when possible. The variability of disease recurrence between 
CHD subtypes raises a number of issues. As in many other studies of the recurrence of 
CHD, the study by Burn et al. (1998) relies on relatively small sample sizes (Oyen et al., 
2009). The overall CHD recurrence will be influenced by the subtypes of CHD that are 
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included in the study given the variability that exists between subtypes. It also raises the 
issue of how one might partition CHD into categories so as to provide the best estimate of 
recurrence risk in offspring while including enough data in each category for the resulting 
estimate to be meaningful. The exhaustive Danish Civil Registration System (DCRS) 
allowed Øyen et al. (2009) to avoid many of these problems. The study focused on 
information stored by the DCRS on 18,708 individuals born with CHD between 1977 and 
2005 out of a total of 1,763,591 individuals. From the population data, Øyen et al. (2009) 
were able to calculate recurrence risk ratios for different subtypes of CHD. The 
recurrence risk ratio compares the recurrence risk of a disease trait in relatives of the 
probands with the share of the population diagnosed with the disease. Øyen et al. (2009) 
found strong variations in the recurrence risk ratio among different subtypes of CHD, 
“ranging from 3-fold to 80-fold increases compared with the population prevalence”. This 
once more clearly demonstrates the existence of a strong genetic component to CHD 
while also emphasizing the variability in this component’s importance depending on 
CHD subtype. Reproduced in Table 1 are the recurrence risks for first-degree relatives 
associated with each CHD subtype as they appear in Øyen et al. (2009). 
CHD phenotype in first degree relative Relative risk 95% confidence interval 
Heterotaxia 79.1 32.9–190 
Conotruncal defect 11.7 8.01–17.0 
AVSD 24.3 12.2–48.7 
Anomalous pulmonary venous return N/A N/A 
Left ventricular outflow tract obstruction 12.9 7.48–22.2 
Right ventricular outflow tract obstruction 48.6 27.5–85.6 
Isolated septal defect 3.41 2.69–4.32 
|_ ASD 7.07 4.51–11.1 
|_ VSD 3.41 2.20–5.29 
|_ ASD+VSD 5.57 0.79–39.5 
Isolated PDA 8.74 5.58–13.7 
 |_ At term 4.8 0.68–34.1 
 |_ Preterm 19.5 10.5–36.1 
Unspecified CHD only 5.22 3.40–8.00 
Other specified CHD 12.6 7.68–20.5 
Overall same heart defect phenotype 8.15 6.95–9.55 
Table 1. Relative risk of recurrence of CHD by family CHD history among first degree relatives in Danish cohort. 
Table is reproduced from Øyen et al. (2009). 
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In chapter 4 and 5, I will explore what these studies said about recurrence risk for first-
degree relatives of TGA and ToF patients respectively.  
The knowledge surrounding environmental factors conducive to CHD remains limited. 
As CHD results from developmental events in the early stages of pregnancy, the focus of 
much of the research into environmental factors has been on maternal exposures (Gorini 
et al., 2014). Gorini et al. (2014) note that maternal exposure to a range of chemicals with 
teratogenic properties, particularly in the first trimester of pregnancy, has been implicated 
in the development of CHD in the newborn. Excessive maternal stress or deleterious 
behaviours during pregnancy; such as smoking, can likewise increase the risk of a child 
being born with CHD (Jenkins et al., 2007). Maternal chronic disease can also act as an 
environmental factor promoting CHD, as illustrated by a recent cohort study by Liu et al. 
(2013) carried out on upward of 2 million mother-infant pairs in Canada. The study 
uncovered multiple significant associations between child CHD and maternal chronic 
diseases such as hypertension and systemic connective tissue disorders. Excluding 
maternal CHD, maternal diabetes shows the strongest associations with CHD in infants, 
with reported odds of 4.65 and 4.12 of observing CHD in the offspring of mothers with 
type 1 and type 2 diabetes. Maternal diabetes has been associated with many CHD 
subtypes, including TGA, VSD, AVSD, PDA, hypoplastic left heart syndrome, 
cardiomyopathy and several conotruncal and outflow tract defects (Jenkins et al., 2007). 
Blue et al. (2012) state that these strong environmental factors, along with strong genetic 
factors, account for 20% of CHD cases; the remaining 80% having some unknown 
multifactorial etiology. 
The first CHD for which genetic factors were identified were those occurring as part of a 
syndrome; where the disease is accompanied by several other extracardiac defects 
(Bruneau, 2008). CHD is a common feature of trisomies 13, 18 and 21 as well as other 
chromosomal aneuploidies (Richards and Garg, 2010). CHDs are also identified as part of 
syndromes caused by copy number variants (CNV). For examples, CHDs are observed in 
a majority of cases of 22q11.2 microdeletion syndrome and Williams-Buren syndrome 
(Richards and Garg, 2010). Syndromic cases of CHD have also been found to be the 
result of SNVs in specific genes. This is the case for Holt-Oram syndrome which is 
triggered by mutations in TBX5, or Allagille syndrome which is caused by JAG1; or 
NOTCH2 in some rare cases, both of which involve cardiac defects (Bruneau, 2008). 
Families in which CHD follows a Mendelian pattern of inheritance have also helped 
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uncover genes that, when mutated, can cause isolated CHD. These include genes that play 
a role in early heart development such as NKX2.5 and GATA4 (Bruneau, 2008). However, 
with a majority of isolated CHD cases being sporadic, the specific contribution of genetic 
factors to CHD has been the source of much debate and mirrors to some extent that of 
other complex diseases. Of particular relevance are the developments that have taken 
place around common disease. Over the past few decades, two competing ideas have been 
advanced to explain common complex disease: The common disease, common variant 
(CDCV) and the common disease, rare variant (CDRV) hypotheses (Schork et al., 2009). 
The CDCV hypothesis postulates that complex disease could be explained as the 
combined action of several common variants each with low penetrance (Schork et al., 
2009). In this context, ‘common’ is understood as an allelic population frequency greater 
than 1% (Manolio et al., 2009). The CDRV hypothesis on the other hand predicts the 
existence of many highly penetrant rare variants, a single rare variant being sufficient to 
trigger complex disease (Schork et al., 2009). Under this hypothesis, variants that 
contribute to complex disease are subject to negative selection and are therefore expected 
to be present at low frequency in the human population (Nelson et al., 2012). A gene can 
be associated to a common disease phenotype through various rare variants acting within 
a specific region of the gene (Iyengar and Elston, 2007). While genome-wide association 
studies (GWAS) have identified thousands of common genetic variants that confer some 
of the risk in developing complex diseases, these variants only explain a modest fraction 
of inherited risk (Zuk et al., 2014). This holds true for CHD as well. Looking at 1,995 
CHD cases and 5,159 controls, a GWAS lead by Cordell et al. (2013a) found an 
association between ASD and the locus 4p16. However, this association only accounted 
for 9% of population-attributable risk for ASD specifically. As GWAS are built around 
the assumption that common complex disease follows the CDCV model, the ‘missing 
heritability’ has been used as an argument in favour of the CDRV hypothesis (Manolio et 
al., 2009). The term ‘missing heritability’ here refers to the observation that many GWAS 
of complex disease only appear to explain a fraction of the estimated heritability for a 
given population; where heritability refers to the amount of trait variation that is due to 
genetic variation in a given population (Visscher et al., 2008; Manolio et al., 2009). The 
CDRV hypothesis has also gained traction as a result of population sequencing studies 
and what these revealed about the distribution of rare variants in the human population. 
The sequencing of 1,092 individuals by the 1000 Genomes Project Consortium (2012) 
has brought to light an abundance of rare variants in all human populations, exceeding 
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what would be predicted from population genetic theory (Altshuler et al., 2010). In this 
context, a variant is considered rare if it has a minor allele frequency (MAF) <0.5%. A 
study by Tennessen et al. (2012) of 15,585 protein coding genes in a large sample of 
individuals of European and African ancestry revealed that out of 500,000 identified 
single nucleotide variants (SNVs), 430,000 had a MAF<0.5%. The recent explosion of 
the human population over the last 10,000 years is partly responsible for the current 
population-wide distribution of rare variants (Keinan and Clark, 2012). Based on data 
from the 1000 Genomes Projects, Marth et al. (2011) showed that variants with a MAF<1% 
include a high proportion of functional variants. Comparing synonymous, missense and 
nonsense variants, Marth et al. (2011) found that the distribution of allele frequencies in 
these three functional categories of variants varied significantly across categories. A 
higher proportion of missense variants were found to be rare compared with synonymous 
variants while a higher proportion of nonsense variants were found to be rare compared to 
both synonymous and missense variants. Marth et al. (2011) reported that 78% of 
nonsense variants were found to have a MAF<1%. Variants that are predicted to be 
deleterious based on evolutionary conservation and potential protein structure or dosage 
changes are also overrepresented among rare variants (Marth et al., 2011; Nelson et al., 
2012). Despite the current interest in the CDRV hypothesis, studies built around it have 
had limited success in identifying the underlying rare variants of many common diseases 
(Auer and Lettre, 2015). The study designs used for rare variant association and their 
limits are further explored in chapter 5.   
As population studies such as those of Burn et al. (1998) and Øyen et al. (2009) make 
clear, CHD comprises a range of distinct subtypes governed by different levels of 
inherited risk. Importantly, estimates of the genetic component of any disease are 
influenced by factors such as the early mortality rate; including fetal loss, associated with 
the disease. Mortality rates vary substantially depending on the cardiac defect (Hoffman 
et al., 2004). Severe cardiac defects are associated with high mortality rates early in life. 
For example, untreated ToF carries an 70% mortality rate in the first 10 years of life, 
TGA a 95% death rate in the first year of life (Starr, 2010; Saremi, 2014). Any mutation 
that increases the risk of developing severe CHD would therefore be expected to be 
strongly negatively selected (Cordell et al., 2013b). Disease-causing variants in patients 
with severe CHD would be expected to be extremely rare or private, having arisen from a 
recent mutation event. In patients with no family history of CHD, the manifestation of 
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CHD can be the result of a de novo mutation occurring in a parental germ cell and being 
passed on to the patient. In chapter 4 and 5 I will describe how these observations 
influenced the approach to each CHD studied. 
In a recent paper on the molecular genetics of CHD, Andersen et al. (2014) list a total of 
55 genes associated with CHD identified via linkage analysis, the mapping of CNVs and 
WES. Using linkage analysis, a technique applied to large pedigrees that draws on 
recombination events to identify which of a set of genetic markers is in close proximity to 
a disease locus, Basson et al. (1997) were able to implicate the transcription factor gene 
TBX5 in the development of Holt-Oram syndrome, an inheritable condition that can 
include heart defects such as ASD, VSD and cardiac conduction defects. Linkage analysis 
was also useful in elucidating disease-causing genes in isolated cases of familial CHD 
such as NKX2.5 and GATA4, both also transcription factor genes (Schott et al., 1998; 
Garg et al., 2003). Three mutations in the transcription factor gene, NKX2.5, were 
uncovered by analysing four families with a history of CHD (Schott et al., 1998). A 
single mutation in GATA4 was found to be responsible for the various CHD phenotypes; 
systematically including ASD, established in one family over five generations (Garg et al., 
2003). In addition to transcription factors, the list of CHD associated genes presented by 
Andersen et al. (2014) includes genes involved in the signalling pathways of the heart, the 
cardiac sarcomere and chromatin modifiers. The authors also point to 500 genes that lead 
to cardiac defects in mice when mutated, inferring that there exists a similar number of 
disease genes for CHD in humans. Focusing on severe CHD, Zaidi et al. (2013) 
sequenced 626 parents-offspring trios, including 362 patients; the offspring, with serious 
cardiac defects not seen in parents. The parents-offspring trios were used to identify 
potentially disease-causing de novo variants occurring in human orthologs of genes 
highly expressed during cardiogenesis in mice. Based on the number of nonsynonymous 
de novo variants occurring in these genes in cases and controls, the authors conclude that 
de novo SNVs altogether contribute to approximately 10% of severe CHD, a contribution 
which they estimate rests on a set of 401 disease genes. Zaidi et al. (2013) also found an 
excess of de novo variants in patients with CHD in genes that affect histone methylation, 
potentially around key developmental genes. 
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1.3. Whole-Exome Sequencing (WES) Studies Of Disease 
1.3.1. Sequencing technologies 
The number of sequencing platforms has expanded dramatically in the past decade. In 
2003, when the Human Genome Project (HGP) was completed, Sanger sequencing was 
the standard technique (Collins et al., 2004). This technique was devised by Fred Sanger 
and his team as far back as 1977 (Sanger et al., 1977). However, over the first decade of 
the millennium, a new range of massively-parallel sequencing platforms were developed 
and collectively referred to as next-generation sequencing (NGS) (Metzker, 2010). These 
platforms were developed to address a demand for fast, cheap and accurate high-
throughput sequencing (Metzker, 2010). Many of these NGS technologies achieved this 
through the parallel sequencing by synthesis of distinct DNA fragments (Mardis, 2013). 
With the incorporation of each nucleotide during sequencing by synthesis, a chemical 
reaction emits a signal, indicating which nucleotide was added (Mardis, 2013). For this 
signal to be captured by the sequencing platform however, the DNA fragments must first 
have been amplified. Amplification is achieved through polymerase chain reaction (PCR) 
which creates local clusters of DNA fragments which signal synchronously the addition 
of each new base (Mardis, 2013). Figure 6 provides an example of the sequencing process 
on the Illumina platform. 
The first commercial NGS platform, released in 2005, was the 454 pyrosequencing 
system. When first released, a single run on the 454 pyrosequencing platform was capable 
of delivering up to 25 million base pairs (Mbps) of sequence over four hours (Margulies 
et al., 2005). This provided a net improvement on Sanger methods which, even today, 
reaches no more than 96 kbps per run (Shokralla et al., 2014). Other NGS technologies 
include the Illumina platform, originally released in 2006, and the ABI SOLiD system, 
released in the following year. Each one of these platforms has been refined over the 
years. The latest versions of both these platforms, the Illumina HiSeq and the SOLiDv4, 
possess throughputs upward of a billion base pairs in their last iterations, as shown in 
Table 2 (Buermans and den Dunnen, 2014; Shokralla et al., 2014). The research 
presented in this thesis revolves almost exclusively on sequence data produced via 
Illumina sequencing, one of the more widely used sequencers today. An overview of 
Illumina sequencing is presented in Figure 6. All three platforms rely on a high-definition 
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camera to capture the signals emitted during sequencing by synthesis (Mardis, 2013). The 
Ion-Torrent, another massively-parallel sequencing platform, presents an innovation in 
that respect (Mardis, 2013). The Ion-Torrent captures a direct by-product of nucleotide 
incorporation, the release of a hydrogen ion, using an electric sensor (Mardis, 2013).  
Sequencing 
platform 
ABI 3730xl 
(Sanger) 
454 GS FLX Illumina 
HiSeq2500 
ABI SOLiDv4 
Output (per run) 96 kbps 450-700 Mbps 200 Gbps 300 Gbps 
Reads (per run) 96 0.7-1 million 3 billion 2.7 billion 
Read length (max) 1-1.5 kbps 700  bps 2 x 100 bps 85 bps 
Run type (SE/PE) SE SE SE & PE SE & PE 
Table 2. Current sequence platform specifications for Sanger sequencing and three NGS platforms. Numbers 
are from Shockralla et al. (2014) and Buermans and den Dunnen (2014). Output and read length are given in 
read base pairs. SE. single end reads; PE, paired end reads. 
 
 
Figure 6. An overview of The Illumina sequencing method. Figure is from Mardis (2013). During library 
preparation (a) DNA fragments are flanked with adapter sequences. These adapters complement adapter 
sequences distributed across a flow cell. After hybridisation, the DNA fragments are amplified using bridge PCR 
(b). This generates local clusters of identical DNA fragments which give off a synchronous fluorescent signal 
during sequencing by synthesis (c).  
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Building on the successes of NGS, new technologies have emerged (Schadt et al., 2011) . 
Unlike NGS technologies, these new technologies do not require an amplification step. A 
sequencer such as the Helicos Genetic Analysis platform is capable of detecting the signal 
emitted for a single DNA molecule (Schadt et al., 2011). Some of these technologies 
present an additional innovation: sequencing in real-time (Mardis, 2013). The 
combination of these innovations is epitomised by the Pacific Biosciences’ single 
molecule, real time (SMRT) system (Mardis, 2013). The SMRT system is able to 
complete an entire run within hours where the original NGS technologies take days (van 
Dijk et al., 2014). Another advantage with many of these new technologies is the ability 
to sequence reads orders of magnitude longer than what can be achieved with NGS 
technologies (Koren and Phillippy, 2015). The SMRT system can sequence reads 50 kbps 
(Koren and Phillippy, 2015). A more recent, technological innovation, the Oxford 
nanopore minION, does not have a well-defined upper limit; its maximum read length 
dependent on the length of the DNA strand that passes through it (Karlsson et al., 2015). 
Platforms such as Oxford nanopore platform no longer use sequencing by synthesis, using 
instead a molecular structure called a nanopore capable of detecting nucleotides passing 
through it (Koren and Phillippy, 2015). One important thing to note however is that many 
of these new technologies do not yet provide the read accuracy necessary to investigate 
SNVs and small indels (Koren and Phillippy, 2015). These technologies are nonetheless 
useful for other purposes such as finishing genome assemblies previously hindered by 
short reads (Koren and Phillippy, 2015).  
1.3.2. Exome capture via target-enrichment 
NGS technologies have greatly enhanced the search for variants underlying various 
disease traits. By sequencing twelve unrelated individuals, four of which were affected by 
Freeman-Sheldon syndrome, a rare autosomal dominant disorder, Ng et al., (2009) first 
illustrated the potential of such practice. After filtering variants found in the four 
Freeman-Sheldon syndrome patients against those found in eight HapMap exomes and a 
database of known variants, dbSNP (Sherry et al., 2001), Ng et al., (2009) found that only 
a single gene, MYH3, had corresponding nonsynonymous rare variants in all four patients. 
Dozens of studies have since identified the genetic underpinnings of many disorders, 
including extremely rare conditions such as Kabuki syndrome (Gonzaga-Jauregui et al., 
2012). What many of these studies have in common is that they favour the use of whole-
exome sequencing (WES) over whole-genome sequencing (WGS). Examples of WGS 
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being used to successfully identify disease variants do exist, as illustrated by a study 
conducted by Nishiguchi et al. (2013)  which established not only new disease-causing 
variants, but also a previously unidentified  disease gene for a progressive blindness 
disease, retinitis pigmentosa. Furthermore, WGS has come to play an increasingly larger 
role in clinical practice, a fact exemplified by large-scale initiatives such as England’s 
100,000 genomes project (Siva, 2015) which includes patients with a whole-range of rare 
diseases and cancers and their relatives. However, the costs involved in both sequencing 
and storage have long been prohibitive for that line of research (Rabbani et al., 2014). 
Teer and Mullikin (2010) originally referred to WES as the “sweet spot before [WGS]”. 
WES offers a relatively cheaper alternative to WGS by focusing the sequencing effort on 
exonic regions of the genome (Teer and Mullikin, 2010). In humans, the exome accounts 
for only 1% of the entire genome, but contains all of the genome’s protein-coding 
sequences (Teer and Mullikin, 2010). Protein-coding regions alone are estimated to 
harbour 85% of deleterious mutations in the whole genome (Majewski et al., 2011). 
In order to focus sequencing on exome regions, an exome capture step is required to 
complete sample processing. The library of genomic DNA fragments obtained for 
sequencing is subjected to target enrichment, a process by which specific DNA fragments 
are captured using a custom set of complementary oligonucleotides which correspond to a 
selected fraction of the genome (Mamanova et al., 2010). While various capture methods 
exist, hybrid capture is the most prominent for whole-exome capture. The most 
commonly used exome capture kits; offered by Nimblegen, Agilent and Illumina, use in-
solution hybrid capture (Chilamakuri et al., 2014).  
Hybrid capture for NGS was first developed by Nimblegen with on-array capture. In a 
paper introducing their approach, Hodges et al. (2007) describe the repurposing of DNA 
microarray for exome capture and sequencing. The DNA microarray hybridisation step is 
used to capture exon targets. The next step for a standard DNA microarray experiment 
would consist in scanning the microarray to detect some chemically-induced signal given 
off by labelled targets (Mamanova et al., 2010). However, in exome capture, the targets 
are not labelled and are instead recuperated for sequencing (Mamanova et al., 2010).  
Building on the success of on-array capture while addressing some of its drawbacks, in-
solution capture hybridisation was developed (Mamanova et al., 2010). With in-solution 
capture, probes are eluted from the DNA microarray and amplified through PCR and 
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subsequently biotinylated. The amplification step creates an excess of probes, which in 
turn allows for target-enrichment to take place with less target DNA. The fragments 
hybrised in a solution are then captured by beads that bind biotin (Gnirke et al., 2009). 
Recent hybridisation techniques use in-solution capture. Table 3 lists the principal exome 
capture technologies. 
Exome capture 
technologies 
Agilent SureSelect 
Human All Exon (v.4) 
Roche NimbleGen 
SeqCap EZ Exome (v.3) 
Illumina  
Nextera & Truseq 
Exome Enrichment* 
Targeted bases 51.1 Mb 64.1 Mb 62.08 Mb 
Number of targets  185,636 368,146 201,071 
Overlap with…    
RefSeq 28.2 Mb 29 Mb 31.9 Mb 
CCDS 27.4 Mb 28.02 Mb 31.02 Mb 
ENSEMBL 29.43 Mb 30.15 Mb 32.07 Mb 
Table 3. Target specifications of the four principal exome capture technologies and their overlap with various 
databases reporting exons. Each technology covers different regions of the human exome. Only 26.2 million 
bases (Mb) targeted are shared by all four capture technologies. The data is obtained from Chilamakuri et al. 
(2014).  *Illumina’s Nextera and Truseq Exome Enrichment technologies use the same targets. 
 
1.3.3. Exome-sequencing study tools 
In order to extract useful information from sequence data originating from WES, a 
number of steps are required. The first step of any sequencing analysis is a thorough 
quality control of the data (Altmann et al., 2012). Quality control is followed by the 
alignment of sequence data to one or more reference sequences and the detection of 
potential variants. Depending on the aim of a WES analysis, the variant data can be 
annotated and filtered according to a set of specific criteria. An overview of the WES 
pipeline is provided in Figure 7.  
For the majority of quality control, alignment and variant calling tools, an estimate of 
base quality is essential (Altmann et al., 2012). NGS platforms are equipped with base 
calling software which determines the quality of the data captured by the sequencer 
(Ledergerber and Dessimoz, 2011). The signals emitted during sequencing-by-synthesis 
and recorded by an image-capture device, are transcribed as base calls (Altmann et al., 
2012). Each base call assignment is accompanied with a value indicating the certainty 
with which the base call was made. This value takes into account properties of the signal 
such as intensity or distance from other clusters, as well as sequencing cycle (Altmann et 
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al., 2012). This base call quality is stored as a Phred-like score (Ewing and Green, 1998; 
Ewing et al., 1998; Altmann et al., 2012). The base call quality is the first assessment of 
sequencing quality and is crucial for quality control. A number of recent software 
programs attempt to improve base quality score assignment, either by providing a 
recalibration of the calling (DePristo et al., 2011) or offering a different base calling 
procedure to the one provided with the platform (Massingham and Goldman, 2012). 
Despite the latter developments, the sequencer’s own base quality scoring system remains 
the most widely used (Altmann et al., 2012). 
 
Figure 7. A typical WES workflow. Some variant callers such as SOAPsnp or GATK require a quality score 
recalibration step. 
Some measure of quality control is important at every stage of sequence analysis. 
However, a clear emphasis is placed on the quality control of raw sequence data as 
problems arising during or prior to sequencing are likely to compromise the entire 
analysis (Guo et al., 2013). At several steps during sample processing and sequencing, 
data might become significantly compromised. For example, during sample and library 
preparation, DNA can undergo degradation or contamination (Robasky et al., 2014). PCR 
amplification can be marred by excessive amplification errors if the genomic data is of 
poor quality (Robasky et al., 2014). During sequencing, signals from DNA fragment 
clusters might overlap, usually as a result of overloading of the sequencer’s flow cell 
(Robasky et al., 2014). Quality control provides the means to assess the integrity of 
sequencing data before any analysis takes place. Many of these problems can be detected 
by studying the distribution of values for some metric in the pool of raw sequence data 
(Ross et al., 2013). This usually includes metrics such as per base sequence quality and 
•Bases are read from sequencer traces.  
•Each call produces a base quality score. 
base calling 
•A number of metrics are used to determine the overall quality of sequence reads. quality control 
•Reads are aligned to one or more reference sequences.  
•Each alignment produces a mapping quality score. 
read alignment 
•base and mapping quality scores are recalibrated to account for systematic 
sequencing biases. Quality score recalibration 
•The aligned reads are compared to a reference for deviations.  
•The caller determines which are sequencing errors and which are genuine variants. 
Variant caling 
•Population frequency and functional annotations are provided for each variant. 
•Variants are filtered to fit the description of the putative disease-causing variant. 
Variant annotating and 
filtering 
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content, per sequence mean quality score and content, sequence length (Patel and Jain, 
2012). Single value metrics, such as the estimated rate of duplications in the data, can also 
help flag up problems with sequencing (Patel and Jain, 2012). In principle, any indication 
of overall poor quality data should result in a new round of sequencing once the source of 
error has been addressed. Another important stage requiring quality control is variant 
calling. Estimating the sensitivity and specificity with which calls were made can help 
assess the reliability of results at every stage. In this context, sensitivity refers to the rate 
with which a caller identifies variants that are present in an individual while specificity 
refers to the rate with which callers exclude variants that are not present in an individual. 
Microarray data has often been used for the purpose of estimating variant calling 
sensitivity and specificity (Houniet et al., 2015). However, microarray data is not always 
available. Publicly available population data can also provide a reliable means of 
estimating sensitivity and specificity (Houniet et al., 2015). Some quality control at each 
stage is important in order to correctly interpret WES study results. 
Even when focused on the exome, sequencing produces a large amount of read data. 
Coupled with the relatively short size of each read and the presence of base miscalls, 
determining the original position of each read in the genome proves to be a computer-
intensive task (Altmann et al., 2012). This is rendered all the more complex by regions of 
the genome that contain repeats or that are homologous to other regions of the genome. 
Sequence alignment is generally achieved by mapping particular sequence reads to 
regions of the genome by comparing these to one or more reference sequences. In the 
case of human genome, reference sequences have two principal sources: the university of 
California Santa Cruz (UCSC) genome assembly and the Genome Reference Consortium 
(GRC) genome assembly (Pabinger et al., 2014). Both assemblies are identical, differing 
only in presentation (Pabinger et al., 2014). In order to provide fast alignment of large 
amounts of short read data, various data structures are used to efficiently access subsets of 
the reference data, read data or both (Li and Homer, 2010). Fast aligners can be broadly 
divided into two categories: those with algorithms based on hash tables and those based 
on prefix/suffix tries (Li and Homer, 2010). Hash tables are data structures that link 
objects, referred to as keys, to corresponding values in a table. The key provides the 
location of the corresponding value through a transformation by a hash function. In this 
context, hash tables can either be used to store information on k-mer subsequences of the 
reference; a solution employed by NovoAlign (Novocraft, 2014b), or information on the 
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reads themselves, an approach used by MAQ (Li et al., 2008). In either case, a particular 
DNA sequence acts as a key for a list of values representing the locations at which the 
particular combination occurs. A prefix/suffix trie; derived from the word “retrieval”, is 
an ordered tree data structures from which a value can be retrieved using the suffixes; or 
prefixes, of a sequence of characters as a key. In the context of alignment, the values will 
refer to the position at which a subsequence starts; or ends if prefix trie. An example of a 
prefix trie is given in Figure 8. 
 
Figure 8. Example of a DNA sequence stored in a suffix tree. Each possible suffix subsequence can be used as a 
key to retrieve the index at which the subsequence starts. Each edge corresponds to a subsequence starting with 
a new character (for the root node: A, T, G and C). For example, TCA can either be followed by A or G, leading 
to two edges. 
 Prefix/suffix tries can take on one of many forms such as: suffix-tree, enhanced suffix 
array and FM-index (Li and Homer, 2010). The widely-adopted aligners in this category 
such as Bowtie (Langmead et al., 2009) and BWA (Li and Durbin, 2009) employ FM-
index (Li and Homer, 2010). As with base calling, the quality of each read mapping is 
given as a Phred score (Li and Durbin, 2009). In this case, the score represents the 
confidence with which a read is aligned. This depends on the number of mismatches 
between a read and its best alignment to the reference (Li and Homer, 2010). In addition 
to base mismatches, most aligners also accept alignments that leave gaps in either the 
read or the reference. When these types of gaps are not errors, they are indicative of the 
presence of a small insertion or deletion. Together, the base and mapping quality scores 
are useful in determining the existence of deviations from the reference corresponding to 
SNVs, insertions and deletions. 
Aligned sequence reads provide a data set from which SNVs and small indels can be 
uncovered. This process is referred to as variant calling (Nielsen et al., 2011). Many 
methods complement variant detection with genotype prediction (Altmann et al., 2012). 
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In this case, the whole process is referred to as genotype calling; variant calling being 
implied. Early implementations of variant calling relied on counting the occurrences of 
nucleotides mapping to a particular position of the reference sequence (Altmann et al., 
2012). Any deviation from the reference sequence that was observed in a set of high-
quality reads above a certain frequency was called as a variant. While this was sufficient 
for revealing variants in loci combining high-quality reads with high read depth, the 
approach did little to address the uncertainties due to errors in base calling and alignment 
and low read depth (Altmann et al., 2012). Whichever exome capture technology is used, 
there is inevitably some variability in sequence coverage; or read depth (Chilamakuri et 
al., 2014). Additionally, high or low GC content reduces the efficiency of PCR 
amplification, leading to a low read depth in the corresponding regions (Aird et al., 2011). 
This early approach has therefore been supplanted by a number of callers using 
probabilistic methods to distinguish genuine variants from sequencing errors (Pabinger et 
al., 2014). With few exceptions, variant callers use the Phred base and mapping quality 
scores as input for their probabilistic models (Pabinger et al., 2014). Methods built on 
Bayes’ theorem, such as those employed by SAMtools (Li et al., 2009a) and GATK 
(DePristo et al., 2011), produce from the sequence data a posterior probability of an 
observed deviation being a variant. 
The sequencing and variant calling of large number of samples has become common 
practice in WGS studies, particularly when applied to population and cancer genomics 
studies (Chen and Sun, 2013; Wang et al., 2013). Originally, population studies employed 
pooled sequencing, where DNA from a cohort of patients was included in a single library 
preparation (Altmann et al., 2011). This was done to reduce costs incurred by sample 
preparation of a large number of individuals (Altmann et al., 2011). However, in recent 
years, population studies have returned to a more traditional approach. The study of ToF 
patients presented in chapter 5 is one such example. In cancer studies, sequencing is 
performed on DNA from tumour and normal cells in order to uncover somatic SNVs 
which may contribute to a particular type of cancer (Larson et al., 2012). Identifying 
variants in these types of sequence data requires callers to work with a different set of 
assumption. Population and cancer studies therefore have their own range of specialised 
variant callers. In WES, multiple sample sequencing and concurrent variant calling can be 
used to detect a variant inherited by multiple individuals in a family. Using the family 
structure to draw relationships between the different samples, callers such as FamSeq 
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(Peng et al., 2013), PolyMutt (Li et al., 2012) and DeNovoGear (Ramu et al., 2013) 
provide joint genotype predictions that are consistent with Mendelian inheritance. More 
details on these approaches to variant calling will be given in Chapter 3.   
Variant calling produces a large list of variants. In order to pinpoint a subset of variants 
that match the description of the putative disease-causing variant, filtering and annotation 
is required (Altmann et al., 2012). The first step is to filter for exome data. Variants that 
fall outside the exome target region are filtered out. Two forms of filtering are then 
applied following variant calling. The first aims to reduce the burden of false-positive 
variants in the list by subjecting it to quality thresholds. For example, variants supported 
by very low read-depths can be unreliable and are therefore often excluded (Nielsen et al., 
2011). The second form of filtering aims to reduce the list of variants to a set most 
relevant to the observed disease and its hypothesised pattern of inheritance (Altmann et 
al., 2012). For example, an autosomal recessive disease in a patient with consanguineous 
parents will require that the individual manifesting the disease be homozygous for the 
variant of interest while parents carrying the disease are heterozygous. Variants present in 
individuals that are not expected to carry the disease-causing variant or absent in 
individuals that are expected to carry the disease-causing variant can likewise be filtered 
out. Additional data is often required for further filtering and variant prioritisation such as 
population frequency data and functional prediction (Wang et al., 2010). Variant 
databases such as dbSNP (Sherry et al., 2001) or the 1000genomes project (Abecasis et 
al., 2012) report countless variants and their corresponding MAFs. If the studied disease 
is predicted to be the result of a very rare allele, variants that have a high MAF can be 
filtered out, leaving only rare variants; typically understood as variants with a MAF<1% 
(MacArthur et al., 2014). Provided there are no obvious candidates among the remaining 
variants, these can be prioritised according to their putative functional impact on protein 
structure. A first distinction can be made between potentially truncating variants; 
nonsense variants, frame-shifting indels and splice site variants, and other non-
synonymous variants. For missense variants, a number of functional predictions can be 
used to support a variant’s deleterious potential (Dong et al., 2015). These functional 
predictions are based on such things as sequence conservation at the variant site and the 
predicted effect of the variant on specific protein structure features (Dong et al., 2015). 
The assumption is that the disruption of a highly-conserved sequence or of a crucial 
protein structure is likely to be damaging. However, many of these functional prediction 
 27 
 
tools were not originally intended as predictors of disease-causing potential (Grimm et al., 
2015). As a consequence of the different criteria underlying different functional 
predictors, the results for a single variant occasionally appear contradictory (Dong et al., 
2015). The accuracy of functional predictors is limited. Dong et al. (2015) measured the 
qualitative prediction performance of 11 functional predictors against a dataset of known 
deleterious and neutral variants and found MutationTaster to have the highest estimated 
accuracy with 86%. Another popular prediction tool, PolyPhen-2 had an estimated 
accuracy of 79%. One should therefore be careful not to over-interpret the predictions 
obtained from these programs. There is a number of services that integrate a variety of 
databases and functional annotation tools into a single pipeline, as is the case with 
ANNOVAR (Wang et al., 2010).  
As a result of additional filtering through annotation, variants can be concentrated into a 
small set of potentially disease-causing variant. The best candidates can be selected for 
sequence validation and functional studies aimed at confirming the link between mutation 
and disease trait. 
1.3.4.  Exome-sequencing study designs 
WES studies aimed at identifying disease-causing mutations can take on a number of 
forms ranging from a simple family-based study to larger case-control studies (Bamshad 
et al., 2011). What particular study design is most appropriate will often depend on the 
type of disease and mutation being studied and the availability of samples. Family-based 
studies are more adequate when the disease trait is identified as segregating in a family in 
a way that suggests the inheritance of a single causative variant. A large number of 
individuals with the disease might not be available for sequencing, but multiple 
individuals in a single family might exhibit the same disease phenotype. To date, the 
genetic underpinnings of dozens of rare syndromes have been identified through family-
based NGS studies (Gonzaga-Jauregui et al., 2012). On the other hand, given a large set 
of individuals with putative rare de novo mutations triggering a single disease, a large 
case-control study may permit the identification of small regions or genes in which 
variations occur more frequently in a case population compared with controls. Because of 
the cost involved in sequencing large numbers of case and controls, the latter type of 
study is still rare (Derkach et al., 2014). This type of study will be discussed in more 
depth in chapter 5.  
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WES study designs are often inspired by previous methods of identifying disease-causing 
mutations which relied on different technologies. From the 1980s onwards, highly 
penetrant mutations were identified through linkage analysis (Bailey-Wilson and Wilson, 
2011; Brunham and Hayden, 2013). Taking advantage of the recombination that occurs 
during meiosis, linkage analysis uses markers to identify regions in the genome that co-
segregate with a disease phenotype in a family. The regions can then be subjected to 
targeted sequencing so that the precise molecular alterations can be identified. Some early 
examples of successful linkage analysis include the identification of a disease locus for 
Huntington’s disease and cystic fibrosis (Gusella et al., 1983; Riordan et al., 1989). 
Brunham and Hayden (2013) report that between 1980 and 2010, the genetic basis of 
upwards of 4,000 Mendelian diseases was elucidated through linkage analysis, 
particularly after the sequencing of the human genome at the turn of the century. The 
sequencing of the human genome enhanced linkage analysis by providing investigators 
with better knowledge of the genes within a locus of interest. However, the introduction 
of NGS technologies has rendered linkage studies largely superfluous. There exist some 
examples in the literature of WGS and linkage analysis being used in tandem. One 
example is the discovery of deletion in the gene PTPN11 in a family with 
metachodromatosis, a disease that affects bone development (Sobreira et al., 2010). The 
region in which that deletion was identified was first determined through linkage analysis. 
A single individual from that family was then analysed using WGS and the deletion was 
uncovered (Sobreira et al., 2010). Nonetheless, WES alone can be used to identify highly 
penetrant alleles and does not require as many samples or as many familial generations 
(Brunham and Hayden, 2013). This makes NGS the ideal technology for investigating 
rare diseases in families, even with small pedigrees, making linkage studies redundant. 
The elucidation of diseases through linkage analysis was progressively supplanted by 
genome-wide association studies (GWAS) as the focus of research moved from 
Mendelian diseases to common complex disease (Antonarakis and Beckmann, 2006). 
Theoretically, GWAS provide a better approach for elucidating diseases that follow the 
common disease common variant (CDCV) model, deriving their strength from large 
numbers of unrelated case and control samples (Saint Pierre and Genin, 2014). GWAS 
use the case-control design in order to identify differences in allele frequency at known 
polymorphic sites. These polymorphic sites in turn provide an association between a 
particular locus containing the causal variant; in linkage disequilibrium with the 
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polymorphic site, and a disease trait. While GWAS has successfully associated a number 
of common diseases with various loci, these loci often only account for a small fraction of 
the estimated heritability in the population under study (Manolio et al., 2009). Efforts 
have been made to adapt GWAS to detect the effect of aggregates of rare variants (Bansal 
et al., 2010). In order for the actual rare variants to be detected, GWAS need to be 
supplemented by NGS studies with which the loci producing the strongest associations 
can be analysed for individual variants (Nejentsev et al., 2009). Variants that are 
extremely rare in the human population; MAF<0.5%, will be undetectable in GWAS 
however due to low power unless a very large number of samples are used. This warrants 
a new strategy. It is in this context that large WES case-control studies are expected to 
take over from GWAS (Cirulli and Goldstein, 2010). The main obstacle remains the cost 
of sequencing large numbers of cases and controls (Derkach et al., 2014). The size of case 
and control sets required to identify rare variants is discussed at length in chapter 5. 
In WES studies, closely related individuals can be used to uncover both inherited and de 
novo disease-causing variants provided the variants exhibit high penetrance. Studies of de 
novo variants,  concentrate on individuals exhibiting a disease trait which is not observed 
in their parents and is suspected to be the result of de novo variants (Bamshad et al., 
2011). Here the assumption is made that the disease-causing variants are dominant and do 
not have incomplete penetrance (Bamshad et al., 2011). A variant with incomplete 
penetrance could be inherited without leading to disease in all carriers. De novo studies 
could therefore be used to investigate traits that are highly deleterious and occur only in 
sporadic cases (Bamshad et al., 2011). De novo variants are identified by sampling 
parents-offspring trios or quartets in which a child is alone in exhibiting a disease trait. 
Sequencing data from parents and sibling provide a set of variants which can be excluded 
from the child (Bamshad et al., 2011). The assumption made here is that a variant 
occurring in two closely related individuals is unlikely to have occurred as the result of 
two distinct mutation events and thus more likely to have been inherited. Assuming 
perfect sequencing, the remaining list of variants would mostly contain de novo variants, 
with the remainder of variants undetected in parents due to mosaicism; where a particular 
variant is only present in certain cell types in an individual. This is the study design 
followed in chapter 4. Familial relationships can also be drawn on to identify variants 
underlying a disease trait. If a disease trait follows a Mendelian pattern of inheritance, it 
can be suggested that it is being caused by a single causal variant, provided this variant 
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shows high-penetrance. Assuming high-penetrance is essential in determining carrier 
status and thus ultimately identifying a causal variant. Candidate variants are identified by 
sequencing related individuals; healthy and affected, and selecting those variants present 
in carriers and absent in non-carriers. Depending on the pattern of inheritance, further 
assumptions can be made about the location of the putative variant or the genotype 
expected in each carrier.   
Case-control studies are largely focused on unrelated individuals and seek to identify 
causal regions or genes in the development of a disease. Case-control studies focused on 
sporadic disease for which de novo variants are suspected are the exception. Siblings are 
assumed not to carry disease-causing variants and can therefore be used as controls. This 
was the strategy adopted for a large autism spectrum disorder study by Sanders et al. 
(2012) in which 238 families were sequenced. These families consisted of 38 parents-
offspring trios and 200 parents-offsprings quartets. The 200 non-affected siblings were 
used as controls, revealing an excess of non-synonymous de novo variants in probands 
and uncovering a gene association between autism and the gene SCN2A. A recent 
example of a case-control study for CHD is the study by Zaidi et al. (2013). This study 
investigates potential causal genes for an array of severe CHD phenotype. The study 
consists of 362 parents-offspring trios where the proband has severe CHD, and 264 
parents-offspring controls. I use the case-control WES study design in chapter 5 and it 
will be discussed at greater length in that chapter. As the focus of WES case-control 
studies shifts towards rare variants of lower effect sizes, increasingly larger case-control 
studies will be required to increase statistical power (Lee et al., 2014b). 
1.4. Conclusion 
With this PhD project, I investigate the genetic underpinnings of severe CHD using WES, 
with a particular emphasis on TGA and TOF. Based on current research on the genetic 
etiology of both these diseases, I conducted bioinformatics analyses of WES studies and 
identified genes that hold potentially disease-causing variants. Additionally, I devise and 
implement a new approach to variant calling with the aim of improving detection of 
variants shared by individuals carrying a disease when a multiply affected, putative 
Mendelian pedigree is being studied. 
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Chapter 2. Methods
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2.1. Overview 
Whole-exome sequencing plays a central role in the research presented in this thesis. In 
this chapter, I will cover the core methods of WES used in data generation. I will first 
specify which NGS and exome capture technologies were used. I will also review the 
recurring tools and metrics used to assist exome data analysis throughout the entire 
project and provide an outline of the hardware enlisted for the analysis. However, since 
bioinformatics methods and pipeline development suitable for the three different study 
designs adopted in my work; analysis of Mendelian families; analysis of de novo variants 
in trio families; and case-control analysis, formed a significant portion of my work, each 
individual chapter of this thesis has its own set of methods developed by me, 
complementing the standard methods described in this chapter. 
2.1.1.  Genome sequencing and exome capture 
While the sample processing, sequencing and exome capture of genomic DNA was not 
performed by me personally, reviewing these aspects may help to understand the various 
analyses I performed. I will therefore briefly describe some of the steps involved in the 
generation of WES data. 
2.1.2. Sequencing and capture 
The required sequencing for this project; including preliminary steps such as sample 
processing and library preparation, was divided between three different research centres:  
 The Institute of Genetic Medicine (Newcastle University, UK) 
 Glasgow Polyomics (University of Glasgow, UK) 
 The McGill University and Génome Québec Innovation Centre (Montreal, Canada) 
DNA was extracted from blood samples originally held at Newcastle’s Institute of 
Genetic Medicine (IGM). Target enrichment for exome capture was performed using 
SureSelect
XT
 Human All Exon 50Mb kit V4 (Agilent Technologies, 2015) from Agilent 
Technologies, USA. Details on the performance of this technology compare to other 
available technologies can be found in Chapter 1.   
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At all three locations, sequencing was performed using the Illumina platform (Illumina, 
2015c). Both UK sites used the Illumina Genome Analyzer IIx (GAIIx) (Illumina, 2012b), 
while The McGill University and Génome Québec Innovation Centre (MUGQIC) used 
Illumina HiSeq 2000 sequencers (Illumina, 2014a). The Illumina GAIIx produces around 
30 million reads per flowcell lane. Each read is 76 base pairs (bp) long. The Illumina 
HiSeq 2000 produces around 180 million bps per flowcell lane. The reads are 101 bp long. 
The HiSeq 2000 is able to process large numbers of samples together using multiplex 
sequencing. All sequencing was done with paired-end reads (Illumina, 2015b). Over the 
course of three years, the sequencing shifted from the IGM to Glasgow Polyomics (GP) 
and finally to the McGill University and Génome Québec Innovation Centre (MUGQIC). 
2.1.3. Quality control 
Before proceeding with sequence analysis, the quality of the raw exome data must be 
assessed. This preliminary quality control step was carried out at the sites where the 
sequencing was performed and some samples may have been sequenced a number of 
times as a result. The quality metrics used in the MUGQIC to assess sequencing quality 
were provided together with the sequencing data. For data emanating from UK locations, 
I have independently produced quality metrics using the NGS QC toolkit v2.2.3 (Patel 
and Jain, 2012). In either case, the quality metrics, using the platform’s base quality score 
(Ewing and Green, 1998; Ewing et al., 1998), included the following: 
 By base position in the read 
o Average base quality score 
o Percentage of reads with base falling within a base quality score range (i.e. 
0-10, 11-20, 21-30, 31-40) 
 By number of reads 
o Read falling within a GC content percentage bracket. (i.e. 0-5,…,95-100) 
o Read average base quality score  
 Percentage base composition (including non-ATGC) 
The NGS QC toolkit also provided a summary of its quality checks, giving a percentage 
of high and low quality reads. By default, NGS QC toolkit sets the threshold of high-
quality at 20 which corresponds to a base calling accuracy of 99%. I also applied this 
threshold to quality metrics generated by MUGQIC. Using these quality metrics, I was 
able to check for irregularities which would betray poor quality data. The first step was to 
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check that high-quality reads represented ≥90% of the data. Following this, I reviewed 
metrics that presented base quality scores by base position in the read to check for any 
sudden drops in quality. I verified that there was no excess of non-ATGC bases and that 
none of the four bases were either significantly over or underrepresented. In addition to 
the previously described quality metrics, MUGQIC also provided the percentage of read 
duplicates; PCR and optical duplicates, per sample providing some additional insight into 
the quality of sequencing at MUGQIC. 
2.2. Data analysis 
2.2.1. Hardware specifications 
The bulk of data analysis was completed on a computer cluster based at the IGM, 
currently running on a Scientific Linux 6.3 (Fermilab, 2014) operating system. Jobs were 
submitted to the cluster using the OGS/GE 2011.11p1 batch-queuing system (Open Grid 
Scheduler project, 2013) for distributed resource management. The hardware on which 
the operating system runs has been upgraded on multiple occasions over the past three 
years.  
At the start of my PhD project, the cluster was composed of a single headnode and 16 
compute nodes. A Dell R510 server node was used as the headnode, while the 16 
compute nodes were distributed across 4 Dell C6100 rack servers. The headnode operates 
on two Intel Xeon E5620 2.40 GHz quad-core processors and 12GB of RAM and has 
19TB of available storage space. Each of the compute nodes operates on two Intel Xeon 
E5640 2.67 GHz quad-core processors, 47GBs of RAM and has 160GB of hard disk 
space. 
In the fall of 2012, a login node and 4 additional compute nodes were added. The 
additional compute nodes share the same specifications as the previous 16 with the 
exception of RAM; 96GBs, and hard disk space; 900GBs. A Dell C1100 server node acts 
as the login node with two Intel Xeon E5640 2.40 GHz quad-core and 24GBs of RAM. In 
2014, a high-intensity compute node; with four Intel Xeon E7-4820 2.00 GHz 8-core 
processors, 520GBs of RAM and 400GBs of hard disk space, was added to the cluster. 
Such upgrades were crucial in order to pursue large scale WES analyses. In addition to 
new login and compute nodes, 2 Dell R510 nodes attached to 2 Dell MD1200 storage 
shelves provide 73TB of lustre storage. 
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In the final year of the PhD project, a computer cluster at Manchester University’s 
Faculty of Medical and Human Sciences was also made available for this project. The 
cluster was primarily used for the data analysis of 871 ToF cases and 500 controls as 
presented in chapter 5. The cluster comprises 10 compute nodes; each equipped with 512 
GBs of RAM and a dual 2.60 GHz 8-core processor. The compute nodes provide a total 
of 55TB of hard disk space. 
2.2.2. Software and scripts 
WES analysis calls upon a whole sequence of programs, requiring some degree of 
automation. Analysis pipelines were devised through a combination of Perl (Perl.org, 
2002) and Bash shell (GNU Project, 2014) scripts which could then be submitted as one 
or more jobs on a cluster’s compute nodes. The scripts were also used to directly filter 
and interpret data without the use of any third-party software. The scripts used for this 
project thesis are a combination of my modification of scripts originally written by 
colleagues and scripts written by myself to fulfil study-specific aims. All of the tools 
described in the following paragraphs were run using scripts. The programming language 
Java was also used to implement a variant caller. Details are provided in chapter 3. 
The Illumina sequencing platform is distributed with its own sequencing software 
pipeline (Illumina, 2015d). For the purpose of our analyses, the use of this pipeline is 
limited to the steps immediately following sequencing: image analysis, base calling and 
file conversion, the latter including demultiplexing where applicable. The two first steps 
do not fall within the remit of my data analysis, but awareness of the version of the 
pipeline used is vital. The data produced at the IGM and GP is provided through the 
Illumina v1.6 pipeline, while data from the MUGQIC goes through the Illumina v1.8 
pipeline. This distinction is important as base call quality is encoded using a different 
range of ASCII values in either version. Starting with Illumina v1.3 and up to v1.7, the 
base quality score was encoded in ASCII with an offset of +64, a format unique to the 
Illumina platform. With Illumina v1.8, the offset changed to +33 to coincide with the 
Sanger format (Illumina, 2012a). The similarity between encodings has been the source of 
much confusion and potentially experimental error (Cock et al., 2010). Alignment tools 
such as BWA (Li and Durbin, 2009) provide an option to convert the illumine-specific 
encoding format into the more broadly accepted Sanger format (Cock et al., 2010). 
Failure to explicitly signal the use of the illumina-specific encoding will result in the 
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incorrect interpretation of base quality scores, with negative repercussions on alignment 
and variant calling. 
Sequence data from a single run of the Illumina GAIIx (Illumina, 2012b) is delivered 
from Illumina’s base calling software in the QSEQ file format (Illumina, 2012a). The 
QSEQ files are divided by lanes and read direction; given paired-end sequencing. For 
sequencing runs performed at the IGM and GP, I converted the QSEQ files into the 
widely-used FASTQ format (Cock et al., 2010) using GERALD, a tool included in 
Illumina’s data analysis pipeline (Illumina, 2015d). For each sequence lane, two FASTQ 
files were produced, each containing reads sequenced from the same end. Where 
sequence data for a single individual was present in multiple lanes, I concatenated the 
corresponding files so that the remaining pairs of FASTQ files all corresponded to a 
single sample. The demultiplexed sequence data delivered from the MUGQIC was sent in 
the BAM file format (Li et al., 2009a). This file provides the required data in compressed 
form, with sequence alignment. To ensure consistency between samples in my analysis, 
this alignment was disregarded. I extracted unaligned sequence data from the BAM files 
(Li et al., 2009a), producing two FASTQ files; given paired-end sequencing, for each 
BAM file. This was achieved using the program Picard (The Broad Institute, 2015c). 
A number of data analysis tools were used repeatedly across studies. For sequence 
alignment I used BWA v0.7.4 (Li and Durbin, 2009). BWA takes a FASTQ file as input 
and produces an alignment in BAM format (Li et al., 2009a). At this stage, encoding that 
was not in the Sanger format was flagged up using the corresponding option in BWA (Li 
and Durbin, 2009). After every sequence alignment, duplicates were removed using 
Picard (The Broad Institute, 2015c).  
Three different variant callers; two widely-used callers and one of my own devising, were 
used: 
 SAMtools v0.1.18 (Li et al., 2009a)  
 GATK UnifiedGenotyper v.2.2.9/ v.3.1.1 (DePristo et al., 2011)  
 BAMily (not yet published) 
The above variant callers can take one or more aligned BAM files, producing a list of 
variants in VCF file format (Danecek et al., 2011). For each variant caller, a different 
approach was used. Using SAMtools, I called variants from parent-offspring trio samples 
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together, while producing individual calls for unrelated samples. Before using GATK’s 
UnifiedGenotyper, I used GATK’s realignment and recalibration tools on each sample 
producing recalibrated BAM files. I then called the entire set of recalibrated samples with 
GATK’s UnifiedGenotyper, producing a single VCF output for all the samples of a single 
study. The use of BAMily is described in chapter 3 and in chapter 4. 
For the purpose of both sequence alignment and variant calling, I used the UCSC genome 
hg19 assembly (UCSC, 2015) in FASTA format. This assembly was used for all analyses 
described in this thesis. Unless stated otherwise, all variant call data were filtered for the 
target regions from the SureSelect
XT
 Human All Exon 50Mb kit V4 from (Agilent 
Technologies, 2015) Agilent Technologies, USA. 
Every variant call is accompanied by a quality score (Q) in Phred format; where the error 
probability is expressed as a score through a logarithmic transformation (Ewing and 
Green, 1998; Ewing et al., 1998). In chapter 4 and chapter 5, I use this score to capture 
high-confidence calls. For GATK, the minimum confidence threshold for high-quality 
variants is a score of Q30 corresponding to a 99.9% probability that the call is correct 
(The Broad Institute, 2015b). I apply this threshold to SAMtools as well. The SAMtools 
and GATK genotype predictions were used as an additional filtering criterion in chapter 3 
and chapter 4. The quality of selected variant calls was also checked using IGV, an 
alignment viewer (Robinson et al., 2011). Using this program I was able to flag potential 
false positives variants by inspecting their sequence context. 
The studies undertaken for this PhD were focused on identifying putative rare variants 
which can cause disease. To filter for variants more likely to fit this description, 
population frequency and functional annotations are required. For this purpose, I used 
ANNOVAR (Wang et al., 2010). ANNOVAR provides gene, region and population data 
annotations for each called locus, by simply adding columns to those already existing in 
the VCF output. This additional information can be used to filter and rank variant call 
data. Using my own scripts, I filter the data using the available annotation. For every 
sequencing analysis, I select non-synonymous variants, falling either in an exonic or 
splice-site region. Known polymorphisms are removed from the list of variants by 
comparing variant call data to population databases such as the 1000genomes project 
(Abecasis et al., 2012) and the NHLBI Exome Sequencing Project (ESP) (NHLBI, 2015). 
Alleles with a minor allele frequency (MAF) ≥1% in either of these databases are filtered 
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out. To filter out additional common variants, some of which are artefacts, I used an in-
house list of variants compiling the results of 418 previous WES analyses. A frequency 
threshold of 1% is also used in this case. In each study, the potential pathogenicity of 
variants is partly determined by their predicted functional effect. Various programs 
provide such predictions via ANNOVAR. These include MutationTaster (Schwarz et al., 
2010), Polyphen-2 (Adzhubei et al., 2010) and LRT (Chun and Fay, 2009). I use these to 
either filter or rank potential disease-causing variants. 
Beyond this step, each study tends to differ. Each study has its own methodology which I 
will describe in the methods section of each subsequent chapters.
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Chapter 3. Design, development and testing of a new approach to variant 
calling
 40 
 
3.1. Summary 
In this chapter, I present the design and implementation of a new approach to variant 
calling. The resulting variant caller, BAMily, is designed to identify putative variants in 
WES data, shared by a subset of individuals, while absent in another subset. This 
approach to variant calling is particularly applicable to pedigrees in which multiple 
related individuals are suspected of sharing a variant causing a Mendelian disease trait. It 
can be described as a two-step detection process. Variants are first detected in a sample 
pool, using all available reads. Variant detection in the pool is then used to assist the 
detection of variant presence or absence in each individual. This approach is particularly 
useful when a variant, well represented in a pool of individuals, is also present in the 
reads from a particular individual but, due for example to low quality or coverage, is 
difficult to distinguish from errors. This approach also involves assigning probabilities to 
undetected variants in single samples of being truly absent or merely unobserved in an 
individual. The desired outcome is a variant caller which can be used to uncover variants 
that segregate with a trait exhibited by groups of individuals, out of a larger set of 
individuals. For example, the variant caller can be part of a NGS study on patients 
exhibiting a disease trait suspected of having a shared origin in the form of one or more 
variants. Families presenting disease traits that follow an autosomal dominant pattern of 
inheritance is one such case. I compare the implementation of this approach against other 
variant callers using data from individuals in pedigrees that have also been analysed using 
genotyping microarray. The results show that my approach provides an advantageous 
balance between sensitivity, specificity and running time that is complementary to 
existing methods. As a consequence, I use this new approach to study 8 families. Previous 
analyses failed to establish plausible disease-causative candidates in most of these 
families. The development of BAMily presents a new opportunity to attempt to resolve 
these families.  
3.2. Introduction 
While NGS platforms produce overall high-quality data from which DNA sequences can 
be determined, library preparation and sequencing involve a range of steps and optical 
technology that introduce significant variability in the quality of the data (Kircher et al., 
2011). Variation in the base call error rate is in large part mitigated by the presence of 
overlapping reads. However, variants can become indistinguishable from errors for loci 
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supported by fewer reads. Regions with low read depth pose an additional problem as 
they may reveal only one of two alleles present at a heterozygous locus (Nielsen et al., 
2011). A survey of WES projects centred on Mendelian disease has led Gilissen et al. 
(2012) to report that specific mutations underlying disease traits will be identified in only 
60% of families. This statement should be treated with great caution as the outcome of a 
WES project will depend on many factors such as the number of carriers sequenced and 
the mode of inheritance observed in a family. Nevertheless, what this estimate conveys is 
the need for improvements in the analysis of WES data.  The challenge for variant callers 
in the past few years has been to extract variants from reads that are difficult to interpret. I 
will quickly review some of the approaches that have been used to interpret low-quality 
data below. 
3.2.1. Improving variant calling 
Addressing the limitations of NGS has motivated the development of a plethora of 
increasingly sophisticated tools for sequence alignment, variant calling and filtering 
(Pabinger et al., 2014). Popular variant callers such as SAMtools or GATK take model 
based approaches and have led to increased rates of variant discovery; particularly when 
compared to the original read counting method, while keeping the rate of false positives 
low (Li et al., 2009a; DePristo et al., 2011). Variant callers rely on estimated calling error 
probabilities. These estimates are generated by the base calling procedures which are 
platform specific and themselves subject to biases. There have been efforts to correct 
known biases, such as the increased propensity for base miscall in later sequencing cycles 
(Altmann et al., 2012). One approach is to train statistical models on sequencing data. 
This is the solution proposed by the integrated caller in the Atlas2 suite which uses a 
logistic regression model trained on exome data to call single nucleotide variants (SNVs) 
and indels (Challis et al., 2012). Challis et al. (2012) report that their caller is thus able to 
mitigate the effects of exome capture such as reference bias and strong variability in 
depth coverage. Another approach involves the use of known single nucleotide 
polymorphisms (SNP) in order to re-estimate the quality of sequence data (Altmann et al., 
2012). By identifying sequencing mismatches from the reference not previously identified 
as nucleotide polymorphisms and treating these as errors, it is possible to derive more 
accurate error rates from the sequence data. This is the concept behind base quality score 
recalibration, first introduced with SOAP and then implemented by GATK (Li et al., 
2009b; DePristo et al., 2011). 
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Current variant callers have the ability to detect variants across multiple samples. This 
provides another potential source of improvement for variant calling. At a single locus, 
the quality and quantity of reads will differ between samples. For a single sample, variant 
detection can be hindered by the lack of high-confidence reads, the scarcity of read data, 
or both (Altmann et al., 2012). Samples that present a high yield of high-confidence reads 
can help with the interpretation of low-confidence reads in another sample. A higher rate 
of variant detection can also be achieved by factoring in the relationships that bind the 
individuals from which these samples originate. In the following section I review WES 
approaches which use the relationship between samples to increase variant detection. 
3.2.2. Variant calling involving multiple samples 
3.2.2.1. Family-based sequencing 
Families provide a context in which rare variants are concentrated in a relatively small set 
of samples. Family-based studies can be used to uncover both inherited and de novo 
variants. Disease-causing variants that result from de novo mutation are identified by 
sampling family trios or quartets in which a child is alone in exhibiting a disease trait. 
Sequencing data from parents and siblings provide a set of variants which can be 
excluded from the child, since they are inherited (Bamshad et al., 2011). This approach to 
variant discovery has revealed the role that de novo variants play in the manifestation of 
neurodevelopmental disorders (Veltman and Brunner, 2012a). Familial relationships can 
also be used to identify mutations causing diseases which follow a Mendelian pattern of 
inheritance. Candidate mutations are identified by sequencing related individuals; healthy 
and affected, and selecting those mutations that segregate with the disease. Family-based 
sequencing studies often rely on variant callers such as SAMtools (Li et al., 2009a) or 
GATK (DePristo et al., 2011). However, recent attempts to improve variant calling in this 
domain have led to the development of callers specifically tailored to family sequencing.  
Family-based studies benefit from pedigree structure which provides a means to relate 
each sequenced individual to all others. For a single locus, the sequence reads from one 
individual are used to determine the presence of absence of a variant in the reads of 
another following Mendelian inheritance. Thus a variant that would typically be difficult 
to distinguish from error at a single locus in an individual, benefits from a confident 
detection of the same variant in a parent individual. The relationship between individuals 
can be used to derive information that either supports or penalizes the genotype 
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predictions that originally arise from an individual's sequence data. This is the principle 
behind family-based variant callers such as FamSeq (Peng et al., 2013) and PolyMutt (Li 
et al., 2012); these callers were published while the present work was in progress. 
Family-based callers exploit shared variation in closely related individuals in order to 
strengthen variant detection for each single individual. While the idea of using shared 
variation in this way has primarily been applied to families, it can also be applied more 
generally to cases where multiple individuals share disease-causing variants without 
necessarily all being closely related as will be discussed later in the chapter. 
3.2.2.2. Pooled sequencing 
The costs involved with WGS, though falling very rapidly, remain an important obstacle 
in the carrying out of large case-control studies (Derkach et al., 2014). While WES 
sequencing provides a cheaper alternative for studies which involve only a few dozen 
samples, it remains often too costly for studies involving several hundreds of samples. 
Even during the period of this PhD, costs for WGS and WES data generation have 
substantially converged; the downstream data processing and storage requirements, 
however, remain significantly different between the two approaches. The demand for 
cheaper large-scale sequencing studies has motivated the development of pooled 
sequencing (Derkach et al., 2014). Pooled sequencing consists in creating a DNA library 
for sequencing from the pooled DNA of all the individuals of a study (Chen and Sun, 
2013). Two population sequences; for cases and controls, are effectively created from 
which the various frequencies of different variants can be estimated.  
This approach focuses on establishing the presence of variants in a given pool without 
assigning these to particular individuals. Variants or clusters of variants likely to play a 
role in the disease under study will be overrepresented in the case pool compared to 
controls. This approach compensates for the variability in sequence data quality by using 
all reads covering a single locus. Variant callers tailored to pooled sequencing include 
SNVer (Wei et al., 2011), vipR (Altmann et al., 2011) and CRISP (Bansal, 2010). One of 
the pitfalls of such an approach however, is that individuals can no longer be 
distinguished. This type of sequencing would therefore not be sufficient to arrive at an 
individualised variant detection. However, such an approach could be used to uncover 
variants as a preliminary step to per individual variant calling. 
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In recent years however, with cross-collaborations providing the means to carry out large 
studies, pool sequencing has been phased out in favour of sequencing individuals in large 
cohorts. The study presented in chapter 5 is one example. 
3.2.2.3. Somatic sequencing 
Population and family-based studies compare sequencing data emanating from multiple 
individuals. In cancer sequencing, the method is adapted to compare data originating from 
a single individual, but different cells (Meyerson et al., 2010). DNA samples obtained 
from tumour cells are compared with samples from non-tumorous somatic cells. As with 
pooled sequencing, sequencing data are produced for multiple DNA samples. Due to 
inevitable admixture of different cell populations, both cancer and cancer-free, mutations 
may manifest as a variant of low frequency. A somatic variant caller, tailored to address 
the particularities of somatic mutations, is thus required (Pabinger et al., 2014). A few 
example of these are Mutec (Cibulskis et al., 2013), Strelka (Saunders et al., 2012), 
SomaticSniper (Larson et al., 2012) and Varscan2 (Koboldt et al., 2012). 
3.2.3.  Aim 
In this chapter, I present a novel approach to variant calling that derives its inspiration 
from some of the approaches previously described. The variant caller is focused on 
identifying variants that are predicted to be shared by a subset of individuals while absent 
in another subset. In the context of a disease trait, these subsets correspond to the pattern 
of inheritance exhibited by the trait. By changing the scope of interest from all variants 
present across the set of individuals to a more meaningful subset of shared variants, we 
can tackle detection of disease-causing variants from a different angle. The caller first 
identifies variants in the pool of individuals we wish to analyse. The pool will be strongly 
enriched for shared variants. In this step, no distinction is made between individuals. 
Variant detections in the pool provide data to make inferences about the existence or 
absence of variants in distinct individuals, leading to variant re-discovery in reads 
previously too difficult to call. Using this approach we can also estimate a probability of 
non-discovery of a true variant or consolidate its absence at loci where no detection has 
occurred. Many variants are likely to be excluded from studies due to poor sequence 
coverage in one or two individuals, resulting in failure to identify causative alleles in 
WES and WGS studies. My approach addresses this problem by estimating the 
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probability that a variant is present even if not observed in an individual’s reads and 
incorporating this probability in the final variant calls assigned. 
3.2.4. Presentation of the 8 families analysed 
Using the new approach to variant calling presented in this chapter, I analysed 8 families, 
in which several members share a disease phenotype. These families were part of a larger 
effort to identify disease-causative variants in families in which the disease trait followed 
a Mendelian pattern of inheritance. The 8 families correspond chiefly to cases unresolved 
at the time of study that had already undergone multiple analyses of WES data. With its 
new approach, BAMily provided the opportunity to analyse these again. The principal 
investigators with clinical responsibility for each family proposed possible modes of 
inheritance based on family segregation. In several of these families, the pattern of 
inheritance of the disease strongly suggested either an autosomal dominant or autosomal 
recessive mode of inheritance with full penetrance. In other families, some patients show 
what could be a dominant disease, but with reduced penetrance. Based on this observation 
and patient availability, a number of individuals in each family were sequenced. In Figure 
9 to 16, I provide the corresponding 8 pedigrees and the justifications that we used to 
assign specific patterns of inheritance conjectured. 
Family 1: 
 
Figure 9. Four individuals exhibit hereditary scleroscing poikiloderma (HSP) with tendon contracture, 
myopathy and pulmonary fibrosis (Mercier et al., 2013). The disease is assumed autosomal dominant. 
*Individuals sequenced. 
Several members of the first family exhibit a very rare disease, hereditary scleroscing 
poikiloderma (HSP) accompanied by muscle defects; tendon contractures and myopathy, 
as well as scarring of the lungs; referred to as pulmonary fibrosis (Mercier et al., 2013). 
The corresponding pedigree is shown in Figure 9. Mercier et al. (2013) describe HSP as 
“a combination of mottled pigmentation, telangiectasia, and epidermal atrophy in the first 
few months of life”. In this context, telangiectasia refers to the visible dilation of 
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capillaries on the surface of the skin. Describing the pedigree presented above, Khumalo 
et al. (2006)  proposed that the disease follows an autosomal dominant pattern of 
inheritance. Two siblings and the unaffected mother were sequenced. 
Individuals in the extended pedigree, reproduced in Figure 10, suffer from 
atrioventricular septal defect (AVSD) and, in two cases, ostium primum atrial septal 
defect (ASD). ASD and AVSD both consist of a gap in the wall that separates left and 
right structures of the heart. Both the atria and ventricles are involved in AVSD, while the 
atria only are involved in ASD (Kaza et al., 2013). Despite the phenotypical differences, 
the development of isolated AVSD shares an embryological mechanism with ostium 
primum ASD, both originating from the abnormal development of endocardial cushions 
that separate the different chambers of the normal heart (Kaza et al., 2013). Therefore, 
family members with either AVSD or primum ASD were considered to have equivalent 
phenotypes in this pedigree. According to D’Allesandro et al. (2015), approximately 30% 
of AVSD are attributable to either chromosomal or single-gene defects. In this family, the 
segregation of CHD, suggests that an autosomal dominant variant with partial penetrance 
is causing the reported septal defects. A total of five individuals; two obligate carriers, 
two individuals with AVSD and one with ASD, were sequenced. 
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Family 2: 
 
Figure 10. Multiple individuals across an extensive family tree present atrioventricular septal defects (AVSD). Disease assumed to be caused by a single variant with reduced 
penetrance. *Individuals sequenced. †A DNA sample that does not match this individual was sequenced due a due to sample mix-up. The sequence data was therefore not retained.
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Family 3: 
 
Figure 11. The disease trait observed in five individuals has been described as atypical Brugada syndrome. 
Disease is assumed autosomal dominant. Individuals with a normal electrocardiogram are marked NE. 
Individuals that did not present the syndrome as a result of Flecainide stimulation are marked NF. *Individuals 
sequenced. 
Family 3 includes several cases of atypical Brugada syndrome (BrS). The phenotype 
observed in the index case of this family was ventricular fibrillation, where cardiac 
muscles of the ventricles contract asynchronously, manifesting as cardiac arrest which 
without prompt defibrillation would prove fatal. The corresponding pedigree is shown in 
Figure 11. BrS describes a change in normal electrical activity of the heart during a 
particular segment of a heartbeat (Antzelevitch et al., 2005). The electrocardiography of 
patients with BrS reveals an elevation of the ST-segment, abnormal heart rhythm; 
arrhythmia, and sudden cardiac death (Antzelevitch et al., 2005). Not all carriers of the 
syndrome show this pattern at resting heart rate. Flecainide can be used to unmask this 
pattern in disease carriers. Whether the patterns were seen at baseline or after injection of 
Flecainide, the clinical examiners determined that the current cases show an 
electrophysiology that deviates from the usual presentation for Brugada and therefore 
identified it as atypical. BrS is typically described as an autosomal dominantly inherited 
disease, with a total of 16 genes currently associated with the syndrome, the most 
common being SCN5A  in which loss-of-function mutations are found in about 20% of 
cases (Brugada et al., 1993). However, studies in families harbouring SCN5A mutations 
have shown low disease penetrance, and recent data have served to further emphasise the 
genetic complexity of the phenotype; for example Bezzina et al. (2013) showed evidence 
for association of common alleles at SCN5A and HEY2 with BrS. 
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Family 4: 
 
Figure 12. Mother and offspring show discordant CHD phenotypes along with other defects. Six pregnancies did 
not come to term. The disease pattern of inheritance is unclear. *Individuals sequenced. 
In the family, represented in Figure 12, a mother and her offspring present complex 
cardiac defects along with a number of other pathologies. The mother has a patent ductus 
arteriosus, a VSD, aortic regurgitation, and a common brachiocephalic trunk. She is 
missing the gall bladder. At 14, she also developed lymphoedema, a defect of the 
lymphatic system that causes tissue swelling with accumulation of lymph fluid (Cemal et 
al., 2011). Additionally, the mother has coeliac disease, an autoimmune disease that leads 
to gluten intolerance (Leeds et al., 2008). The surviving child has dextrocardia; the major 
axis of the heart is orientated towards the right mirroring the position of a normal heart 
(Bernasconi et al., 2005). Other heart defects include VSD and an interrupted aortic arch 
(IAA). Another child, who died during intrauterine gestation, displayed a common arterial 
trunk, ASD, subvalvular VSD and ventricular hypertrophy. The presence of bilaterally tri-
lobed lungs suggests laterality disturbance is responsible for the observed cardiac 
malformations. Another child, who died soon after birth, exhibited VSD, abnormal lung 
lobation, a small adrenal gland and spleen and hypospadias; where the urethra is 
misplaced. This child is also characterised by the absence of a gall bladder. The mother-
daughter pair was sequenced. 
Family 5: 
 
Figure 13. A sibling pair, both sequenced, exhibit double-outlet right ventricle. A number of possible modes of 
inheritance are possible for this family. *Individuals sequenced. 
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In the family depicted in Figure 13, a pair of siblings was found to share double-outlet 
right ventricle (DORV). DORV describes a range of defects that involve the aorta and 
pulmonary artery both arising from the right ventricle (Obler et al., 2008). The results of a 
study by Obler et al. (2008) suggest that a little under half of cases of DORV arise as a 
result of chromosomal abnormalities. Beyond chromosomal abnormalities, a number of 
SNVs and indels have been implicated in the development of DORV, both in humans; for 
example in CFC1, and knockout mice (Obler et al., 2008). In this particular family, the 
parents and two other siblings do not exhibit the disease. A number of modes of 
inheritance can be hypothesised for this family. Only the sibling pair with DORV has 
been sequenced. This was justified by the absence of a clear disease-carrying status for 
parents. 
Family 6: 
 
Figure 14. A sibling pair in a nuclear family exhibit major aortopulmonary collateral artery with pulmonary 
atresia. One patient (II:1) presents a number of other cardiac defects. Neither parent presents a disease 
phenotype. A number of modes of inheritance are possible for this family. *Individuals sequenced. 
In the family represented in Figure 14, the two siblings exhibiting major aortopulmonary 
collateral artery (MAPCA) with pulmonary atresia (PA). Additionally, the female sibling 
has a VSD, a right-sided aortic arch and a left-sided innominate vein. Pulmonary atresia 
with VSD and MAPCA is typically considered a variant of the tetralogy of Fallot 
phenotype (Prieto, 2005). MAPCA describes the persistence of arteries branching off 
from the aorta and supplying the pulmonary system in the event of an underdevelopment 
of the pulmonary valve and arterial system (Boshoff and Gewillig, 2006). MAPCA is 
often the result of PA which occurs when the pulmonary valve leaflets are fused shut 
(Bailliard and Anderson, 2009). While neither parent exhibited the disease, the presence 
of MAPCA in both offspring suggests that some genetic factor could be causing the 
disease. To explore this possibility, all four individuals were sequenced. 
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Family 7: 
 
Figure 15. Three related cousins, each exhibit Tetralogy of Fallot. The manifestation of ToF in cousins suggests 
some genetic variant with partial penetrance could underlie these cases. *Individuals sequenced. 
Three distantly related cousins; represented in Figure 15, were found to each exhibit 
Tetralogy of Fallot (ToF). A description of ToF is given in Chapter 1 and further details 
provided in chapter 5. Each of the three patients was initially treated separately and then 
discovered to be related. Using linkage analysis to determine segments of DNA identical 
by descent, it was determined that III:1, III:3 and III:5 were cousins (personal 
communication). The recurrence of ToF in three closely related individuals suggests the 
possibility of some genetic variant with reduced penetrance underlying the disease. 
Family 8: 
 
Figure 16. A sibling pair; one of which is deceased, have relapsing cardiomyopathy. Parents have been found to 
be consanguineous. As a consequence, the disease is assumed autosomal recessive. *Individuals sequenced. 
In Family 8, a sibling pair exhibits relapsing dilated cardiomyopathy. Neither parent is 
affected. Crucially however, the parents are consanguineous; they are first cousins. This 
suggests that the disease is autosomal recessive. The pedigrees are reproduced in Figure 
16. The cardiomyopathy in this family is described as relapsing as both affected members 
have experienced heart failure on multiple occasions. Cardiomyopathies are diseases of 
the heart muscle, encompassing a number of structural and functional defects (Sisakian, 
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2014). Dilated cardiomyopathy, the most common form of cardiomyopathy, is 
characterised by either the left or both ventricles being dilated and, consequently, 
dysfunctional (Sisakian, 2014). Up to 40% of dilated cardiomyopathies are found in 
Mendelian cases (Sisakian, 2014). All four members of the nuclear family were 
sequenced. Also of note, both affected siblings suffered intractable epilepsy and had 
significant learning difficulties. The male sibling died of heart failure. The female sibling 
after two relapsing episodes requiring support with a cardiac Ventricular Assist Device 
(VAD) and Extracorporeal Membrane Oxygenation (ECMO) received a heart transplant. 
The study of these 8 families is the first WES study to incorporate this new approach to 
variant calling. This chapter therefore not only covers the design, implementation and 
testing of this approach; through BAMily, but also presents its first application. 
3.3. Methods 
I devised a novel approach to variant calling. To implement this new approach, I used the 
Java programming language. The program takes in a set of samples in the BAM file 
format (Li et al., 2009a) with a carrier status applied to each. The status allows the variant 
caller to distinguish samples in which we expect to see a mutated allele from those in 
which no such allele should be found. The program also allows users to set a number of 
variables, such as the number of independent alleles expected in the pool based on the 
relationship between individuals. Decryption of the binary-encoded BAM files is handled 
by the SAM-JDK library (The Broad Institute, 2015c). The calls that are generated by a 
variant caller are stored in files that follow the VCF file specification (Danecek et al., 
2011) although a few columns are specific to this implementation. The approach was 
implemented in a program: BAMily. The accuracy of calls made by this implementation 
was then tested. 
3.3.1. Measures of shared variant detection quality 
The value of our approach and its implementation can be measured in its ability to 
correctly identify variants shared by a predetermined subset of individuals that are absent 
in another subset. Both sequencing artefacts and variants that do not segregate with the 
predetermined pattern need to be excluded and are therefore considered negatives. A 
comparison of known genotypes with the variants presented by our caller allows us to 
estimate sensitivity and specificity of the program. In this context, sensitivity corresponds 
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to the rate with which the caller identifies variants that are known to follow the desired 
pattern of inheritance. Let        be to the number of variants known to follow the 
desired pattern of inheritance, where   corresponds to variants identified by the variant 
caller and  corresponds to those missed by the caller. We have: 
            
 
 
 
Specificity corresponds to the rate with which the caller excludes variants that do not 
follow the desired pattern of inheritance as well as genotype mis-assignments resulting 
from sequencing artefacts. Let      correspond to the number of variants that are 
known not following the desired pattern of inheritance, where   corresponds to variants 
correctly excluded by the variant caller, while   corresponds to those incorrectly detected 
by the caller. We have: 
            
 
 
 
Data produced using genotyping microarray provides a list of SNPs present in a single 
individual. Data from the individuals used for sequencing can be used to estimate the 
sensitivity and specificity of different variant callers. While it is true that microarray data 
are not devoid of error, it is sufficiently accurate for the purpose of estimating sensitivity 
and specificity, as was first published by Ng et al. (2009). Positions were separated 
between those that carried alleles that that followed the pattern of interest and those that 
did not. The former was used to estimate sensitivity while the latter was used to estimate 
specificity. Any positions not represented in the microarray were excluded. 
Exome sequencing and microarray data were obtained for 21 complete parent-offspring 
trios and a set of five additional individuals; three first cousins, their mutual uncle and 
one unrelated individual, from previous experiments. The 21 trios were obtained from a 
study of Tetralogy of Fallot (ToF) in which the offspring in each trio is the affected 
proband. Sequencing was performed on the Illumina GAIIx (Illumina, 2012b) with target 
enrichment for exome capture using SureSelect
XT
 Human All Exon 50Mb kit (Agilent 
Technologies, 2015).  The Infinium HD Human660W-Quad Beadchip (Illumina, 2015a) 
was used as genotyping microarray. The chip has markers for 657,366 SNPs and copy 
number variants (CNV) spanning the entire length of the genome. For each of the 21 trios, 
around 13,726 positions represented in the microarray were within sequencing targets. 
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The microarray data did not always provide a clear genotype assignment. For each trio, 
positions missing a genotype assignment were excluded from the evaluation. There are 
therefore some small differences in the number of positions represented per trio. In order 
to measure the effect of sample set size on caller performance, I used five samples; four 
originating from a single family, which were included in a large quantitative genetic study 
of hypertension. Figure 17 shows the corresponding pedigree for the 4 related individuals. 
In this case, the sequencing was performed on the Illumina HiSeq 2500 (Illumina, 2014b). 
Samples were aligned using BWA v0.7.4 (Li and Durbin, 2009). For the five additional 
individuals, genotypes were available for 14,087 positions. Differences between these 
two sets are largely due to differences in the sequencing platform used. 
 
Figure 17. Pedigree of the four related individuals included in my analysis. Samples were originally sequenced as 
part of a hypertension study. *Individuals sequenced. 
First I assessed variants shared between a father-child pair and absent in the mother in 
each of our trios. This corresponds to the variant calling step that would be used in the 
search for a paternally-inherited disease-causing variant. To do this, I derived a sensitivity 
and specificity measurement for each trio. This measurement was performed using five 
different variant callers: SAMtools v.0.1.18 (Li et al., 2009a), GATK UnifiedGenotyper 
v3.1.1 (DePristo et al., 2011), GATK+FamSeq, GATK+PolyMutt and BAMily. FamSeq 
v.1.1.0 (Peng et al., 2013) and PolyMutt v.0.1.5 (Li et al., 2012) used the genotype 
likelihoods produced by GATK. For each caller, with the exception of BAMily, I filtered 
for variants shared by father-child pair and not by the mother using their respective 
genotype calls. This last step is already integrated into BAMily’s design.  
I then made a series of sensitivity and specificity measurements on the additional five 
individuals, investigating the effect of the number of individuals analysed and their 
relatedness on sensitivity, specificity and the number of variants produced. Starting with 
 55 
 
three samples, I first singled out variants shared between two related individuals and 
absent in the unrelated individual, getting an average sensitivity and specificity from each 
possible arrangement of samples. The same was done with four and five samples, each 
time searching for variants shared by the individuals that were related. Following this, 
using sample from all five individuals, I performed every possible combination of 
assuming non-carrier status of one, then two, of the related individuals and obtained 
sensitivity and specificity measures. The unrelated individual here serves to exclude 
variants that are not family-specific and to prevent common sequencing artefacts from 
being detected as variants. 
 
3.3.2. Application of BAMily to the WES study of 8 families 
The WES analysis of the 8 families follows some of the methods outlined in Chapter 2. 
As in other studies, sequencing was performed at the Institute of Genetic Medicine (IGM) 
using the Illumina Genome Analyzer IIx (GAIIx) (Illumina, 2012b). Target enrichment 
for exome capture was performed using SureSelect
XT
 Human All Exon 50Mb kit V4 
(Agilent Technologies, 2015) from Agilent Technologies, USA. I used BWA v0.7.4 (Li 
and Durbin, 2009) for sequence alignments, Picard (The Broad Institute, 2015c) for 
duplicate removal and BAMily for variant calling. In the analysis of each family using 
BAMily, I added one individual from Family 1 as non-carrier (I:3, see Figure 9) to better 
exclude any systematic errors that might be shared between individuals and therefore 
preclude the possibility of these errors being called as genuine shared variants. For 
comparison, I also called variants using SAMtools v0.1.18 (Li et al., 2009a). SAMtools 
assigns a genotype to each individual for every variant site. Variants were selected if the 
corresponding genotype assignments fit the pattern of inheritance agreed upon on at the 
outset of the analysis. This step was not required for BAMily, with the pattern of 
inheritance being set as part of the variant calling. For either caller, I excluded variants 
not called with high-confidence (Q30). I used the online implementation of Annovar 
(Chang and Wang, 2012) to access the latest version of annotation tools described in 
Chapter 2. In this particular case, I incorporated the ExAC (The Broad Institute, 2015a) 
population database into the analysis. Using a criterion of exclusion lower than that 
outlined in Chapter 2 (MAF≥1%), when filtering against the 1000genomes risks the 
exclusion of rare pathogenic variants, the database being based only on 1,092 genomes of 
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variable coverage, and thus the estimates of allele frequencies >1% being subject to 
considerable error (Abecasis et al., 2012). On the other hand, ExAC aggregates exome 
sequencing from 60,706 unrelated individuals meaning that alleles with frequencies >0.5% 
can be confidently recognised from the dataset as polymorphisms (The Broad Institute, 
2015a). I therefore excluded any variant with a MAF>0.5% in ExAC. I also filtered the 
list of variants against an in-house list of variants already found in 418 previous WES 
analyses. This step excludes variants that have been uncovered before in studies of 
different conditions undertaken at our institute. Those analyses used the same laboratory 
methods and similar bioinformatics pipeline, and are therefore likely to represent 
systematic errors rather than disease-causing variants of interest. MutationTaster 
(Schwarz et al., 2010), Polyphen-2 (Adzhubei et al., 2010) and LRT (Chun and Fay, 2009) 
were used to assess potential pathogenicity. The resulting list of variants was evaluated 
using resources such as the Online Mendelian Inheritance in Man (NCBI, 2015) and 
GeneCards (Rebhan et al., 1998) compendiums. These results provided information on 
the gene context for each variant. I also referred back to results from previous analyses, 
performed either by me or colleagues. I used the integrative genomics viewer (IGV) 
(Robinson et al., 2011) in order to inspect each variant’s sequence context. This tool was 
invaluable in picking out probable artefacts in low complexity regions and among indels. 
I selected probable disease-causing variants for validation if they appeared in genes which 
could conceivably play a role in the disease. For example, for a CHD phenotype, variants 
appearing in genes expressed in the embryonic heart or genes leading to a cardiac defect 
in mouse models were retained. I report the variants that were sent for validation in 
Section 3.4.5. I also used the opportunity presented by this analysis to look for CNVs. For 
this purpose, I used ExomeDepth (Plagnol et al., 2012). I looked for CNVs found across 
all putative disease variant carriers in a family that stretched across at least 0.1Mbs. The 
confidence with which each CNV call is made is given with a Bayes factor (BF). I 
selected CNVs called with high confidence (BF≥30). ExomeDepth requires controls, 
ideally with the same overall read depth. Sequence data from 20 of the parents of 
probands with transposition of the great arteries (TGA); presented in Chapter 4, were 
used as controls. 
3.4. Results 
In this section I first present the design for my new approach to variant calling which I 
implemented as the variant caller BAMily. I then present the results of multiple 
 57 
 
performance tests which provide a means of assessing BAMily in the context of other 
widely-used variant caller. Finally, I report the results of the integration of BAMily in the 
WES studies of 8 families. 
3.4.1. A new approach to variant calling 
Let us assume that we have a set of sequenced individuals and some putative variant we 
hypothesise to be present in some individuals while absent in others. Let   be the number 
of individuals in which that variant is present and m the number of individuals in which it 
is absent. Let   represent the calling results from the entire pool of samples. For that same 
locus, let Si represent the calling results for individual  , such that              . Let 
  be the status for a variant in the pool and    the status for a variant in individual   such 
that              . At each locus, the presence of a variant is given as   while the 
absence of a variant is signalled by  . For each locus, we want to know the probability a 
variant is detected in   individuals and not detected in   individuals. My approach can 
be summed up as the following expression:  
                                               
                  
 
   
                  
   
     
 
(1) 
I use Bayes' theorem to determine the probability that a variant is present in individual  , 
given sequence data; from both the individual and pool, and the variant detection status in 
the pool of samples: 
                 
                                       
                                            
 (2) 
Conversely, the probability that a variant is not present in an individual given the data is: 
                                    (3) 
The characteristic feature of my method's two-step nature is the dependence of the variant 
status    on the pool's variant status  . 
Let us assume that for a variant to be detected in the pool, it must be present in at least 
one individual in that pool. Following this assumption, a variant will be present in at least 
one allele within a pool of   independent alleles. The probability of detecting a variant in 
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a single individual i therefore depend on detection in the pool. The probability of a variant 
in individual i given its presence in the pool is as follows: 
              
 
 
 (4) 
And the probability of absence is as follows: 
              
   
 
 (5) 
We assume that it is not possible for a variant absent in the pool to be subsequently 
present in any single individual. We can therefore make the following assertions: 
                 (6) 
                  (7) 
Given the calling results T, the probability of presence in the pool can also be obtained by 
applying Bayes' theorem: 
           
                 
                     
 (8) 
The probability of absence in the pool is similarly given by: 
                        (9) 
In order to define the prior probability of detecting a variant from the sample pool, we 
must first define the prior probability of a variant being present at a locus for a pair of 
individuals. Let that event be defined as    for an individual  . A generally accepted 
approximation for this is      (Li et al., 2008). For a small    , the prior can be 
extended to a pool of samples and approximated in the following manner: 
                      
 
    
      (10) 
This set of expressions has been implemented in the variant caller BAMily. 
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3.4.2. Base call accuracy across reads from individual 
Equation 2 requires a probability that the sequence data from individual   fits a particular 
detection assignment. The following equations are based on the genotype likelihood 
equation proposed for Heng Li’s statistical framework for SNP calling (Li, 2011). The 
sequence data    can be described as a set of   reads, with   reads corresponding to 
reference reads (alternatively, the base assignment with the highest count that is not the 
variant of interest) and     reads corresponding to reads showing the variant. We can 
describe these reads in terms of their error probabilities such that    is the error 
probability associated with read  . The error probabilities are determined from base and 
mapping scores in the PHRED format called quality scores. This format, along with the 
formula required to convert quality scores into error probabilities, are detailed in two 
papers (Ewing and Green, 1998; Ewing et al., 1998) and will therefore not be described 
here. How a quality score    is obtained from mapping and base quality is shown in 
Equation 16. From the genotype likelihood equation presented in Li (2011) we derive the 
following probabilities: 
                
 
   
        
 
  
 
     
 (11) 
                     
 
   
   
 
     
 
(12) 
As with other variant callers, error probabilities below a certain threshold are excluded. In 
this implementation, for a read   to be counted requires       ; although this value can 
be changed by the user. 
3.4.3. Base call accuracy across reads from pool 
Equation 8 also requires a probability that sequence data fit with a particular detection 
assignment. Let   be the error probability associated with all reads containing the variant 
of interest. We have the following probabilities: 
              (13) 
and 
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 (14) 
At each base position, there are 3 possible incorrect base call assignments, the sum total 
probability of which is given by the conditional error probability. Depending on the true 
base being interpreted by the sequencer, some erroneous base call assignments will be 
more or less probable. Given that we cannot know the true base being sequenced, we 
make the simplifying assumption that each incorrect assignment has an equivalent 
probability of arising in sequencing leading to Equation 14.  
The error probability for all reads containing the variant of interest   is obtained from the 
sum total of quality scores in the PHRED format once converted into error probabilities 
(Ewing and Green, 1998; Ewing et al., 1998). We can write this quality score   as the 
sum of quality scores for   overlapping reads containing the variant of interest with    the 
quality score for read  : 
     
 
   
 (15) 
Each base in a read is associated with a base call quality score    and a mapping call 
quality score  . The overall quality score qj combines these two qualities as follows: 
              (16) 
 
3.4.4. Caller performance 
I measured the running time of each caller on sequence data from five individuals. For 
five individuals, SAMtools requires approximately 8 hours to run. Given that BAMily 
reports a subset of all variants, its running time depends on the carrier status assigned to 
each individual. Running time for five individuals fluctuates between 6-8 hours. Both of 
these programs were run on a single core. By contrast, GATK's realignment and 
recalibration steps require an average 6 hours per sequenced individual, using two cores 
in each case. GATK’s UnifiedGenotyper then requires an additional 8.5 hours running on 
4 cores. FamSeq and Polymutt require GATK to run and therefore can offer no running 
time advantage. 
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I provide an array of sensitivity and specificity estimates for the five variant callers using 
the method describes in Section 3.3.1. I first performed measurements on trios, focusing 
on the shared variants between father and child, excluding all variants shared with the 
mother by either. From the sensitivity and specificity estimates obtained for 21 distinct 
trios, I determine an average sensitivity and specificity for each variant caller tested. 
Summaries of these results are provided in Table 4 and Figure 18 with the standard error. 
 SAMtools GATK FamSeq PolyMutt BAMily 
Sensitivity % 95.87 97.98 98.02 97.76 98 
Specificity % 99.62 99.91 99.87 99.91 99.91 
Table 4. Mean sensitivity and specificity computed over 21 trios compared to microarray data. These results are 
also reproduced in Figure 18.  
 
Figure 18. Mean sensitivity and specificity computed over 21 trios compared to microarray data. Represented 
with the mean is the standard error. Variants are required to be predicted as present in father and child, but not 
mother, to be called. GATK and BAMily are here shown to overlap. 
Over 21 parent-offspring trios, the combination of GATK+FamSeq presents the highest 
overall sensitivity. However, this comes at a cost in specificity. Likewise, the 
combination of GATK+Polymutt presents the highest overall specificity, but this comes 
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at the cost of sensitivity. GATK and BAMily sensitivity and specificity largely overlap. 
BAMily's average sensitivity appears higher, however the difference is not significant (p-
value=0.197, paired Wilcoxon signed-ranked test). However, it is important to measure 
BAMily’s performance when a larger sample set size is being used, since BAMily is 
designed to incorporate relationship information from multiple family members, and trio 
families would not be anticipated to fully utilise the advantages of this method. 
I therefore measured sensitivity and specificity for various sample set sizes using 
sequence data from three cousins, their mutual uncle and one unrelated individual, as 
shown in Figure 17. I first focused on variants shared between cousin pairs and cousin-
uncle pairs, excluding variants shared with the unrelated individual. I then proceeded to 
increase sample size by incrementally adding one of the remaining cousins or uncle to 
each pair. In each case, I identify variants shared between the newly added individual and 
related individuals from the previous call, excluding once more variants present in the 
unrelated individual. 
As sample size increases, we observe an overall increase in specificity and decrease in 
sensitivity. Additionally, we observe a decrease in the number of variants produced with 
an increased sample set size. Increasing the number of individuals in which shared 
variants are sought effectively reduces the number of candidates that will have to be 
screened. Within a particular set size, the number of variants produced decreases 
depending on genetic distance between samples. Samples from cousin trios produce more 
SNVs than uncle-cousins trios for example. GATK, GATK+Polymutt and BAMily show 
similarly high specificity while GATK+FamSeq displays the highest sensitivity for any 
case. As before however, the combination of GATK with either Polymutt or FamSeq 
leads to a decrease in one of these indicators. As with the parents-offspring trios, BAMily 
and GATK provide a similar balance between sensitivity and specificity. Results are 
presented in Table 5 and Figure 19. 
Still using the set of five individuals, I analysed the data assuming that one of the cousins 
or uncle was a non-carrier and produced variant calls excluding variants from that 
individual and the unrelated individual. This was repeated with each family individual, 
testing every possible combination and obtaining an average. I then assumed two samples 
were non-carriers and proceeded in the same manner. I found that specificity increases as 
the total number of variants produced is further reduced. As expected, the total number of 
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variants produced is higher with genetic distance from the non-carriers. In scenarios 
where the uncle was assumed to be a non-carrier, fewer variants were produced. 
Sensitivity and specificity for all callers start to align. However, with a smaller number of 
variants, one missed variant has a large impact on sensitivity as can be seen in the results 
shown in Table 6. 
 SAMtools GATK FamSeq PolyMutt BAMily 
Variants present in cousin-uncle pair, absent in unrelated individual (3 trios) 
Sensitivity % 96.88 97.79 97.98 97.51 97.73 
Specificity % 99.9 99.95 99.83 99.94 99.94 
False discovery % 1.05 0.53 1.8 0.62 0.62 
…in cousin-cousin pair, absent in unrelated individual (3 trios) 
Sensitivity % 96.74 97.72 97.86 97.51 97.72 
Specificity % 99.9 99.95 99.81 99.96 99.95 
False discovery % 1.12 0.54 2.14 0.45 0.6 
…in uncle-cousins trio, absent in unrelated individual (3 quartets) 
Sensitivity % 96.85 97.48 97.82 97.35 97.52 
Specificity % 99.91 99.96 99.83 99.96 99.94 
False discovery % 1.5 0.6 2.8 0.69 0.98 
…in cousins trio, absent in unrelated individual (1 quartet) 
Sensitivity % 96.7 97.11 97.25 96.97 97.11 
Specificity % 99.9 99.97 99.87 99.97 99.94 
False discovery % 1.82 0.56 2.35 0.56 1.12 
…in uncle-cousins quartet, absent in unrelated individual (1 quintet) 
Sensitivity % 96.66 97.01 97.36 96.84 97.01 
Specificity % 99.92 99.97 99.88 99.96 99.96 
False discovery % 1.96 0.72 2.81 0.9 1.08 
Table 5. Sequence data and microarray data comparison for various sample sizes with cousin-cousin and uncle-
cousins arrangements shown separately. In this table, positions refer to the positions covered by the microarray 
data. For a more complete set of metrics, see Appendix, Table S1. 
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Figure 19. Sequence data and microarray data comparison for various sample sizes (In this case, the average of 
cousin-uncle pairs is used to illustrate a sample size 2). Each point represents an increase in sample size when 
reading from right to left; with sensitivity decreasing. 
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 SAMtools GATK FamSeq PolyMutt BAMily 
Variants in cousins, absent in uncle and unrelated individual (1 quintet) 
Sensitivity % 96.2 96.2 96.2 96.2 96.2 
Specificity % 99.97 99.99 99.99 99.99 99.98 
False discovery % 2.56 1.3 1.3 1.3 1.94 
…in uncle-cousins trio, absent in one cousin and unrelated (3 quintets) 
Sensitivity % 95.99 97.18 97.92 97.18 97.77 
Specificity % 99.98 99.99 99.94 99.99 99.98 
False discovery % 1.37 0.91 3.64 0.91 1.33 
…in cousin pair, absent in uncle-cousin-unrelated trio (3 quintets) 
Sensitivity % 96.52 97.85 97.47 97.85 97.85 
Specificity % 99.98 99.99 99.98 99.99 99.99 
False discovery % 1.38 0.6 1.38 0.6 1.17 
…in uncle-cousin pair, absent in cousins-unrelated trio (3 quintets) 
Sensitivity % 95.38 97.03 97.38 97.18 96.84 
Specificity % 99.98 99.99 99.96 99.99 99.99 
False discovery % 1.83 0.5 2.65 0.69 0.69 
Table 6. Sequence data and microarray data comparison for a fixed sample size of five, assuming different pairs 
and trios of individuals to be non-carriers. In this table, positions refer to the positions covered by microarray 
data. For a more complete set of metrics, see Appendix, Table S2. 
The measurements shown in Table 4 and Figure 18 as well as Table 5 and Table 6 
indicate that BAMily is overall more sensitive and specific than SAMtools, more 
sensitive than GATK+Polymutt and more specific than GATK+FamSeq. For large 
sample set sizes ≥4, BAMily closely mirrors GATK's sensitivity as shown in Table 5, 
occasionally appearing more sensitive. Regardless of the sample size, BAMily's 
specificity is either matched or lower than that of GATK's. Given the diminishing size of 
the total variant output with each new sample, a slight decrease in specificity is not 
particularly disadvantageous. 
3.4.5. Analysis of the 8 families 
The analysis of 8 families using BAMily and SAMtools revealed a number of variants 
that appeared to have disease-causing potential. This demonstrates the applicability of the 
approach implemented as BAMily. Table 7 provides a list of candidates that were sent for 
validation.
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Family ID Phenotype Carrier status (genotype for SAMtools) Rare variants Predicted deleterious* Candidates retained 
   BAMily SAMtools BAMily SAMtools  
Family 1 HSP mother non-carrier, offspring 
(heterozygous) 
84 55 23 20 3** 
Family 2 ASD/AVSD All carriers (heterozygous) 25 1 3 1 0 
Family 3 BrS All carriers (heterozygous) 77 18 45 1 1**† 
Family 4 Complex CHD All carriers (not specified) 177 128 50 43 2 
Family 5 DORV All carriers (heterozygous) 175 116 36 39 5** 
Family 6 MAPCA Mother and offspring carriers, father non-
carrier/ Father and offspring carriers, 
mother non-carrier (heterozygous) 
69/94 64/74 17/23 27/24 1 
Family 7 ToF All carriers (heterozygous) 114 4 51 2 0 
Family 8 Relapsing 
cardiomyopathy 
All carriers (heterozygous in parents, 
homozygous in offspring) 
17 9 7 6 3 
Table 7. Number of rare variants detected by BAMily and SAMtools in each family following filtering. *Predicted as possibly delirious (or equivalent) by Polyphen2, MutationTaster 
and LRT; or an indel. **Candidates retained was not predicted as deleterious by all pathogenicity predictors. † Candidate was not found by BAMily.
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Family ID Position  Nucleotide and amino acid change 
(transcript)* 
Gene Validated 
Family 1 chr3:19479731 c.G1253A:p.R418Q (ENST00000328405) KCNH8 Yes 
 chr8: 11412934 c.G713A:p.R238Q  (ENST00000259089) BLK Yes 
 chr17:11572991 c.T3233G:p.I1078S (ENST00000262442) DNAH9 No 
Family 2 No candidates  
Family 3 chr16:88792738 c.C3922G:p.L1308V (ENST00000301015) PIEZO1 No 
Family 4 chr4:114276906 c.G7132A:p.E2378K  (ENST00000357077) ANK2 No 
 chr22:19213864 c.G1825A:p.D609N (ENST00000427926) CLTCL1 In progress 
Family 5 chr3:193855858 c.G679A:p.G227S (ENST00000232424) HES1 In progress 
 chr5:42700088 c.A602G:p.E201G (ENST00000230882) GHR No 
 chr5:118556760 c.G7679A:p.G2560D (ENST00000311085) DMXL1  No 
 chr6:87969514 c.C6167A:p.S2056Y (ENST00000369577) ZNF292 No 
 chr6:105609396 c.C389T:p.A130V (ENST00000254765) POPDC3 In progress 
Family 6 chr9: 139409980 c.G1858T:p.D620Y (ENST00000277541) NOTCH1 Yes 
Family 7 No candidates  
Family 8 chr2: 27427777 c.C757T:p.253W (ENST00000310574) SLC5A6 Yes 
 chr2: 29383269-
29383270 
c.1470_1471del:p.R490fs 
(ENST00000320081) 
CLIP4 Yes 
 chr5:1681999 c.G1324A:p.D442N (ENST00000332966) SLIT3 Yes 
Table 8. List of candidates selected for validation work from BAMily and SAMtools analysis. *For brevity, 
variant is shown for one transcript only. 
 In Family 1, I rediscovered three missense variants found in a previous analysis in genes 
KCNH8, BLK and DNAH9. All three were detected by SAMtools and BAMily. LRT was 
unable to produce a pathogenicity prediction for the variant in BLK, but both Polyphen2 
and MutationTaster predicted the variant to be deleterious. I sent the candidates for 
validation and two were found to be genuine variants, as show in Table 8. The variant in 
BLK was of particular interest. A review of the literature on BLK reveals that the gene 
coincides with a region previously associated with keratolytic winter erythema (KWE) 
(Appel et al., 2002). Beyond the fact that both KWE and HSP are skin disorders, they 
share similar symptoms such as the high skin pigmentation; or hyperkeratosis, and 
sclerosis of the hands and feet (Appel et al., 2002; Mercier et al., 2013). A parallel 
investigation of this family had found evidence that the variant causing HSP in Family 1 
was in the gene FAM111B (Mercier et al., 2013). The evidence supporting a causative 
role for the FAM111B variant was the presence of two more variants, including one de 
novo variant, in the same gene in four unrelated families exhibiting a similar phenotype 
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(Mercier et al., 2013). The FAM111B variant reported in that paper was not retained in 
my analysis, as it was predicted to be benign by the pathogenicity predictor 
MutationTaster. Nonetheless, this variant was detected by both BAMily and SAMtools. 
Despite these findings, BLK could still play a role in the disease, possibly as a phenotypic 
modifier. Study of the additional families with this very rare disorder would be necessary 
to test this hypothesis. ExomeDepth did not reveal any CNV candidates. 
In Family 2, BAMily and SAMtools found few variants both rare and predicted 
deleterious. In SAMtools, the only rare variant found to be deleterious by Polyphen2, 
LRT and MutationTaster had been identified in previous analyses, but had failed 
validation through Sanger sequencing. BAMily identified 25 rare variants segregating 
with disease but 15 were predicted to be benign by all pathogenicity predictors. 
Furthermore, several variants occurred within the same set of genes, suggesting false 
positives. For example, 13 variants were all found in killer cell immunoglobulin-like 
receptor (KIR) genes in a region known for being highly polymorphic (Middleton and 
Gonzelez, 2010). No candidates were retained. No rare CNVs were found to be shared 
between individuals. 
In Family 3, BAMily and SAMtools also found few variants when all filters were applied. 
BAMily identified 43 rare indels, but most were clearly false positives based on allele 
frequency in calls and further inspection in IGV. I therefore looked for rare variants 
predicted to be deleterious by at least one pathogenicity predictor. I selected a missense 
variant discovered through SAMtools in PIEZO1 and predicted to be deleterious by 
MutationTaster and Polyphen2. This variant was not found through BAMily. The gene 
encodes an ion channel protein which could play a role in vascular development (Ranade 
et al., 2014). Validation work revealed that the variant was present in only 4 of the 5 
sequenced individuals. The clinical genetics team responsible for the care of this family 
have since discovered a deletion spanning the entire length of SCN5A in all carriers 
(personal communication). SCN5A is the principal causative gene for BrS (Brugada et al., 
1993). This gene-wide deletion could not have been identified with the SNV-focused 
methods used in the comparison between variant callers. However, CNV analysis using 
ExomeDepth did corroborate this finding in all five carriers, with one notable distinction: 
the CNV was found to span the entire length of two genes rather than one, SCN5A and 
SCN10A. The latter has also been implicated in cases of BrS (Hu et al., 2014). Also, 
although deletions spanning SCN5A have been reported in BrS, deletions spanning both 
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SCN5A and SCN10A have not. The cardiac electrophysiology phenotype of the family 
was noted to be atypical for BrS; whether this reflects haploinsufficiency of both SCN5A 
and SCN10A will be the subject of further investigation.  The deletion also stretched 
across the last exon of the gene EXOG, a gene previously not thought to be involved in 
BrS. 
In family 4, given the difficulty in ascribing a mode of inheritance for the putative variant, 
I only filtered out homozygous reference genotypes, accepting any variant found in both 
sequenced individuals. I rediscovered a missense variant in ANK2 from a previous 
analysis through both SAMtools and BAMily. The gene is not known for playing a role in 
cardiogenesis, but has been associated with long-QT syndrome. However, the variant 
failed validation. Another particular missense variant stood out, being located in CLTCL1. 
This was again detected by both SAMtools and BAMily. 22q11.2 deletion syndrome 
typically encompasses CLTCL1 among other genes, suggesting that it could play a role in 
some of the phenotypes observed in patients with the syndrome (Michaelovsky et al., 
2012). CHDs present in patients with 22q11.2 deletion syndrome can include IAA and 
VSD (Kobrynski and Sullivan, 2007). ExomeDepth did not reveal any CNV candidates. 
In Family 5, I rediscovered three missense variants from one of my previous analyses. 
The variants were detected by both callers. The variants in GHR, DMXL1 and ZNG292 
respectively, failed to validate. I also found new candidates, again with both callers. I 
found a missense variant in HES1 predicted deleterious by MutationTaster, LRT and 
Polyphen2. HES1 in mouse is expressed in the second heart field during cardiogenesis 
and is essential for outflow tract development (Rochais et al., 2009). Loss of the gene in 
mice led to a displacement of the aorta over ventricles and a VSD (Rochais et al., 2009). I 
also found another missense variant in POPDC3 which, despite only being predicted to 
be deleterious by LRT was nonetheless of interest as it shares sequence similarity with 
BVES which is associated with another conotruncal defect, Tetralogy of Fallot; see 
chapter 5 (Wu et al., 2013). Both these genes were discovered based on a chick gene 
ortholog which is preferentially expressed during chick cardiogenesis (Andree et al., 
2000). HES1 and POPDC3 are now awaiting validation. No candidate CNVs were found.  
Given the difficulty in applying a carrier status to parents in Family 6, I ran BAMily 
twice for this family, each time with one of the parents identified as a disease carrier. 
Despite the large number of rare variants detected as a result, one candidate stood out due 
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to the family’s MAPCA phenotype. From the analysis in which the mother was predicted 
to be a disease-carrier, a missense variant in NOTCH1 was found in the two siblings and 
the mother by both BAMily and SAMtools. The variant was predicted as deleterious by 
all pathogenicity predictors. NOTCH1 is part of the Notch signalling pathway which 
plays a key role in cardiogenesis (Niessen and Karsan, 2008). MAPCA has been 
identified as a secondary cardiac anomaly in patients with ToF harbouring a JAG1 
mutation (McElhinney et al., 2002). This is significant as JAG1 is part of the Notch 
signalling pathway (Niessen and Karsan, 2008). In NOTCH1, mutations have been 
reported as causing a range of aortic valve diseases (Garg et al., 2005). No candidate 
CNVs were found. 
Few variants were found by SAMtools and BAMily together in Family 7, none of which 
were convincing candidates. BAMily detected 51 rare variants predicted to be deleterious 
by MutationTaster, Polyphen2 and LRT. However, 30 were indels, most of which were 
likely false positives; which I determined using IGV. Multiple variants were found in the 
same genes. For example, 9 missense variants were found in CTBP2 suggesting these 
were false positives. No candidates were retained. Additionally, no large rare CNVs were 
found to be shared among them. 
In Family 8 both lists of variants predicted to be deleterious shared 3 variants, which 
corresponded to the candidates selected. Three candidates, in CLIP4, SLC5A6 and SLIT3 
respectively were validated. The variant in CLIP4 was a frameshift deletion. The gene is 
expressed in vascular endothelial growth factor-induced embryoid bodies (Rebhan et al., 
1998). The other two candidates are missense variants predicted to be deleterious by all 
pathogenicity predictors. SLC5A6 is a sodium-dependent multivitamin transporter 
(Rebhan et al., 1998). It has been found to be expressed in the embryonic mouse heart at 
E14.5. SLIT3 is expressed in cardiomyocyte-like progenitor cells (Rebhan et al., 1998). It 
is also expressed in rat vascular smooth muscle cells. Mice with a disrupted Slit3 gene 
show right ventricular hypertrophy (Eppig et al., 2015). No candidate CNVs were added 
to this list. 
3.5. Discussion 
3.5.1. BAMily performance 
I assessed five different variant callers: SAMtools, GATK, GATK+FamSeq, 
GATK+Polymutt and BAMily. By comparing genotype and sequence data, I estimated 
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the sensitivity and specificity of each of these variant callers given sequence data from 
three to five individuals, with different degrees of relatedness. For each variant caller, I 
recorded the total running time required to call variants for five individuals. For GATK, 
crucial pre-calling steps such as base quality score recalibration were factored into 
running time measurements. 
When comparing standalone variant callers; SAMTools, BAMily and GATK, the latter 
two presented the best balance between sensitivity and specificity overall. The variant 
callers that rely on GATK, FamSeq and Polymutt, would typically be expected to build 
on GATK's sensitivity and specificity advantage, providing a marked improvement in at 
least one metric without significantly affecting the other. However, my tests revealed a 
different picture. Figure 18 and Table 5 and Table 6 show a gain of sensitivity when 
FamSeq was applied to GATK output in most of the scenarios I tested, but at the expense 
of specificity. The GATK+FamSeq calling strategy produced the lowest specificity across 
all five callers tested. With Polymutt, the gains for the scenarios we have tested were even 
less clear. Polymutt provided a slight advantage in specificity overall, best illustrated in 
Figure 18, but in many cases, GATK specificity remained unchanged where Polymutt 
was applied. The overall sensitivity attributed to Polymutt was lower than GATK's, as is 
apparent in Table 5. For the scenarios shown in Table 6 sensitivity remained unchanged 
whether PolyMutt was applied or not, with only one exception. From these measurements, 
I conclude that, for the scenarios explored, Polymutt and FamSeq do not lead to an 
improvement of the results already produced by GATK. 
With data from five individuals, BAMily and SAMtools were able to produce variant 
calls in less than 9 hours running on a single core. By contrast, GATK's genotyping step 
alone required a similar amount of time to run on four cores. To this running time must be 
added that of recalibration and realignment steps that preceded genotyping and that also 
required multiple cores in order to run smoothly. GATK's total core running time was 
largely in excess of what was observed for SAMtools and BAMily. Thus, SAMtools and 
BAMily present a substantial running time advantage over GATK. 
While SAMtools and BAMily present running times that fall within the same range, 
BAMily had an overall higher sensitivity and specificity. Accounting for running time, 
sensitivity and specificity together, BAMily presents a discernible advantage over GATK 
as well. While GATK and BAMily have comparable sensitivities and specificities across 
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a number of scenarios, BAMily is able to deliver results in substantially less time. With 
my approach thus provides an advantageous balance between sensitivity, specificity and 
running time. Studies that aim to uncover variants present in one set of individuals and 
absent in another can greatly benefit from variant calling following this approach. 
3.5.2. BAMily’s usage in the analysis of 8 families 
The design and implementation of a new approach to variant calling provided an 
opportunity to re-analyse families for which samples were sequenced, but no disease-
causing candidates were found. Having undergone several rounds of analysis with no 
success, many of these cases are likely to remain unresolved with current WES 
approaches. Gilissen et al. (2012) reported a similar experience, with 60% of their WES 
projects centred on Mendelian disease leading to the discovery of causal variants, leaving 
many cases unresolved. However, some families could be elucidated with the shifts in 
approach that a variant caller such as BAMily can provide.  
Using BAMily and SAMtools to analyse these 8 families revealed candidates in 5 out of 8 
families. At the time of writing, many validations are still in progress (performed by 
laboratory colleagues and not part of my thesis work). However, for two families, 
candidates have already been succesfully validated. In Family 1, this is the case for a 
variant in BLK. The gene in which the mutation was found has been implicated in the 
development of KWE, which shares characteristics with HSP (Appel et al., 2002). As 
mentioned briefly in Section 3.4.5, a candidate in FAM111B was found through a cross-
collaboration predating my analysis. This variant had been missed from several analyses 
as it was classified by MutationTaster as benign. The presence of two other variants in the 
same gene in four distinct families with HSP provided evidence that the gene was 
probably misclassified (Mercier et al., 2013). Although this variant appears to be the 
likeliest cause of HSP in Family 1, there is still room to consider the variant in BLK as a 
candidate or a contributing factor to the disease. In Family 8, three variants were 
validated, in SLIT3, CLIP4 and SLC5A6. Of particular interest is the variant in SLC5A6; 
solute carrier family 5 member A6, as another gene encoding for a solute carrier, 
SLC25A3, has previously been implicated in cardiomyopathy (Mayr et al., 2007). 
Demonstrating the disease-causing potential of any of the candidates listed in Table 7, 
through experimental assays for example, would provide further validation for the new 
approach to variant calling proposed implemented with BAMily. 
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3.6. Conclusion 
In this chapter, I designed and programmed a new variant caller; BAMily, based on a new 
approach to variant calling. This approach focuses on detecting variants that are 
distributed in a specific way among a group of individuals. As such, it is primarily 
targeted at pedigrees. I evaluated the performance of the caller against other available 
programmes and confirmed it had comparable; and occasionally higher, accuracy coupled 
with its reduced computation demand. I incorporated the caller to a WES analysis of eight 
families for which previous analyses using older approaches had been unsuccessful. The 
use of the new caller resulted in the identification of strong candidate genes in two 
families that will require biological validation in future work. This completely new 
approach to variant calling will also be useful for future WES studies. 
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Chapter 4. De novo mutations in transposition of the great arteries
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4.1. Summary 
Transposition of the great arteries (TGA), while being one of the more common and 
severe forms of CHD, still remains poorly understood. The absence of familial precedents 
for the disease (in particular, relatively low sibling recurrence risks) has led to the 
hypothesis explored in this chapter that the manifestation of TGA in these individuals is 
the result of single, rare, large effect, de novo mutations. The following study focuses on 
the identification of de novo variants via whole-exome sequencing and analysis of family 
trios and one quartet. With this study I attempt to identify genes that play a role in normal 
development of the great arteries and that, when mutated, predispose to TGA. Three 
different variant callers are used towards fulfilling these aims: SAMtools, GATK and 
BAMily, with the latter acting as a filter. The variants called as a result are the main focus 
of the study. 
4.2.  Introduction 
4.2.1. Transposition of the great arteries. 
As briefly described in chapter 1, TGA is one of the most common and severe forms of 
CHD, but its origins remain poorly understood (Unolt et al., 2013). With an incidence of 
0.2 per 1,000 live births, it is the fourth most common CHD (Unolt et al., 2013; Saremi, 
2014). Untreated, TGA carries a 95% mortality rate in the first year of life (Saremi, 2014). 
Isolated cases represent half of all TGA while cases accompanied by extra cardiac defect 
account for 10% of all TGA (Martins and Castela, 2008). TGA takes on a number of 
forms, but can be broadly categorised as either dextro-transposition of the great arteries 
(D-TGA) or levo-transposition of the great arteries (L-TGA).   
D-TGA is the most frequent form of TGA. Patients with D-TGA have switched arteries 
arising from the ventricles (Saremi, 2014). The aorta arises from the right ventricle, while 
the pulmonary artery arises from the left ventricle. This creates two separate circuits, with 
oxygen-poor blood circulating around the body while oxygen-rich blood is continually 
recirculated to the lungs. In a little over half of D-TGA cases, the pulmonary artery and 
aorta run parallel to each other instead of crossing as they would in a normal heart 
(Saremi, 2014). 
 76 
 
 
Figure 20. Dextro-transposition of the great arteries (D-TGA). In the above case, the TGA is accompanied by an 
ASD and PDA. Arrows indicate blood flow.  Abbreviations: RA: right atrium, RV: right ventricle, LA: left 
atrium, LV: left ventricle, SVC: superior vena cava, IVC: inferior vena cava, MPA: main pulmonary artery, Ao: 
aorta, TV: tricuspid valve, MV: mitral valve, PV: pulmonary valve, AoV: aortic valve. ASD: atrial septal defect, 
PDA: patent ductus arteriosus. Image from the Centers for Disease Control and Prevention, National Center on 
Birth Defects and Developmental Disabilities available at: http://www.cdc.gov/ncbddd/heartdefects/TGA.html 
L-TGA is the rarer form of TGA, accounting for less than 1% of all CHDs (Warnes, 
2006). Patients with L-TGA have both switched arteries and atria. As a consequence, 
normal blood flow is maintained (Warnes, 2006). For this reason, L-TGA is also 
commonly referred to as congenitally-corrected TGA (C-TGA). 
The exact mechanisms at work during embryological development that lead to TGA 
remain largely unknown (Unolt et al., 2013). Two theories have been advanced on the 
subject. One theory, proposed by Goor and Edwards (1973),  describes TGA as the result 
of an incomplete rotation of the aorta around the body’s vertical axis, towards the left 
ventricle. The arteries find themselves aligned over the wrong ventricular outflow tracts. 
This theory is inspired by Goor’s own observations on human embryos (Goor et al., 
1972).  Goor and Edwards’ theory also accounts for various other conotruncal defects, 
such as double outlet right ventricle (DORV) and tetralogy of Fallot (ToF). These defects 
also present a displacement of the arteries relative to the ventricles. In patients with 
DORV, the aorta and pulmonary artery arise from the right ventricle (Obler et al., 2008). 
In patients with ToF, described in chapter 1 and chapter 5, the aorta is displaced over both 
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ventricles while the pulmonary artery is stenotic (Nelson et al., 2014). According to this 
theory, each distinct defect is the product of the same incomplete rotation, arrested at 
different stages of development, with TGA representing the most extreme end of the 
spectrum (Unolt et al., 2013). Another theory, proposed by De la Cruz et al. (1977) sees 
TGA as the result of an abnormal development of the wall that separates the developing 
aorta and pulmonary artery. Instead of developing as a normal spiral, it develops linearly, 
the future aorta positioning itself above the right ventricle, leading to TGA. A recent 
study by Bajolle et al. (2006) lends more credibility to the first theory. By studying mice 
with mutated Splotch and Pitxc2δc genes, the authors were able to experimentally 
associate conotruncal defects with the arrested rotation of the aortic outflow tract.  
A number of environmental risk factors are thought to contribute to the development of 
TGA. Martins and Castela (2008) point to maternal exposure to a number of teratogens; 
rodenticides, herbicides and antiepileptic drugs, and maternal diabetes as some risk 
factors. Maternal diabetes,  has been identified as a risk factor for CHD in general (Wren 
et al., 2003). Wren et al. (2003) report a 5-fold increase of CHD in newborns with 
diabetic mothers. However, maternal diabetes is especially relevant to TGA. TGA 
represents 14.4% of all CHD in newborns with diabetic mothers (Wren et al., 2003). In 
this case, Wren et al. (2003) report a 17-fold increase in TGA in newborns with diabetic 
mothers (Wren et al., 2003). Other environmental risk factors associated with TGA 
include maternal infection, ingestion of ibuprofen and exposure to ionising radiation 
during pregnancy and in vitro fertilisation (Unolt et al., 2013).  
The genetic underpinnings of TGA remain largely unresolved. Unlike many other CHDs, 
TGA is rarely observed in association with a chromosomal defect (Fahed et al., 2013). 
Because of the extremely high and early mortality rate associated with the disease 
preceding recent surgical advances (Saremi, 2014), variants that contribute to disease risk 
are unlikely to be common in the population. For common variants to influence TGA risk 
would require some form of balancing selection given the deleteriousness of the disease. 
Additionally, highly penetrant dominant variants are unlikely to be passed on. Familial 
cases of the disease are thus expected to be particularly rare. 
In the study by Burn et al. (1998) first mentioned in chapter 1, no cases of parent-
offspring TGA were reported. Burn et al. (1998) suggest therefore that TGA is a sporadic 
defect. However, in their comment on the study, Digilio et al. (1998)  point to several of 
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their studies that support Mendelian inheritance of TGA in a select number of cases. In 
one such study, Digilio et al. (2001) found recurrence risks of CHD of 0.5% and 1.8% in 
parents and siblings of patients with TGA. The authors propose that some of this risk can 
be explained as cases of monogenic or multigenic inheritance. These few possible 
examples of familial TGA establish some genetic basis for the disease. However, the 
majority of TGA cases are sporadic (Digilio et al., 2001). Given these facts, it can be 
hypothesised that de novo mutation may play a substantial role in accounting for sporadic 
TGA. 
TGA is rarely accompanied by extracardiac defects, with the exception of laterality 
defects (Unolt et al., 2013). TGA has been reported in cases of heterotaxy, a disease 
where organs develop on the opposite side of the body leading to a host of morphological 
defects (De Luca et al., 2010). TGA has been frequently reported as part of asplenia 
syndrome, a type of heterotaxy characterised by the absence of a spleen (Unolt et al., 
2013). In mice, knockouts of Smad2 and Nodal genes lead to TGA, with an added right 
pulmonary isomerism; where the morphology of the left lung takes on characters of the 
right lung, usually in more than half of cases (Unolt et al., 2013). The association 
between laterality defects and TGA has led researchers to study genes involved in 
establishing the left-right body plan in isolated TGA cases (Goldmuntz et al., 2002; De 
Luca et al., 2010). A study by De Luca et al. (2010) found mutations in FOXH1, ZIC3, 
NKX2.5 and NODAL in familial TGA cases. CFC1 has also been implicated in patients 
exhibiting TGA (Goldmuntz et al., 2002). A recent study of 362 cases of severe CHD 
included 47 patients with TGA (Zaidi et al., 2013). Three de novo variants were 
uncovered in TGA patients: one in a known laterality gene, SMAD2, and two in genes not 
previously-associated with TGA or laterality defects, NAA15 and RAB10. The WES study 
presented in this chapter is focused entirely on TGA. The probands used for the study 
comprise 32 patients exhibiting the disease. There is no previous family history of CHD 
in any of these cases. This leads to the hypothesis that the disease phenotype is brought 
about by single rare large effect de novo mutations. 
4.2.2. Family-based WES for uncovering de novo mutations  
Each individual is born with several variants that they do not share with either of their 
parents. Such mutations arise in the parental gametes, and occasionally during early 
embryonic development, and are referred to as de novo (Ku et al., 2012). Before the 
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advent of NGS, estimates of the rate of de novo per base mutation in a single genome for 
a single generation varied between 1.1×10
-8
 and 3×10
-8
 
 
(Conrad et al., 2011). Using 
WGS, Conrad et al. (2011) provide a similar, yet more accurate, per base estimate of 
1.18×10
-8
. This translates to an average of 74 new single nucleotide variants (SNVs) per 
newborn, with variation in rate between individuals found to be correlated with paternal 
age (Kong et al., 2012; Veltman and Brunner, 2012b). With a genome that spans over 3 
billion base pairs, any two unrelated individuals are exceedingly unlikely to share a de 
novo variant. De novo mutations will also tend to be more deleterious on average, having 
not been subjected to selection over multiple generations (Veltman and Brunner, 2012b). 
This leads Veltman and Brunner (2012b) to conclude that de novo mutations are the likely 
source of many sporadic disease cases. 
An estimated 85% of all deleterious mutations are expected to lie in the protein-coding 
regions contained in the human exome, which itself covers 1% of the genome (Majewski 
et al., 2011). Using the figures above, we can estimate the rate of de novo variants in the 
exome to be 0.74 on average per newborn. An earlier estimate by Robinson (2010) placed 
that figure at around 0.89. However, these mutations are expected to play a significant 
role in non-inherited; or sporadic, disease (Veltman and Brunner, 2012b). De novo 
variants are more deleterious on average than inherited variants, that have been subject to 
natural selection over many generations (Veltman and Brunner, 2012b). A single de novo 
could therefore be responsible for a sporadic disease in an individual.  
Both de novo CNVs and SNVs contribute to the risk of a number of neurodevelopmental 
diseases, such as autism spectrum disorder (AD) and schizophrenia. In chapter 1, I 
described one study by Sanders et al. (2012) which revealed an excess of non-
synonymous de novo variants in 238 patients with autism spectrum disorder (AD) when 
compared with 200 healthy siblings. Focusing on truncating de novo variants in genes 
expressed in the brain revealed a large contrast, with an odds ratio of truncating to 
synonymous variant in cases and controls of 5.65. A more recent example, a large-scale 
study of de novo variants in 1,078 AD patients compared with 343 unaffected siblings, 
revealed an excess of genes with more than two de novo non-synonymous variants in 
patients (Samocha et al., 2014). Samocha et al. (2014) compare their results against a 
model of the rate of de novo mutation per gene; with the rate of mutation overall and in 
functional subsets factored in as well, for each variant type. The number of mutation 
events in healthy siblings was found to fit the model. However, an excess of truncating 
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variants was found in AD patients. Furthermore, an excess of genes with at least 2 de 
novo mutations was found in AD patients for all variant types except synonymous 
variants. Here again, results from the healthy siblings fit the model’s expectations. These 
findings strongly implicate de novo mutation affecting specific protein-coding genes in 
the development of sporadic AD. One study of AD by O’Roark et al. (2012b) was able to 
establish a paternal bias in de novo variants, accounting for the increase of AD risk with 
paternal age using a combination of gene sequencing. O’Roark et al. (2012b) sequenced 
the exome of 209 trios and 50 unaffected siblings, using markers for haplotype phasing to 
determine the origin of de novo variants. Studies suggest that de novo variants could also 
play a role in the manifestation of schizophrenia (Xu et al., 2011). While schizophrenia 
shows a strong familial preponderance, patients with no family history have been reported 
(Xu et al., 2011). Several studies of schizophrenia have focused on the contribution of de 
novo copy number variants (CNV) to the disorder, including one study by Xu et al. (2008) 
which found that de novo CNVs were 8 times more frequent in 152 schizophrenia patients 
then in 159 unaffected patients. To identify de novo SNVs potentially contributing to 
sporadic cases of schizophrenia, Xu et al. (2011) sequenced the exome of 53 parents-
offspring trios; in which only the offspring had schizophrenia, and 22 unaffected trios. Xu 
et al. (2011) found a large excess of non-synonymous de novo variants in patients with 
schizophrenia compared with healthy controls. They also found a ratio of de novo non-
synonymous variants to de novo synonymous variants in the case population exceeding 
what would be expected in the general population. It remains difficult to demonstrate 
which particular de novo variants contribute to these neurodevelopmental disorders, 
particularly if the genes have not previously been implicated in the disease. However, in 
all these studies, the excess of non-synonymous variants; especially truncating variants, 
strongly suggest an important role for de novo variants in these pathologies. 
For CHD, the role of de novo mutation has been investigated in a study conducted by 
Zaidi et al. (2013). The authors have chosen to focus on severe sporadic CHD cases; 
which include TGA cases. Presumably, this choice was operated under the assumption 
that severe cases would be more likely to be caused by de novo variants. The authors 
selected 4,169 genes known to be highly expressed during mouse cardiogenesis and 
compared the incidence of de novo variants in gene orthologs in 362 severe CHD patients 
and 264 controls originating from parent-offspring trios. Zaidi et al. (2013) uncovered a 
significant excess of de novo changes; both synonymous and non-synonymous, in the 
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selected genes in CHD cases compared to controls. The contrast between cases and 
controls was more pronounced for truncating variants, amounting to an odds ratio of 7.5. 
This excess was particularly pronounced in histone-modifying genes. Many of the genes 
in which de novo variants were found involved the writing, removing and reading of 
histone methylations. This class of genes is known for its regulation of gene expression 
(Bruneau and Srivastava, 2014). Mutations in those genes could therefore have far-
reaching consequences on cardiac cell differentiation, potentially leading to many of the 
defects observed in CHD patients (Bruneau and Srivastava, 2014). Based on the rate of 
non-synonymous de novo variants in these gene orthologs in cases compared to controls, 
Zaidi et al. (2013) put forward the idea that de novo mutation contributes 10% of severe 
CHD (95% confidence interval: 5-15%). Ultimately, this estimate relied on similarities in 
high gene expression during cardiogenesis between mice and humans and could therefore 
be an underestimate (Zaidi et al., 2013). It is also important to emphasise here that this 
conclusion pertains only to severe CHD. In a commentary, Bruneau and Srivastava (2014) 
reported this last conclusion by Zaidi et al. (2013) as applicable to sporadic CHD in 
general. However, it is possible that de novo mutation does not play as great a role in 
milder forms of sporadic CHD. 
The study of putative de novo mutations underlying genetic diseases requires the 
sequencing of disease patients and their unaffected parents (Bamshad et al., 2011). For 
rare genetic diseases, it is possible to first identify potentially de novo candidate 
mutations in cases via WES and then confirm which mutations are de novo via gene-
targeted Sanger sequencing of the entire family trio or by using modified molecular 
inversion probes (O'Roak et al., 2012a). An early study by Hoischen et al. (2010) 
illustrates this practice with the WES of four patients with Schinzel-Giedion syndrome. 
Patients with Schinzel-Giedion syndrome present severe mental retardation, distinctive 
facial features and several organ and bone abnormalities (2010). In each of the four 
patients, Hoischen et al. (2010) uncovered a variant at a different locus in SETBP1. 
Confirmation of the variant and its de novo nature was obtained through targeted 
sequencing of the corresponding family trios. Hoischen et al. (2010) also used targeted 
sequencing on eight more cases, revealing additional variants, the total set clustering 
within an 11bp exonic region. However, locus heterogeneity is common in genetic 
disease, whereby mutations occurring in distinct genes lead to the same disease trait 
(Veltman and Brunner, 2012b). In this context, the putative disease-causing de novo 
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mutations in individuals exhibiting a shared disease phenotype could be located in 
different genes, making it difficult to pick out likely candidate genes. Studies involving a 
disease trait for which locus heterogeneity is suspected call for entire trios to be analysed 
via WES. Neurodevelopmental disorders illustrate the fact that de novo mutations at 
different loci can lead to the same trait (Hoischen et al., 2014). Hoischen et al. (2014) 
report that schizophrenia could be the product of mutation in more than 500 distinct genes. 
The first study involving the WES of parent-offspring trios was performed by Vissers et 
al. (2010) and centred around 10 patients with sporadic mental retardation. De novo non-
synonymous variants were identified in 9 genes, with six variants retained as probably 
disease-causing based on functional evidence. Crucially, these six de novo variants were 
all found in distinct genes. The CHD study by Zaidi et al. (2013) previously mentioned 
provides another example of locus heterogeneity. A total of 37 genes in cases were found 
to harbour potentially disease-causing de novo variants, with 34 genes harbouring only 
one variant. Furthermore, the authors estimate to total number of disease-associated genes 
to be around 400. 
The following study involves 32 patients exhibiting TGA. By sequencing the 31 
corresponding parent-offspring trios as well as a single nuclear family of four (the 
additional sibling being unaffected), I seek to uncover de novo mutations potentially 
responsible for triggering TGA. Multiple variant callers are enlisted for this purpose, 
producing a consensus list of candidate variants. For those variants most likely to be 
pathogenic, validation work was performed by colleagues based in the laboratory. Several 
layers of annotation, data-mining and pathway analysis are used to elucidate a potential 
association between each variant and TGA. 
4.3. Methods 
The sequencing of the samples required for this study was shared between three institutes: 
Newcastle’s Institute of Genetic Medicine (IGM) and the Glasgow Polyomics (GP) 
research facility in the United Kingdom and the The McGill University and Génome 
Québec Innovation Centre (MUGQIC). The share of sequencing was distributed as shown 
in Table 9. Target enrichment was performed using Agilent’s SureSelectXT Human All 
Exon 50Mb kit V4 (Agilent Technologies, 2015). The quality control applied to 
sequencing does not differ from what was described in Chapter 2. 
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Institute 
Patients 
sequenced 
families complete 
after sequencing 
First sequencing 
run date 
Last sequencing 
run date 
IGM 43 12 23/08/2012 08/03/2013 
GP 24 22 16/05/2013 25/07/2013 
MUGQIC 30 32 05/03/2014 20/10/2014 
Table 9. Distribution and duration of WES for institutes involved. Sequencing was spread across the duration of 
the PhD. 
The sequencing of 32 families was spread across the entire PhD project. As such, I have 
re-analysed families on multiple occasions, prompting progressive refinements to the 
methods used. For the purpose of this thesis however, I will focus primarily on the 
methods used in my final analysis. 
I performed sequence alignment for 97 samples using the aligner BWA v0.7.4 (Li and 
Durbin, 2009). Originally, I used NovoAlign v2.7.13 (Novocraft, 2014b). However, 
NovoAlign’s main advantage, namely its higher sensitivity, comes at the price of a longer 
running time (Novocraft, 2014a). With the significant number of individuals involved in 
this study and limited computing resources at first, I eventually selected BWA v0.7.4 (Li 
and Durbin, 2009) over NovoAlign. For consistency, I re-aligned the few samples 
originally aligned using NovoAlign with BWA. I removed duplicates using Picard (The 
Broad Institute, 2015c). 
During the project, I used three different variant callers to identify variants present in the 
aligned sequence samples: 
 SAMtools V0.1.18 (Li et al., 2009a) 
 GATK UnifiedGenotyper v.2.2.9 (DePristo et al., 2011) 
 BAMily (For more details, see chapter 3) 
SAMtools and GATK UnifiedGenotyper were used to create a consensus list of high-
confidence variants. There are some discrepancies between variant callers, even when 
only high-confidence variants are considered (O'Rawe et al., 2013). These discrepancies 
are particularly evident with indels which are generally more difficult to detect than 
SNVs (O'Rawe et al., 2013). The assumption here is that variants reported by two widely-
used callers are more likely to reflect the existence of actual variants. Consensus between 
callers therefore serves as a final quality filtering criterion for candidate variant selection. 
BAMily’s strength resides in its ability to detect variants present across multiple samples 
 84 
 
and absent across others, even if the evidence for occurrence in single samples is weak. 
Using BAMily to detect variants present in a single proband will produce many more 
false positives than in SAMtools and GATK. However, BAMily can help with the 
exclusion of false positives that arise from variants being called incorrectly in parents. In 
this study, BAMily therefore plays the role of a filter. The process by which BAMily calls 
variants across multiple samples is described in chapter 3. The consensus between 
SAMtools and GATK, with the filtering step provided by BAMily, results in a final 
consensus list of variants. 
I performed variant calling using SAMtools and BAMily by family unit. For each variant 
site, SAMtools assigns a genotype to each member of the trio. I searched variant sites at 
which the genotypes were consistent with a de novo variant in the offspring. In other 
words, I selected variant sites where the offspring was predicted to be heterozygous for 
the variant while both parents were predicted as homozygous for another base, most 
likely the reference. BAMily does not require this filtering step, as the expected variant 
assignment for each individual must be established prior to variant calling, as discussed in 
chapter 3. I therefore set BAMily to provide calls for variants present in the offspring, but 
absent in parents; and sibling in the quartet. With GATK’s UnifiedGenotyper, all aligned 
samples were called for variants in a single run. As detailed in chapter 2, variant calling 
with the UnifiedGenotyper is preceded by a number of realignment and recalibration 
steps. As with SAMtools, I filtered for variant sites for which the genotype assignment 
suggested a de novo variant. For all variant callers, variants outside the exome target 
regions were excluded. As described in chapter 2, I only considered variants that passed 
the high-confidence quality threshold Q30. As variants found to be de novo are unlikely 
to reoccur in any of the other trios, I excluded variants found in any of the 32 pairs of 
parents and the unaffected offspring. 
The resulting variants were then annotated using ANNOVAR (Wang et al., 2010). 
Variants were retained if they represented non-synonymous changes in an exonic or 
splice region and were rare. A variant was considered rare if it had a minor allele 
frequency (MAF) of <1% according to both the 1000g (Abecasis et al., 2012) and the 
NHLBI Exome Sequencing Project (ESP) (NHLBI, 2015) population databases. In 
addition to the population databases from ANNOVAR (Wang et al., 2010), an in-house 
list of variants detected in previous exome studies; totalling 418 exome sequences, helped 
to exclude more variants from the list. 
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The filtered list of variants detected by SAMtools and GATK produced several candidates. 
Candidates were further prioritized depending on the consensus of multiple functional 
prediction tools. Originally, these were limited to MutationTaster (Schwarz et al., 2010) 
and Polyphen2 (Adzhubei et al., 2010), but LRT (Chun and Fay, 2009) and 
MutationAssessor (Reva et al., 2011) were eventually incorporated into the analysis. The 
full list of prioritised variants is presented in the Section 4.4. 
The Integrative Genomics Viewer (IGV) (Thorvaldsdottir et al., 2013) provided an 
additional tool for inspecting candidates and eliminating variants in high repeat regions or 
indels that appeared to be artefacts when viewed in their full sequencing context. This 
was followed by a review of the genes candidate variants appeared in, using the Online 
Mendelian Inheritance in Man (NCBI, 2015) database as well as several resources housed 
by the GeneCards compendium (Rebhan et al., 1998). Variants selected as candidates 
were communicated to colleagues (see acknowledgments) at the IGM and at Manchester 
University’s Institute of Cardiovascular Sciences for validation through Sanger 
sequencing. 
I investigated the genes in which de novo variants were found using a number of pathway 
analysis tools. I first analysed genes in STRING v.10 (Jensen et al., 2009), followed by 
EnrichNet (Glaab et al., 2012). STRING provides a method for evaluating and visualising 
potential functional links between proteins (Jensen et al., 2009). The functional links are 
built around several categories of evidence; represented as color-coded edges in 
STRING’s network view, that tie the activity of two proteins; or their putative homologs 
in other species, together (Jensen et al., 2009). Evidence in each category is accompanied 
by a confidence score which adds up to a combined score; on a scale from 0 to 1. 
Functional links with a score above 0.4 are represented as edges in STRING’s network 
view (Jensen et al., 2009). I looked at the functional links between the protein products of 
the genes from my final list of variants. Additionally, I looked for enrichment in gene 
ontology (GO) terms (Gene Ontology, 2004) and KEGG interaction pathways (Kanehisa 
and Goto, 2000). Applying my own scripts to STRING data, I determined the shortest 
functional pathways between protein products. Using EnrichNet, I interrogated a number 
of pathway databases. I also submitted the genes in which de novo variants were found in 
SAMtools and GATK separately. 
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Recently, the  ExAC (The Broad Institute, 2015a)  population database was released for 
public use. The database contains variant calls from 60,706 unrelated individuals. I 
therefore used this database to further annotate my final list of variants. 
This study has undergone a number of iterations over the course of three years. The 
following section presents the results of the WES study in its final iteration. 
4.4.  Results 
Identifying potentially disease-causing de novo variants required filtering large amounts 
of variant data. Within exome targets, SAMtools detected an average of 38,137.4 high-
confidence variants (Q30) per individual while GATK presented an average of 45,690.6 
high-confidence variants per individual. These large quantities of variant data required 
various rounds of filtering to be applied in order to restrict each list to variants most likely 
to result from actual de novo mutations with disease-causing potential. Table 10 provides 
an average for all of these steps for the probands. 
Variant 
caller 
Total Detected as 
de novo 
Rare In exon or 
splice site 
Non-
synonymous 
Not in-
house* 
Detected by 
BAMily 
SAMtools 38,656.3 21.7 15.1 6.6 4.8 3.6 1.2 
GATK 45,525.6 27.9 12.6 7.1 4.9 3.4 1.2 
Table 10. Average number of high-confidence variants in probands at different stages of the filtering process by 
variant caller. *Not previously detected in-house in 418 exomes.  
Consistent with the extremely low number of de novo variants expected in a single exome; 
estimated to be 0.74 as described in Section 4.2.2, the number of high-confidence variants 
predicted as de novo by both SAMtools and GATK for any proband was many orders of 
magnitude lower than its total number of high-confidence variants. However, to get to a 
final list of de novo variants with fewer false positives, a number of steps were required. 
De novo variants are no more likely to occur at a common variant site than anywhere else 
in the genome. Variants that coincided with common variants were thus almost certainly 
false positives. Excluding non-rare variants, as well as any variant that was not in a splice 
site or exon, brought the average number of SNVs and indels per individuals closer to the 
estimate of Section 4.2.2.  
The number of predicted non-synonymous de novo SNVs and indels called for each 
proband varied although tended to converge with each filtering step. The average number 
of variants per proband, the range of value across probands and the total number of 
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variants by variant caller are given in Table 11. The average number of variants identified 
by SAMtools and GATK was only slightly in excess of the expected average. The 
consensus between the two callers is likely to discard some of the remaining false 
positives with BAMily providing an additional filter for false positives. 
Variant 
Caller 
Average (per proband) Range Total  
SNVs indels SNVs indels SNVs Indels 
SAMtools 2.3 1.3 0-9 0-4 73 41 
GATK 3.3 0.1 0-20 0-1 105 4 
Table 11. Average and range of non-synonymous de novo variants per proband once all filtering has been 
applied. Also given is the total number of variants by variant caller. 
Once filtering with BAMily was applied, the number of variants produced by each caller 
and both caller were further reduced to the numbers shown in Figure 21. 
4.4.1. De novo variants identified by consensus. 
Of the 47 variants found post-filtering, around 51% were shared by both SAMtools and 
GATK UnifiedGenotyper. This represented a total of 23 SNVs and a single indel. GATK, 
with its IndelRealigner step, provided a conservative number of indel detections. Before 
the application of the filter provided by BAMily, GATK had detected a total of 4 indels, 3 
of which were shared with SAMtools. By contrast, SAMtools produced a list of 42 indels, 
most of which were likely to have been artefacts. The share of SNVs and indels identified 
by SAMtools and GATK post-filtering; including the application of GATK, is shown in 
Figure 21. 
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Figure 21. Distribution of variants detected in 32 probands post-filtering in both variant callers. BAMily was 
used as a filter. 
Variant were found among 14 out of a total of 32 probands. In total, 24 variants were 
found, corresponding to a ratio of de novo variants per proband of 0.75, close to the 0.74 
described in Section 4.2.2. The variants, and the genes and families in which they 
occurred, are summarised in Table 12. 
The 24 variants found post-filtering included 2 nonsense variants and a single frameshift 
deletion. These were found in genes ZNF227, GDPGP1 and ENTPD2 respectively. The 
possible pathogenicity of the remaining 21 missense variants was based on pathogenicity 
predictions from four functional predictors as shown in Table 13. 16 out of 21 missense 
variants were flagged as probably pathogenic by at least one of the functional predictors. 
Among these 16 variants, 4 variants were predicted as at least possibly pathogenic; or 
equivalent, by Polyphen2, LRT and MutationTaster, with support from MutationAssessor. 
The 4 variants were found in ANGPTL2, PROK1, PHLPP2 and PDE4D respectively. 
Each variant in the consensus list occurred in a distinct gene. I will henceforth refer to 
each variant by the gene in which it occurred.  
The genes in which the variants in the consensus list occur have not previously been 
associated with TGA or other conotruncal defects. None have been identified as laterality 
genes. None of these genes are orthologs for the 276 genes highly expressed in the 
developing mouse heart as compiled by Zaidi et al. (2013). The closest association to this 
list is the presence of a paralog of KCNJ12, known as KCNJ2.
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Family Gene Position (hg19) Nucleotide and amino acid change (transcript) 
33 ANGPTL2 chr9:129856079 c.G944C:p.G315A (ENST00000373425) 
KCNJ12 chr17:21319408 c.G754A:p.D252N (ENST00000331718, ENST00000583088) 
LMOD3 chr3:69168173 c.G1333A:p.E445K (ENST00000420581, ENST00000489031) 
ZNF419 chr19:58004899 c.G974A:p.S325N (ENST00000221735), c.G977A:p.S326N 
(ENST00000424930) 
70 CPT2 chr1:53675809 c.A463G:p.M155V (ENST00000371486) 
85 ZNF577 chr19:52376725 c.T518C:p.L173P (ENST00000301399) 
216 RBP5 chr12:7280940 c.A148G:p.M50V (ENST00000266560) 
222 FAM208B chr10:5789201 c.C3817A:p.L1273I (ENST00000328090) 
PROK1 chr1:110998906 c.T251C:p.L84P (ENST00000271331) 
245 DCDC1 chr11:31327850 c.A520G:p.I174V (ENST00000452803) 
GREB1 chr2:11758998 c.G991A:p.V331M (ENST00000396123) 
RAD52 chr12:1034628 c.G531C:p.K177N (ENST00000358495) 
280 PHLPP2 chr16:71713341 c.T202A:p.S68T (ENST00000568004), c.T988A:p.S330T (ENST00000393524),  
c.T988A:p.S330T (ENST00000568954) 
ZNF227 chr19:44732650 c.C112T:p.R38X (ENST00000313040) 
311 GDPGP1 chr15:90785068 c.C928T:p.R310X (ENST00000558017) * 
312 PDE4D Chr5:58271514 c.C1110A:p.D370E (ENST00000317118), c.C1077A:p.D359E 
(ENST00000358923), c.C1983A:p.D661E (ENST00000340635), 
c.C1575A:p.D525E (ENST00000360047) ,c.C1617A:p.D539E 
(ENST00000405755), c.C1593A:p.D531E (ENST00000503258), 
c.C1791A:p.D597E (ENST00000507116), c.C1800A:p.D600E 
(ENST00000502484) 
ENTPD2 chr9:139945759 c.450delC:p.Y150fs (ENST00000312665, ENST00000355097) 
388 COL11A2 chr6:33134330 c.C4031T:p.A1344V (ENST00000361917) **, c.C4094T:p.A1365V 
(ENST00000374708) **, c.C4352T:p.A1451V (ENST00000341947) ** 
GPR17 chr2:128409078 c.G853A:p.V285I (ENST00000393018, ENST00000272644) 
478 KRTAP4-6 chr17:39296424 c.C316T:p.R106C (ENST00000345847) 
501 HECTD4 chr12:112622770 c.G9484A:p.V3162M (ENST00000377560)**, c.G9562A:p.V3188M 
(ENST00000550722)** 
503 CREB3L3 chr9:4157266 c.C431T:p.P144L (ENST00000078445, ENST00000602147,  
ENST00000602257),  c.C428T:p.P143L (ENST00000595923) 
SNX13 chr7:17937012 c.T70C:p.F24L (ENST00000409604, ENST00000428135) 
540 ZFHX3 chr16:72829270 c.T4569A:p.S1523R (ENST00000397992), c.T7311A:p.S2437R 
(ENST00000268489) 
Table 12. The 24 variants from the consensus list identified by family. For brevity, only well supported 
transcripts are shown here unless unavailable. Well supported transcripts are described in Ensembl as being 
supported by one or more non-suspect mRNA. *Transcript has support level 2 meaning that the best supporting 
mRNA has been flagged as suspect **Transcript has support level 5 meaning that the reported structure is not 
constructed from any single transcript. More on transcript support levels available at: 
http://www.ensembl.org/Help/Glossary?id=492 
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Family Gene pathogenicity prediction* 
Polyphen2 LRT MutationTaster MutationAssessor 
33 ANGPTL2 probably damaging deleterious disease causing medium 
 
KCNJ12 benign deleterious disease causing neutral 
 
LMOD3 benign neutral polymorphism medium 
 
ZNF419 possibly damaging N/A polymorphism low 
70 CPT2 benign neutral disease-causing neutral 
85 ZNF577 probably damaging N/A polymorphism high 
216 RBP5 benign neutral disease-causing low 
222 FAM208B benign neutral polymorphism low 
 
PROK1 probably damaging deleterious disease-causing medium 
245 DCDC1 benign neutral polymorphism neutral 
 
GREB1 benign deleterious polymorphism neutral 
 
RAD52 benign deleterious disease-causing medium 
280 PHLPP2 probably damaging deleterious disease-causing low 
 
ZNF227 Nonsense mutation 
311 GDPGP1 Nonsense mutation 
312 PDE4D 
Probably 
damaging deleterious disease-causing medium 
 
ENTPD2 Frameshift deletion 
388 COL11A2 benign deleterious polymorphism neutral 
 
GPR17 benign neutral polymorphism neutral 
478 KRTAP4-6 N/A unknown N/A medium 
501 HECTD4 benign N/A, N/A neutral 
503 CREB3L3 benign N/A polymorphism neutral 
 
SNX13 
probably 
damaging deleterious N/A low 
540 ZFHX3 benign deleterious disease-causing low 
Table 13. Pathogenicity prediction of each variant based on the output of four functional predictors. *Possible 
predictions for each program are as follows: Polyphen2: probably damaging, possibly damaging, benign; LRT: 
deleterious, neutral, unknown; MutationTaster: disease-causing, disease-causing automatic [nonsense or known 
disease-causing in dbSNP], polymorphism, polymorphism automatic [any known variant in dbSNP not identified 
as disease-causing]; MutationAssessor: high, medium, low, neutral. 
Submitting the 24 corresponding genes to STRING (Jensen et al., 2009) revealed possible 
functional links between some of the protein products. Although the set of proteins was 
not enriched in interactions (p-value=1.63E-1), possible functional links were found 
between PDE4D, PHLPP2 and ZNF227. While an interaction between 3 proteins among 
24 is not statistically significant (1.03E-1), the interactions were nonetheless noteworthy 
in that they occurred between three particularly strong candidate genes. The functional 
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links, between these proteins and between GPR17 and PROK1, are represented by 
STRING’s network view shown in Figure 22. Both functional links to PHLPP2 were 
predicted on the basis of several types of evidence, including the interaction of putative 
homologs in other species. The functional link between PHLPP2 and ZNF227 gave a 
combined score of 0.44. This was based on the co-mention of these two proteins; as well 
as putative homologs, in five publications; as determined through their abstract. There 
was also evidence of co-expression of homologs in plasmodium falciparum as well as 
evidence for protein-protein interactions in several species; specifically evidence of 
protein binding in Drosophila melanogaster. The functional link between PHLPP2 and 
PDE4D gave a combined score of 0.82. This was also based on co-mention in five 
publications; but only for putative homologs, and co-expression of homologs in 
plasmodium falciparum. Evidence of protein-protein interactions was based on homologs 
in Saccharomyces cerevisiae. The evidence for a functional link between GPR17 and 
PROK1 was particularly strong, leading to a combined score of 0.9. This score was based 
on both proteins appearing in the G alpha (q) signalling pathway stored in the Reactome 
Pathway database (Croft et al., 2014). It is worth noting however that GPR17 was 
predicted to be benign by a consensus of functional predictors. No significant GO term or 
KEGG pathway enrichments were found. 
 
Figure 22. STRING network view of the protein products and predicted functional links for 23 genes in which de 
novo variants were found (DCDC1 was not available for network view). The different types of evidence for 
functional links between proteins are represented by edges. Evidence for functional links between proteins was 
derived from text-mining (yellow), experimental work (pink) and co-expression data (black) and association in a 
curated databases (blue). 
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Using the list of functional links between proteins in STRING, I determined the 
functional distance between each of the 24 proteins corresponding to my list of genes. 
The number of functional links separating each gene via its protein product is given in the 
Appendix, Figure S1. Ultimately, the analyses using STRING were inconclusive, 
providing no additional information by which the variants of interest could be further 
prioritised. 
Submitting the 24 genes from the consensus list via EnrichNet (Glaab et al., 2012) did not 
provide further evidence of enrichment for specific pathways. I submitted two additional 
gene lists to EnrichNet based on the list of de novo variants found in SAMtools and 
GATK separately. No pathway enrichment was found for either of those lists of genes. 
DNA samples for 11 trios were sent away for Sanger validation work. The validations 
centred on 16 of the 24 de novo variants called by SAMtools and GATK, selected 
according to functional prediction; showed in Table 13. Variants were selected for 
validation work if they were considered as at least probably deleterious; or equivalent, by 
one of the functional predictors used. This meant that variants which were considered 
only possibly deleterious by one predictor; such as the variant in ZNF419, but otherwise 
benign, were not selected. Table 14 lists the gene variants for which validation work was 
requested and the subsequent results. 
Family Gene Confirmed de novo? 
33 ANGPTL2 yes 
 KCNJ12 Parental traces unclear, gene is possibly paternally inherited 
70 CPT2 yes 
85 ZNF577 yes 
216 RBP5* yes 
222 PROK1 yes 
245 GREB1 yes 
 RAD52 yes 
280 PHLPP2* yes 
 ZNF227* yes 
311 GDPGP1 yes 
312 PDE4D yes 
 ENTPD2 yes 
388 COL11A2 yes 
503 SNX13 yes 
540 ZFHX3 Validation in progress 
Table 14. DNA samples from 11 families were sent away for validation work. A total of 14 variant sites were 
confirmed to harbour a de novo variant in the proband. Validation work for KCNJ12 remains ambiguous, 
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variant potentially paternally inherited. *Validation work at these variant sites was done in an earlier iteration 
of the project, but the variants were rediscovered in this final iteration.  
All but two of the variants detected by SAMtools and GATK were confirmed to be de 
novo; with one variant still awaiting validation. This proves that my pipeline is able to 
accurately identify variants that appear to be de novo from blood samples. It is still 
possible that some of these variants are not de novo, but the result of mosaicism, which I 
will explain in Section 4.5. 
4.4.2. Evidence of processes relevant to cardiogenesis in genes for which de novo 
variants were uncovered using WES. 
Available information on each of the 16 genes selected in the previous section was 
obtained using GeneCards (Rebhan et al., 1998)  and the OMIM (NCBI, 2015) 
compendiums. Here I provide a summary of findings in genes that support a potential role 
in the normal development of the heart. 
One approach taken in uncovering a role for the genes in cardiogenesis was to look at 
whether the mRNA product of that gene had been reported as differentially expressed in 
embryonic tissues relating to the cardiovascular system. Results for 3 genes are shown in 
Table 15. These results rely largely on the LifeMaps database, which is part of the 
GeneCards suite (Rebhan et al., 1998). It is worth noting that, for a number of genes, this 
information was not available. Therefore, the absence of reported expression in the 
embryonic heart tissue cannot be interpreted as an absence of a role in cardiogenesis. 
Gene Expression in embryonic heart tissue 
ANGPTL2 Atrioventricular canal cells in the dorsal aorta and outflow tract 
GREB1 atrioventricular canal cells 
ENTPD2 atrioventricular node cells 
Table 15. Positively differentiated expression in embryonic heart tissue of mRNA reported for genes of interest. 
Data collected by LifeMaps, part of the GeneCards suite (Rebhan et al., 1998). 
Expression in adult heart can also provide some clues as to a potential role in 
cardiogenesis. ANGPTL2 has been reported as highly expressed in the adult heart 
(Rebhan et al., 1998; Kim et al., 1999). ENTPD2 was also reported as expressed in the 
adult heart (Rebhan et al., 1998). One of PDE4D’s many protein products, isoform 7, has 
been detected in heart and skeletal muscle (Rebhan et al., 1998). Once again, it is difficult 
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to conclude that a gene was not expressed in heart tissue where annotations were not 
present or potentially incomplete. The expression of PROK1 was identified as limited to 
endocrine tissue in the ovary, testis, placenta and adrenal gland, which could be an 
argument for ruling it out as a contributor to cardiogenesis (LeCouter et al., 2003). 
Nonetheless, there is no information on the gene’s expression in embryonic heart (Rebhan 
et al., 1998). 
Using  the Mouse Genome Informatics (MGI) database (Eppig et al., 2015), I surveyed 
mouse knockouts in genes homologous to the genes of interest. Once again, I looked for 
genes which, when mutated, lead to an abnormal cardiovascular phenotype or embryonic 
lethality. The results are shown in Table 16. 
Gene Mouse gene homolog Abnormal cardiovascular phenotype in mouse 
ANGPTL2 Angptl2 None 
COL11A2 Col11a2 None 
CPT2 Cpt2 None 
ENTPD2 Entpd2 None 
GDPGP1 Gdpgp1 None 
GREB1 Greb1 None 
KCNJ12 Kcnj12 None 
PDE4D Pde4d Increased cardiac muscle contractility 
PHLPP2 Phlpp2 None 
PROK1 Prok1 None 
RAD52 Rad52 None 
RBP5 Crabp1 None 
SNX13 Snx13 Abnormal cephalic vascularization, small number of capillaries in 
neural folds (embryonic lethality during organogenesis). 
ZNF227 None / 
ZNF577 None / 
ZNFHX3 None / 
Table 16. Abnormal cardiovascular system phenotype in mutated mice. Where mice homologs of the genes were 
found, gene knockouts were available. Data collected by the Mouse Genome Informatics database (Eppig et al., 
2015). 
Mutated mice in two homologs were found to lead to an abnormal cardiovascular 
phenotype. However, neither led to TGA or any other conontruncal defect in mice. 
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4.4.3. Re-evaluation of the data using ExAC. 
The recent release of ExAC (The Broad Institute, 2015a) presents an additional 
opportunity to establish whether the variants in the consensus list have been previously 
reported. In Table 17 are shown the allele counts in ExAC; with corresponding MAF, for 
each variant found both in the consensus list and in the ExAC database. This list includes 
variants that were confirmed to be de novo through Sanger sequencing, such as GDPGP1 
and GREB1. The variant occurring in KCNJ12, which could not be confirmed as de novo, 
was found in ExAC with a MAF which suggest that the variant is unlikely to be de novo 
in the proband. 
Gene Allele count MAF 
ANGPTL2 0 / 
COL11A2 0 / 
CPT2 0 / 
ENTPD2 0 / 
GDGP1 1 8.24E10
-6
 
GREB1 11 1.73E10
-4
 
KCNJ12 229 1.89E10
-3
 
PDE4D 0 / 
PHLPP2 0 / 
PROK1 0 / 
RAD52 0 / 
RBP5 0 / 
SNX13 0 / 
ZNF227 0 / 
ZNF577 0 / 
ZNFHX3 0 / 
Table 17. Variants found by SAMtools and GATK that are also present in ExAC, listed by the gene these occur 
within. 
Some of the cohorts included in ExAC belong to disease-specific population studies. 
Some of these studies involve heart disease patients, but these focus on the development 
of heart disease later in life rather than CHD. Given that CHD can accompany other 
diseases, a few patients with CHD phenotypes could have been included in one of these 
disease-specific populations. Therefore, it is difficult to determine what the presence of 
some of the variants of this study in ExAC might signify for disease-causing potential. 
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4.5. Discussion 
4.5.1. WES study considerations in uncovering de novo variants 
The WES study presented in this chapter was based on the hypothesis that de novo point 
mutations and indels significantly contribute to the incidence of TGA. In previous studies, 
focused on familial TGA, a number of rare variants were uncovered in laterality genes 
ZIC3, CFC1 and NODAL (Unolt et al., 2013). These studies established TGA as a disease 
which can be caused by one or a small group of mutated genes. However, the measured 
recurrence rate in relatives of patients with TGA across studies remains low, with most 
cases of TGA considered sporadic (Digilio et al., 2001; Unolt et al., 2013). The 
overwhelming share of sporadic cases could be explained to some extent by the 
deleteriousness of the disease. TGA is a highly lethal CHD, with 95% of patients dying 
within the first year of life when the transposition is not surgically corrected (Saremi, 
2014). With only recent generations having benefitted from corrective surgery, most 
mutations predisposing to TGA having arisen in patients in the past are expected to have 
been eliminated by natural selection. De novo variants are thus suggested to play a large 
role in sporadic TGA. Another hypothesis is that environmental factors play the larger 
role in the development of TGA. In Section 4.2.1, I mentioned some of the known 
environmental triggers. 
Studying de novo variants using WES presents its own series of challenges. As in other 
WES studies, variants might be missed due to low quality reads and low read depth 
(Altmann et al., 2012). This is discussed in chapter 1 and again in chapter 3. In this 
context, the issue extends to whether a variant detected in the proband can be considered 
de novo. Given perfect sequence coverage, a variant can be considered de novo if is 
detected in the proband but not in either parent. In reality however, variant sites may have 
too few reads in one or both parents, making a genotype assignment difficult. Filtering 
such cases out, as has been done in the present study, can exclude genuine de novo 
variants. Another possible approach is to rely on other types of filtering to differentiate de 
novo variants from inherited variants. This can be done for example by using a stringent 
MAF threshold. This approach presents its own problems. Population databases, such as 
the ESP (NHLBI, 2015) may contain miscalls reported as a low frequency variants. It is 
also possible that a few of these rare variants will match de novo variants. Additionally, 
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using a stringent MAF will not be able to filter out variants that are not de novo but have 
nonetheless occurred as a result of a recent mutation event. In chapter 1, I reviewed the 
literature around the distribution of variants in the human population which found an 
abundance of rare variants compared to what would be expected from population genetic 
theory (Altshuler et al., 2010). This will include many variants not present in either the 
1000g or ESP database. 
As shown in Table 10, the number of variants detected as de novo was in excess of the 
number of variants expected. True de novo variants had to be extracted from this list. In 
Section 4.2.2, I mentioned the rate of de novo variants as being 0.74 in the exome per 
individual. Provided de novo variants are indeed causing TGA, the actual rate of de novo 
variants per exome will be slightly higher due to selection bias. However my results from 
de novo detection are still one order of magnitude higher. This will once more largely be 
imputable to sequencing error and the incorrect assignment of genotypes by SAMtools 
and GATK. Mosaicism in parents might also contribute to this effect. Mosaicism refers to 
the presence of cell lines with different genotypes at a given locus within a single 
individual due to a postzygotic de novo mutation event (Biesecker and Spinner, 2013). A 
variant could have therefore been detected as de novo in a proband whilst being inherited 
if it is not present in the blood cells from the parents; or appears with low frequency, in 
the parent that carries the variant (Biesecker and Spinner, 2013). Conversely, a 
postzygotic de novo mutation event can lead to mosaicism in the proband. The resulting 
variant could thus cause the manifestation of TGA while not being detected in DNA from 
blood samples. It is difficult at this time to determine the contribution of somatic mutation 
to CHD as few studies have investigated this possibility. In one recent study of cardiac 
tissues and blood samples from 52 unrelated patients with ToF, Huang et al. (2013) 
identified two somatic variants in GATA6; a gene previously implicated in CHD, in 
patients. To my knowledge, no somatic variants have been reported as a trigger for a case 
of TGA yet. 
The rate of variants identified in my study once filters have been applied is at around 0.75 
per proband. This is close to the rate of de novo variants found in the literature as 0.74. 
Validation work suggests that this final list of variants does in fact mostly contain genuine 
de novo variants, with only 1 of 15 variants sent for validation not confirmed to be de 
novo; with another variant pending validation. However, the difficulty is in knowing how 
many de novo variants were missed as a result of sequencing and filtering. It is possible 
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that the rate of actual de novo variants in the 32 probands is higher. There is also little 
indication as to which of these variants could be disease-causative beyond functional 
predictions. Variants were not found in genes already associated with TGA or heterotaxy. 
Likewise, no two variants were found in the same genes. This last point must be 
contrasted with the sample size used for this study. A total of 32 proband were studied, 
with consensus list variants found in 14 probands, some of which appear to be unlikely to 
be disease-causative. In their study of the contribution of de novo variants in severe 
sporadic CHD, Zaidi et al. (2013) estimated that a total of 400 genes, when mutated, 
could be contributing to severe sporadic CHD. The consequence of such locus 
heterogeneity for small studies is that overlap in genes with disease-causing de novo 
variants would be unlikely to occur. If their conclusions can be applied to single CHD 
subtypes; in this case TGA, this could explain why my study only does not include two de 
novo variants in the same gene. In the following section, I describe the de novo variants 
predicted to be deleterious found in 11 probands. 
4.5.2. De novo variants by family 
The WES study focused on 32 families. The final consensus list contained 24 variants 
across 14 probands. 16 variants in 11 probands were predicted to be probably deleterious; 
or equivalent, by at least one functional predictor. 
In the proband of family 33, a total of 4 candidates were detected by SAMtools and 
GATK. The variants are distributed among four genes: ANGPTL2, KCNJ12, LMOD3 and 
ZNF419. Only variants in ANGPTL2 and KCNJ12 were predicted as probably deleterious. 
It was not possible to establish whether the variant in KCNJ12 is a de novo variant in the 
proband. However, using ExAC, I determined that the variant, although rare was unlikely 
to be a de novo given it was identified in 229 other individuals. At the very least, its 
presence across this many individuals suggests that it is not disease-causing. ANGPTL2 
appears to be the most likely to be pathogenic. According to RefSeq annotation (Pruitt et 
al., 2014), ANGPTL2 is part of an ensemble of angiopoietins, proteins expressed almost 
exclusively in the vascular endothelium. Angiopoientins are responsible for the formation 
of new blood vessels; or angiogenesis, and thus are part of the vascular endothelial 
growth factor (VEGF) family. ANGPTL2 is also abundantly expressed in adult heart and 
embryonic atrioventricular canal cell tissues (Rebhan et al., 1998; Kim et al., 1999). 
Possibly underscoring a role in the formation of the great arteries is the mouse homolog 
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gene Angptl2’s role in the inflammation  leading to abdominal aortic aneurysm (AAA) 
(Tazume et al., 2012). Tazume and his team were able to demonstrate an abundant 
expression of the Angptl2 protein in macrophages within vessel walls and to show a 
reduction of aneurysm size and vessel structure destruction in mice with Angptl2-
deficient macrophages. Mice knockouts in Angptl2 display a reduced distribution of 
microphages at inflammatory sites (Eppig et al., 2015). Based on the current evidence, 
the best candidate in this family appears to be the variant in ANGPTL2. 
In family 70, a candidate was found in gene CPT2 and predicted as disease-causing by 
MutationTaster, but benign; or neutral, by others. CPT2 encodes an enzyme that 
contributes to the transfer of fatty acid from the cytosol to mitochondria for oxidation 
(Longo et al., 2006) The enzyme produced by CPT2 is active within the mitochondrial 
inner membrane (Longo et al., 2006). To date, genes involved in cardiogenesis have not 
been found to act through mitochondria (Gelb and Chung, 2014). From this I have 
concluded that the gene is unlikely to play a role in cardiogenesis. 
In family 85, one candidate was found in ZNF577, a gene encoding for a zinc finger 
protein. Pathogenicity predictions are mixed. Few annotations exist for this gene that 
could be used to either support or rule out a role in cardiogenesis. The distribution of 
truncating variants in ZNF577, as seen in ExAC, suggests that the abnormal activity of 
ZNF577 could be tolerated by the organism. 
In family 216, one candidate was found in RBP5 and predicted as disease-causing by 
MutationTaster, but benign otherwise. RBP5 encodes for a retinol binding protein, retinol 
being the alcoholic form of vitamin A (Folli et al., 2001). According to Folli et al. (2001), 
gene expression in adult is largely specific to the kidney. However, the identification of a 
de novo variant in a gene that encodes a retinol binding proteins remains interesting. TGA 
has been reported as associated with high maternal intake of retinol supplements 
(Loffredo et al., 2001). Retinoic acid, the active form of vitamin A, is used to induce 
TGA in newborn mice via ingestion in the mother (Unolt et al., 2013). Retinoic acid 
antagonists are also used to induce TGA, suggesting that normal cardiac development 
depends on a balance in the level of retinoic acid (Cipollone et al., 2006). Additionally, 
Nash et al. (2015) identified a variant in RBP5 shared between 5 distantly related patients 
with total anomalous venous return (TAVR) that they suggests contributes to the disease. 
Briefly, a TAVR occurs when all pulmonary veins are malpositioned during 
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cardiogenesis, leading to the wrong connections being made. While TAVR and TGA are 
two distinct CHDs, these have been observed together, which could be indicative of some 
shared etiology (Raff et al., 2002). There are a number of reasons to be cautious about the 
results presented by Nash et al. (2015). Firstly, the variant has a MAF of around 9%. 
According to the authors, the variant is overrepresented in patients with TAVR, but not in 
patients with heterotaxy. Secondly, the gene selected for knockdown in zebrafish, rbp7a, 
only shares 51% sequence similarity with RBP5. A little under half of the mutant 
zebrafish display abnormal right-side looping of the heart which, at the very least, 
establishes a role for retinol binding proteins in cardiogenesis (Nash et al., 2015). On this 
basis, a role for the RBP5 de novo variant found in this family’s proband should not be 
excluded. It can be hypothesised that a mutated RBP5, leading to a malformed protein 
that cannot bind retinol as effectively as a normal protein, could decrease the level of 
retinol available to the cell in the developing heart. This would then lead to less retinoic 
acid, with the mutation having the effect of a retinoic acid antagonist. 
In family 222, two candidates were found, in FAM208B and PROK1 respectively. The 
variant in gene FAM208B; for which few resources exists, is predicted to be benign. On 
the other hand the variant in PROK1 is predicted as pathogenic by all four pathogenicity 
predictors used in this study. PROK1, which encodes a prokineticin protein, belongs to 
the VEGF family (LeCouter et al., 2003). This is the second variant identified in a gene 
belonging to the VEGF family in the consensus list with ANGPTL2. As its early name, 
endocrine-gland-derived vascular endothelial growth factor, suggest, it is specifically 
expressed in endocrine tissue in the ovary, testis, placenta and adrenal gland (LeCouter et 
al., 2003). This targeted expression makes PROK1 an unlikely actor in cardiogenesis and 
by extension, unlikely to be a cause of TGA when mutated. 
In family 245, the candidates were found in DCDC1, GREB1 and RAD52. The variant in 
DCDC1 is largely predicted to be benign with some prediction of deleteriousness for the 
other two genes. RAD52 encodes a protein that plays an integral role in double-strand 
break repair and DNA recombination (Park et al., 1996). This specific role suggests that 
the protein probably does not play a role in cardiogenesis. GREB1 is characterised by its 
high expression in estrogen-receptor-positive breast tumors (Ghosh et al., 2000). It is also 
expressed in prostate cancer tissue (Rae et al., 2006). Relevant to this study is its 
expression in atrioventricular canal cells in embryonic tissue, a characteristic it shares 
with ANGPTL2 (Rebhan et al., 1998). However, the strongest evidence for a potential 
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role for GREB1 in causing TGA is the previous identification of a CNV in a patient with 
malposition of the great arteries (MGA) which overlaps this gene (Fakhro et al., 2011). 
Fakhro et al. (2011) tested the expression of GREB1 in Xenopus Tropicalis using in situ 
hybridization and found expression patterns that suggested that the gene could indeed 
play a role in left-right patterning; and cardiogenesis in general (Rebhan et al., 1998; Kim 
et al., 1999). The subsequent gene knockdown conducted by Fakhro et al. (2011) did not 
lead to an abnormal left-right looping phenotype. Despite this, GREB1 remains a strong 
candidate in this present study. An interesting finding using ExAC was the identification 
of 11 other unrelated individuals with the same variant. It is possible that these 
individuals were part of one of the disease-specific population studies incorporated by 
ExAC, although this cannot be confirmed at this time (The Broad Institute, 2015a). None 
of the studies focus on CHD, but it is possible that some patients with multiple defects 
including CHD would have been incorporated to a study on the basis of the extracardiac 
defects. 
In family 280, two candidates were found, in PHLPP2 and ZNF227 respectively. Both 
candidates have a high disease-causing potential, with the variant in ZNF227 being a 
truncating variant. PHLPP2 encodes a protein which is known to mediate 
dephosphorylation of several genes (Brognard et al., 2007). Of particular interest is the 
action of PHLPP2 on AKT1, a gene embedded in the VEGF signalling pathway 
(Brognard et al., 2007). PHLPP2 acts to suppress AKT1’s activity (Brognard et al., 2007). 
PHLPP2 is thus a third gene in the final list of variants found to be involved with the 
VEGF pathway. As with the ZNF577 variant, there are few annotations about ZNF227. 
The de novo variant in this case is a nonsense variant. However, the distribution of 
truncating variants seen with ExAC suggests that truncating variants in this gene might 
not cause a deleterious phenotype.  
In family 311, a candidate nonsense variant was found in GDPGP1. GDPGP1 regulates 
GDP-D-glucose levels in cells (Adler et al., 2011). Few annotations exist about this gene. 
The variant in GDPGP1 was validated as an actual de novo variant, but has also been 
identified in an individual reported in ExAC. Additional information on the patient 
identified in ExAC could either support or rule out this variant as a cause for TGA. Given 
the specific nature of the protein function, a role in cardiogenesis is unlikely. 
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In family 312, two candidate variants were found, in PDE4D and ENTPD2 respectively. 
Both appear to be strong candidates based on functional prediction, the latter being a 
frameshift insertion. PDE4D acts on cyclic AMP (cAMP) (Houslay et al., 2007). The 
cAMP molecule acts as a regulator for different cell processes, with specialised functions 
in different cell types (Houslay et al., 2007). PDE4D, a member of the phosphodiesterase 
family, in turn, regulates the action of cAMP (Houslay et al., 2007). Different isoforms 
are expressed in different tissues, with isoform 7 being most expressed in heart and 
skeletal muscle. PDE4D appears to be associated with heart failure, but not severe cardiac 
defects arising during cardiogenesis (Houslay et al., 2007). ENTPD2 encodes for an 
enzyme in the cell membrane of the ectonucleoside triphosphate diphosphohydrolase 
family (Chadwick and Frischauf, 1997). The gene is expressed in atrioventricular node 
cells in the embryonic heart and  in the adult heart (Rebhan et al., 1998). The presence of 
a frameshift insertion makes ENTPD2 an interesting candidate, but there seems to be little 
literature hinting at a role for ENTPD2 in cardiogenesis. 
In family 328, two variants were identified, one in COLL1A2 and the other in GPR17. 
Both variants are largely predicted as benign with the exception being an assignment of 
‘deleterious’ by LRT for the variant in COL11A2. COL11A2 encodes an alpha chain for 
type XI collagen (Lui et al., 1996). In turn, type XI collagen is important for skeletal 
integrity (Lui et al., 1996). Diseases associated with mutations in COL11A2, such as 
Stickler syndrome, largely involve skeletal defects and  hearing loss (Rebhan et al., 1998). 
Around half of patients with Stickler syndrome also have a regurgitating mitral valve 
(Liberfarb et al., 1986). There does not appear to be any described cases of Stickler 
syndrome with TGA. As established earlier, TGA is seldom seen with extracardiac 
defects (Unolt et al., 2013). 
In family 503, two candidates were found in CREB3L3 and SNX13 respectively. The 
variant in CREB3L3 is predicted to be benign. The variant in SNX13 is predicted to be 
deleterious by Polyphen2 and LRT. SNX13 belongs to the sorting nexin family of proteins 
and  is involved in intracellular trafficking (Rebhan et al., 1998). Interestingly, knockout 
of the homolog gene in mice can lead to abnormal blood vessel morphology and is lethal 
to the mouse embryo (Zheng et al., 2006). Another member of the sorting nexin family, 
SNX10, has been found to act in a regulatory pathway for ciliogenesis; the development 
of cell cilia (Chen et al., 2012). Although still highly speculative, this presents the 
possibility of a role for mutated sorting nexins in ciliopathy; diseases of dysfunctional 
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cilia. The implication for TGA being that disorders relating to abnormal cilia can result in 
heterotaxy, a feature that accompanies some cases of TGA (Ware et al., 2011). 
In family 540, the candidate is in gene ZFHX3 and is predicted as potentially deleterious 
by LRT and MutationTaster. ZFHX3 encodes a transcription factor with several 
homeodomains and zinc finger motifs (Rebhan et al., 1998). The gene has been linked to 
atrial fibrillation, but not any form congenital cardiac defect (Benjamin et al., 2009). 
The variants in these families do not occur in heterotaxy genes or genes associated with 
TGA. There does not appear to be any unifying theme to categorise these variants. 
Several are involved in the VEGF pathway, but this association does not reach 
significance. Furthermore, one of the genes in this pathway, PROK1, is specific to tissues 
that did not include the heart. A few variants occur in genes that could play a role in TGA 
based on evidence from previous experiment. This is the case for example of variants in 
RBP5 and GREB1. A role for SNX13 also seems possible. No two candidates were found 
in the same gene; however the cohort was relatively small in size. A larger cohort of 
sporadic TGA cases might help further elucidate the present cases. Variants found in 
these same genes in other WES studies of sporadic TGA could lend credibility to some of 
the candidates identified in this study. This extends to the study of de novo CNVs in TGA 
patients which might also reveal CNVs affecting the same genes identified in this study. 
Finally, it cannot be ruled out that the scarcity of candidates could be an indication that 
TGA is largely caused by environmental factors. 
4.6.  Conclusion 
The WES analysis of 32 families; 31 parent-offspring trios and a single quartet, has 
revealed a number of de novo variants distributed across 14 of the probands affected by 
TGA. The rate of de novo per proband is close to what would be expected with 0.75 de 
novo variants detected per proband. Among 24 de novo variants detected to date, 16 are 
predicted to be probably deleterious; or equivalent, by at least one pathogenicity predictor 
and 14 have been validated. None of the variants detected occur in genes previously 
associated with TGA or heterotaxy. The genes were also not part of a list of 276 genes 
highly expressed in heart compiled by Zaidi et al. (2013). There was no unifying theme 
associating a subset of the genes found with disease. Despite all this, the existing 
literature suggests that the variants that occur in several genes could be disease-causative. 
These include the variants in GREB1, RBP5 and SNX13. Other variants identified in this 
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study could have an impact on the development of TGA through some as of yet unknown 
mechanism. The genes in which these variants were found can be compared to those that 
appear in future studies. The re-occurrence of any of these genes in future WES studies of 
TGA patients would be further evidence that these genes, when mutated, are involved in 
ToF. If TGA can be caused by de novo mutations in many distinct genes, large trio 
studies will be required to better determine which genes, when mutated cause ToF. 
 105 
 
Chapter 5. Whole-exome sequencing study of 824 patients with 
Tetralogy of Fallot
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5.1.1. Summary 
Tetralogy of Fallot (ToF) is a complex form of congenital heart disease (CHD) combining 
four heart morphological defects: a large ventricular septal defect, a displacement of the 
aorta over the septal defect, a narrowing of the pulmonary valve and a thickening of the 
right ventricular wall. The most common form of cyanotic CHD, its genetic etiology 
remains nonetheless largely unresolved. In this chapter, I present a large-scale WES study 
involving 824 unrelated ToF patients with sequencing performed at McGill University 
and the Génome Quebec Innovation Centre (MUGQIC). This study focuses on 
identifying genes that potentially play a role in the development of ToF using various 
approaches. In a first stage, I categorised rare variants according to their potential to 
disrupt normal protein function. I compared the genes in which these rare variants occur 
to sets of genes previously associated with CHD in the literature. In a second stage, I 
identified clustering of rare variants across the length of gene coding sequences (CDS) 
and exons in the 824 ToF cases. I hypothesised that rare variants influencing the disease 
trait would cluster in ToF patients. The genes in which clustering occurred were also 
compared to sets of genes implicated in CHD. In the final stage of my study, I conducted 
a pathway analysis using STRING v.10 (Jensen et al., 2009) and Enrichnet (Glaab et al., 
2012). With STRING, I checked the list of genes in each cluster category for an 
enrichment of protein-protein interactions. I then used Enrichnet to determine if the genes 
fell within any specific pathways or processes. Using interaction data from STRING, I 
looked for genes in each cluster category that might directly interact with known ToF 
genes. To test the assumptions made at every step of the study, I used a second set of 490 
cases with various neurodevelopmental disorders, obtained from the UK10K project, as 
comparators. This study reveals that rare single nucleotide variants (SNVs), truncating or 
otherwise predicted to be deleterious, in known ToF genes are found in 4.4% of patients 
with ToF. This suggests that genes previously identified as influencing ToF through 
single highly-deleterious variants only account for a small fraction of ToF cases. The 
study of SNVs clustering in ToF patient revealed the novel candidate FLT4 and 
established NOTCH1 as contributors to ToF. Overall, results of the study suggest that, 
despite the identification of both known and potentially novel genes influencing the risk 
of ToF, single highly-penetrant variants do not play a major role in ToF, implying a more 
complex genetic etiology is at work in many patients presenting ToF. 
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5.2. Introduction 
5.2.1. Tetralogy of Fallot 
As described in Chapter 1, ToF is one of the most common forms of CHDs accounting 
for 7-10% of all CHD pathologies (Bailliard and Anderson, 2009). It is the most common 
form of cyanotic CHD which is characterised by an intermittent or permanent bluish 
appearance as a result of low blood oxygenation (Apitz et al., 2009). The principle 
abnormality is an antero-cephalad deviation of the ouflow tract septum, resulting in four 
linked phenotypic features: a ventricular septal defect (VSD), a displacement of the aorta 
over the VSD, a narrowing of the pulmonary valve; described as pulmonary stenosis (PS), 
and a progressive thickening of right ventricular wall, or right ventricular hypertrophy 
(RVH) (Bailliard and Anderson, 2009; Nelson et al., 2014). The VSD occurs in the 
anterior part of the muscular ventricular septum and is typically quite large (Lev and 
Eckner, 1964). As a result of the septal defect and of an aorta overriding both ventricles, 
blood circulation is perturbed, with oxygen poor blood that has not traversed the 
pulmonary circulation being ejected to the systemic circulation, a phenomenon described 
as shunting (Lev and Eckner, 1964). The PS, which can occur at different levels along the 
pulmonary outflow tract, also greatly perturbs blood circulation, restricting blood flow 
through the lungs (Anderson and Weinberg, 2005). Stenosis is occasionally associated 
with the incomplete development of the pulmonary valve, described as hypoplasia, with 
either a fusion of leaflets; pulmonary atresia (PA), or a complete absence of the 
pulmonary valve (Bailliard and Anderson, 2009). The absence of the valve leads to blood 
flowing back into the right ventricle. The right ventricular hypertrophy is considered a 
secondary phenotype, developing progressively as the right ventricular muscle works to 
compensate for the PS (Nelson et al., 2014) . In addition to the four principal 
morphological defects that characterise ToF, there exist a number of additional minor 
cardiac defects. Bailliard and Anderson (2009) report that a quarter of ToF patients have 
their aortic arch on the right. Half of patients with PA have a persistent patent ductus 
arteriosus which provides blood with access to the pulmonary artery via the aorta 
(Bailliard and Anderson, 2009). In some cases, the large VSD characteristic of ToF is 
accompanied by additional smaller septal defects, both of the ventricles and atria. The 
tricuspid valve is occasionally found to be displaced over both ventricles in ToF patients 
(Bailliard and Anderson, 2009).  
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Arthur Louis Étienne Fallot, described ToF as the abnormality underlying the majority of 
cases of “la maladie bleue” (Anderson and Weinberg, 2005). Cyanosis is the main 
physical sign associated with ToF, although it is absent from some mild cases (Lev and 
Eckner, 1964). The degree of cyanosis depends on the level of severity of the underlying 
defects, particularly the extent of the PS. In a clinical study of infants with ToF, 
Shinebourne et al. (1975) describe cases of persistent cyanosis. The authors point to 
pronounced infundibular stenosis, which involves a diminished pulmonary valve ring, as 
the root cause of the severity of cyanosis in these patients. Shinebourne et al. (1975) also 
describe patients with intermittent cyanosis, brought on by crying, which gradually 
increases over time. Other outcomes of ToF include loss of consciousness, heart murmurs, 
shortness of breath and eventually, heart failure (Shinebourne et al., 1975). Without 
surgery, 80% of affected individuals die before the age of 10 (Starr, 2010). However, 
thanks to advances in modern surgery, patients who undergo complete surgical repair in 
early life show an 85% survival rate over the first 30 years of life (Bailliard and Anderson, 
2009). 
The disease etiology of ToF has yet to be fully uncovered. ToF has been reported as a 
component of several syndromes; diseases characterized by several defects in distinct 
tissues and organs. These include patients with chromosomal aneuploidy, such as 
trisomies of chromosomes 13, 18 and 21, as well as large copy number variants (CNVs) 
inducing disorders such as 22q11.2 deletion syndrome (Nelson et al., 2014). A 22q11.2 
deletion has been estimated to be present in 15% of ToF patients, a proportion that rises 
to 40% when considering patients with PA (Nelson et al., 2014). Although it is important 
to note that 22q11.2 deletion syndrome refers to a range of phenotypes that do not all 
include ToF or CHDs in general. When 22q11.2 deletion syndrome does cause ToF, the 
defect is often accompanied by several extra-cardiac defects. 
A few patients with isolated ToF; unaccompanied by extra-cardiac defects, have been 
described as members of apparently Mendelian families. For example, a missense variant 
in JAG1 was shown to follow an autosomal dominant pattern in a family with multiple 
CHD phenotypes, including ToF (Eldadah et al., 2001). No family member presented 
Alagille syndrome, typically caused by mutation in JAG1 (Eldadah et al., 2001).  
However, the majority of ToF cases studied are sporadic. Excluding ToF patients with 
22q11.2 microdeletions, Burn et al. (1998) found a recurrence risk of CHD in siblings of 
2.2% and of 3.1% in offspring hinting at a strong, but complex, genetic component 
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underlying isolated non-Mendelian ToF (Burn et al., 1998). A genome-wide association 
study (GWAS) carried out on 839 ToF patients; some of which are included in the study 
in this chapter, and 5159 controls, conducted by Cordell et al., (2013b), suggests that 
common variants influence the risk of ToF. This includes single nucleotide 
polymorphisms (SNPs) in regions 12q24 and 13q32, the latter SNPs coinciding with the 
GPC5 locus. The identification of common variants influencing the risk of ToF in region 
12q24 is consistent with a candidate gene study, carried out on some of the same patients, 
which revealed an association between a common variant in PTPN11 and the disease 
(Goodship et al., 2012). However, as Cordell et al. (2013b) point out, ToF is associated 
with a high and early mortality rate and therefore severely reduced reproductive fitness. 
Alleles conferring additional risk of an individual developing ToF would be expected to 
be constrained by natural selection to allele frequencies lower than the ~5% which 
typically yield GWAS signals. We therefore expect rare and de novo genetic variants to 
play a substantial role in the development of ToF. Greenway et al. (2009) identified 11 
rare CNVs in ToF patients that were either absent or extremely rare (>0.001) in a set of 
controls. Greenway et al. (2009) highlight their discovery of CNVs, predominantly 
duplications, occurring in region 1q21.1, in 5 of 114 ToF patients and none of their 
controls. The association between duplications in region 1q21.1 and ToF was later 
confirmed by the work of Soemedi et al. (2012a) and Silversides et al. (Silversides et al., 
2012). Small duplications coinciding with the GJA5 locus, suggests this gene plays a role 
in the development of ToF and other forms of CHD (Soemedi et al., 2012a). Results from 
case-control studies of CNVs in ToF suggest that large CNVs are significant contributors 
to the disease burden in ToF (Silversides et al., 2012; Soemedi et al., 2012a; Soemedi et 
al., 2012b). This is true whether or not one chooses to include patients with a 22q11.2 
deletion. 
To date, few genes have been conclusively associated with ToF. Studies attempting to 
uncover genes that contribute to ToF through indels and SNVs have largely focused on 
sequencing genes thought to be good candidates. This typically includes genes that 
coincide with known CNVs in ToF such as TBX1 which resides in the 22q11.2 region, 
and genes previously associated with CHDs (Griffin et al., 2010). Table 18 provides a 
summary of genes associated with ToF to date through gene sequencing studies. 
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Gene Patients with rare variant Size of control set Reference 
NKX2-5 9/201* 50 (McElhinney et al., 2003) 
ZFPM2 2/47 120 (Pizzuti et al., 2003) 
GATA4 1/201* 159
†
 
(Tomita-Mitchell et al., 
2007) 
CFC1 8/121* 125 (Roessler et al., 2008) 
FOXH1 5/121* 
 
TDGF1 2/121*  
GDF1 3/121* 125 (Roessler et al., 2009) 
NODAL 12/121*  
JAG1 2/94* 100 (Bauer et al., 2010) 
TBX1 3/93 500 (Griffin et al., 2010) 
GJA5 2/178 784 (Guida et al., 2013) 
GATA6 2/52 200 (Huang et al., 2013) 
GATA5 2/35* 200 (Jiang et al., 2013) 
BVES 4/114 400 (Wu et al., 2013) 
FOXA2 4/93 500 (Topf et al., 2014) 
FOXC1 4/93 
 
FOXC2 2/93 
 
HAND2 1/93 
 
NKX2-6 1/43* 200 (Zhao et al., 2014) 
TBX5 2/94 200 (Baban et al., 2014) 
Table 18. Gene sequencing studies that report a causal link between a gene and ToF. *Study includes case 
patients with different CHDs, the number reported is the number of case patients with ToF. †105 additional 
controls were tested for two specific variants in exon 6. 
Given the heterogeneity of loci causally linked with isolated ToF, extracting genetics 
insights from WES studies rather than through individual candidate gene sequencing calls 
for a large set of cases and controls. 
5.2.2. The study of disease with locus heterogeneity using WES 
Many rare diseases are caused by single highly-penetrant rare variants occurring within a 
specific locus. While ToF is a common cardiac defect, it can be hypothesised that many 
cases of the disease are also result from single highly-penetrant rare variants. The 
distinction with rare disease is in the number of different loci at which the disease-causing 
variant may arise, a phenomenon referred to as locus heterogeneity (Bamshad et al., 
2011). 20 genes have already been causally linked to ToF, as shown in Table 18. To 
identify the gene regions in which rare variants causing a particular disease occur, a large 
set of unrelated patients that share the disease is needed. Given a large set of cases, 
variants contributing to a disease trait will form detectable clusters within specific regions 
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of a gene or genes which, when mutated, lead to the disease. Given reliable sequencing 
data, clusters can be uncovered using the Wd statistic (Lange, 1997). There will also be a 
higher frequency of case patients with variation in genes contributing to the disease 
compared to a random sample of the population. To capture this frequency increase 
requires a reference set that can represent this random sample of the population. 
The development of NGS techniques, particularly WES, provides researchers with new 
opportunities in elucidating the genetic etiology of diseases such as ToF, although it also 
presents its own challenges (Bansal et al., 2010). Disease-causing rare variants have to be 
extracted from the background of human variation and sequencing error. For any NGS 
study, filtering criteria to extract genuine rare variants of functional significance from the 
rest of variation are essential (Altmann et al., 2012). Filtering criteria need to be 
consistent across cases and controls in order to avoid introducing bias that may confound 
the results of a study. Ideally, case and control samples need to be sequenced together. 
This avoids the kind of bias that arises from using different sequencing and capture 
technologies and protocols for cases and controls (Derkach et al., 2014). It also avoids 
sequencing bias that may arise from the same sequencing platform being calibrated 
differently (Derkach et al., 2014). Differences in read depth between cases and controls 
can lead to differences in MAF estimation and, as a consequence, to spurious associations 
while true associations are missed (Derkach et al., 2014). Derkach et al. (2014) provide a 
method, the Robust Variance Score (RVS), to address these biases. With this method, 
Derkach et al. (2014) aim to make publicly available genome-wide data suitable as 
controls for large NGS case-control studies. Using large public control resources across 
studies could have a transformative effect, similar to what was seen in GWAS as first 
illustrated by The Wellcome Trust Case Control Consortium (WTCCC) study which 
compared 14,000 cases from 7 common diseases to 3,000 controls (Burton et al., 2007). 
However, the efficacy of this method remains to be confirmed through independent 
studies.  
In NGS case-control studies, testing whether a single rare variant is associated with a 
disease trait requires a number of sequenced samples in excess of what can often be 
practically achieved. For example, Lee et al. (2014b) estimate that 460 individuals would 
have to be sequenced in order to ensure a 99% probability of sampling an allele with a 
minor allele frequency (MAF) of 0.5%. Single variant testing becomes particularly 
problematic if a number of the variants associated with a disease trait are expected to be 
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private, in other words, only in a single individual. Another thing to remain mindful of is 
that there are large numbers of rare variants in the human genome, as confirmed by 
Tennessen et al. (2012), which will not be associated to disease. The study I present in 
this chapter is based on the assumption that a major cause of isolated sporadic ToF are 
single highly-penetrant rare variants. However, for many diseases, including some 
subtypes of CHD, a more complex etiology has been proposed over the years, leading to 
the methods that I will now present (Gelb and Chung, 2014). Given a CHD with a more 
complex genetic etiology of ToF, one of the following methods could form the basis of a 
future WES study design.  
The alternative to single variant testing mentioned above is to perform a multiple variants 
test. For this kind of test, distinct variants are aggregated according to some feature, such 
as a shared gene region or functional relevance (Bansal et al., 2010). This process is often 
referred to as collapsing (Dering et al., 2011). Collapsing involves a summarisation of the 
presence of rare variants within some unit of interest in both case and control samples 
(Bansal et al., 2010). All collapsing methods can be refined by selecting which type of 
variant to collapse. For example, collapsing can focus on rare truncating variants or 
variants predicted to be deleterious in genes or groups of genes (Dering et al., 2011). Lee 
et al. (2014b) describes five broad categories of multi variant tests: burden and adaptive 
burden tests, variance-component tests, omnibus tests and the exponential combination 
test. The first four sets of tested have been implemented in a number of methods working 
on different assumptions about patient sequence data (Lee et al., 2014b). 
Burden tests were the first to be devised, with Mogenthalier and Thilly’s (2007) ‘Cohort 
Allelic Sums Test’ (CAST). CAST represent collapsing in its simplest form: a binary 
value is assigned to each gene region in an individual depending on the presence or 
otherwise of rare variants in that region (Lee et al., 2014b). The results of CAST over 
cases and controls can be summarised as a score using Fisher’s exact test (Moutsianas and 
Morris, 2014). The assumption made here is that the mere presence of rare variants in a 
region increases disease risk (Lee et al., 2014b). To test a dominant genetic model; where 
each rare variant in some region contributes to the disease risk, the binary value becomes 
a count of the number variants in the region, a model underlying the MZ test by Morris 
and Zeggini (2010). The disadvantage of this approach is that any rare variant that has no 
effect on the disease trait will interfere with the signal of any real association. The 
aforementioned methods require a MAF threshold above which variants are excluded 
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from the test (Lee et al., 2014b). The presence of variants that are too common and 
therefore likely to be in cases and controls may interfere with the signal emanating from 
large effect rare variants associated with the disease. Setting a MAF threshold can lead to 
the exclusion of causal variants if too low or the inclusion of many non-causal variants if 
too high (Moutsianas and Morris, 2014). Both will reduce the test’s power. Putative 
differences in effect can be partially captured through a variant’s rareness. With their 
‘Weighted Sum Test’ (WST), Madsen and Browning (2009) replace the MAF threshold 
with a weighting system which varies as a function of a variant’s known MAF. Rarer 
alleles will be given a higher weight. The attribution of weights to variants is further 
explored by the ‘Combined and Multivariate and Collapsing’ (CMC) method which 
attempts to capture the effect of both rare and common variants on a disease trait, 
assigning weight in intervals (Li and Leal, 2008).   
Burden test have largely been superseded by adaptive burden tests, a number of methods 
that account for the possibility that specific variants within a collapsed region can have 
trait-decreasing effects or no effect at all (Lee et al., 2014b). Given that the actual 
direction of the effect of each variant is not known, estimates are made through a 
marginal model. In these tests, such as Han and Pan’s (2010) aSum test, variants that are 
estimated to have a trait-decreasing effect are given a negative weighting  (Moutsianas 
and Morris, 2014). One of the pitfalls of these methods however is that, in order to 
determine the statistical significance of a possible association, the test has to be carried 
out on every possible marginal model arising from a different distribution of the trait 
amongst individuals tested (Moutsianas and Morris, 2014). In other words, the model 
needs to account for all the possible phenotype distributions across a set of individuals. 
This makes scaling up the tests to the whole-exome or whole-genome impractical, if not 
impossible (Moutsianas and Morris, 2014). This issue is addressed by variance-
component tests, also referred to as dispersion tests (Lee et al., 2014b; Moutsianas and 
Morris, 2014). Unlike burden tests, variance-component tests were designed to account 
for trait-decreasing and neutral effects (Lee et al., 2014b). Variance-component tests 
analyse  the variance in genetic effects between variants in a group (Lee et al., 2014b). A 
test statistic is produced for each variant and it is the variance in these statistics that is 
analysed (Lee et al., 2014b). In the `Sequence Kernel Association Test’ (SKAT), the 
distribution of effects is compared with what would be expected under the null hypothesis 
of no association with a disease trait (Wu et al., 2011). As with burden testing, different 
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methods built around variance-component exists to address different assumed models of 
inheritance. To study a single trait with no covariates, the C-alpha test can be used (Neale 
et al., 2011). While variance-component tests provide their best results when a small 
fraction of variants influence the trait and are better equipped than burden tests to deal 
with trait-decreasing variants, burden tests still offer the best results when most variants 
within a specific region are trait-increasing (Lee et al., 2014b). Omnibus tests combine 
burden and variance-component tests, in an attempt to capture the advantages provided by 
both types of test (Lee et al., 2014b). However, this makes omnibus tests computationally 
intensive. 
In this chapter I present a WES case study involving 867 patients with ToF. Selecting 824 
cases for which variant calls presented high specificity, I first looked for rare variants 
called in genes previously implicated in ToF or CHD. This was followed by an analysis 
of the clustering of rare variants across the coding sequence (CDS) of genes and exons. 
Finally, I subjected genes containing rare variants to pathway analysis. At every stage in 
the case study, results were compared to those obtained in 490 patients with various 
neurodevelopmental disorders. This study reveals that rare truncating variants in known 
ToF genes; previously uncovered through gene sequencing studies, are found in 0.8% of 
patients, and rare variants predicted to be deleterious (excluding truncating variants) in 
3.6% of patients. Results from the study of clusters indicate that FLT4 and NOTCH1 are 
overrepresented in ToF patients. Furthermore, evidence suggests that FLT4 directly 
interacts with other genes that have been implicated in CHD. At the time of writing, this 
dataset represented the largest exome-sequencing study of a homogeneous CHD 
phenotype yet reported. 
5.3. Material and Methods 
The study initially included a total of 867 patients living in Northern Europe and 
presenting isolated ToF. DNA extracted from blood and saliva samples were provided by 
several laboratories working with Newcastle’s Institute of Genetic Medicine (IGM) as 
shown in Table 19. WES was performed at the McGill University and the Génome 
Quebec Innovation Centre (MUGQIC) using the Illumina HiSeq 2000 (Illumina, 2014a). 
The exome capture was performed using Agilent SureSelectXT Human All Exon 50Mb 
kit (Agilent Technologies, 2015). 
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Location Number of Samples 
Bristol Royal Hospital for Children, UK 70 
CONCOR, Netherlands 63 
Leeds General Infirmary, UK 147 
Centre for Human Genetics, Leuven University, Belgium 83 
Royal Liverpool Children’s Hospital NHS trust, UK 119 
Newcastle Royal Victoria Infirmary, UK 127 
Institute of Genetics, Nottingham University, UK 72 
Department of Cardiovascular Medicine, Oxford University, UK 142 
The Children’s Hospital at Westmead, Australia 44 
Table 19. Locations from which blood and saliva samples were obtained from 867 ToF patients. 
This large series of ToF cases was initially supposed to be accompanied by a sequencing 
matched reference set. However, we were not able to obtain this sequencing matched set. 
I therefore acquired sequencing data from the UK10K project European Genome-
Phenome Archive (EGA) for use as a comparator sample. Access to EGA was limited to a 
few studies. UK10K healthy controls were only available as low-coverage whole-genome 
sequencing (WGS) data. A number of WES disease cohorts were available for use as a 
comparator sample. These cohorts involved patients from the UK and Ireland, presenting 
various kinds of neurodevelopmental diseases. The four WES studies I selected include 
patients with autism spectrum disorder (AD), schizophrenia and mental retardation. These 
are summarised in Table 20. I selected cases for which the sequence data matched 
MUGQIC’s sequencing strategy; sequencing and exome capture using Illumina HiSeq 
2000 and Agilent SureSelectXT Human All Exon 50Mb kit. This further restricted the 
number of cases available to me. In total, I obtained 500 neurodevelopmental (NDD) 
cases to be used as controls in a prospective case-control study. Once I determined that a 
case-control study would not produce meaningful results due to systematic differences 
between the ToF and UK10K NDD data, I repurposed the NDD cases as a second set of 
samples against which to test the assumptions made at each stage of my WES case study. 
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Study name Pathologies studied Number of cases included 
in my study 
UK10K_NEURO_MUIR psychoses and mental retardation 48 
UK10K_NEURO_ABERDEEN schizophrenia 266 
UK10K_NEURO_ASD_GALLAGHER autism spectrum disorder 72 
UK10K_NEURO_EDINBURGH schizophrenia 114 
Table 20. Studies from which NDD cases were acquired. The study UK10K_NEURO_MUIR contains sequence 
data from the Illumina GAIIx which was consequently excluded. 
The work this study involves required large amounts of computing power and storage. I 
therefore carried out my analysis on two different computer clusters: Lampredi2; hosted 
at Newcastle University, and Hydra; at Manchester University. The clusters are described 
in detail in Chapter 2 in Section 2.3.1. I accessed the latter remotely from Newcastle. ToF 
and NDD sequence data files were provided in the BAM file format and the reads were 
extracted to produce FASTQ files in order for me to perform my own alignment. It was 
important for sequence alignment and variant calling to be consistent across all sets. The 
same process is described in Chapter 4. I performed alignments using BWA (Li and 
Durbin, 2009), removed duplicates using Picard (The Broad Institute, 2015c), and called 
variants using SAMtools (Li et al., 2009a), filtering out calls falling outside of the exome 
capture’s target region. In addition to ToF and NDD cases, I downloaded sequence data; 
in BAM file format, from 875 unrelated individuals present in the 1000genomes project 
(1000g) (Altshuler et al., 2012). I used the same procedure to get my own sequencing 
alignment. However, variant calls were restricted to a subset of loci of interest first 
identified in ToF and NDD cases and described below. 
For the purposes of the study, I estimated the sensitivity and specificity of each set of 
variant calls using population data, a technique described by Houniet et al. (2015). In this 
context, sensitivity corresponds to the rate with which the caller identifies variants at sites 
where variants are present. Specificity corresponds to the rate with which the caller does 
not identify variants at sites where variants are absent. A large number of erroneous 
variant calls can quickly become unmanageable in a large-scale study, masking the signal 
from genuine variants. I have therefore excluded from the study any cases that presented 
a specificity of ≤99%. In other words, any case that was likely to include many false 
positives. This means that the final case study effectively includes 824 ToF cases from 
867. Similarly, I retained 490 NDD cases out of 500 for this study. Every stage of the 
WES study involves this set of cases. 
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Given that ToF cases and NDD cases were sequenced independently, I set out to 
determine whether the two sets of cases were comparable and therefore whether NDD 
could be used as controls. To provide an ideal comparison, presence of a disease trait 
should be the only characteristic that differentiates a disease case set from a comparator 
set. Differences in sequencing or set composition can be the source of biases between sets, 
making an objective case-control comparison difficult. In order to determine this, for 
every gene I counted the number of cases with at least one high-confidence (Q30 in 
SAMtools) rare synonymous variant, testing for the hypothesis that no significant 
difference exists in counts between ToF cases and NDD cases. The comparison was done 
using Fisher’s exact test, producing a set of p-values that was then compare to a standard 
chi-square distribution. To determine whether sequencing bias might disappear with 
variants called with higher confidence, I repeated the same operation using a higher 
threshold for confidence (Q60). 
For this WES study, I only retained variants called with high-confidence (Q30). Using 
ANNOVAR (Wang et al., 2010), I annotated each set of  variant calls, providing me with 
the information needed to apply different filtering criteria. I used it to extract rare variants. 
Variants present in the 1000g and the Exome Variant Server (EVS) with a MAF≥1% 
were excluded from the study as too common to be of interest (MacArthur et al., 2014). I 
also excluded variants with a frequency of ≥1% in 418 in-house exomes from other 
studies. I excluded all variants shared between ToF and NDD cases and any variant 
appearing with a frequency of ≥1% in either set. In addition to removing common 
variants, these steps are also expected to remove a number of overrepresented sequencing 
artefacts. To further remove likely artefacts, I excluded any variant falling within a 
segmental duplication. Segmental duplications were detected using GenomicSuperDups 
which is part of ANNOVAR annotation (Wang et al., 2010). As a result of the difficulties 
inherent in indel calling, indel calls produced by SAMtools were much less reliable than 
those produced for SNVs. Indels were therefore removed from list of variants. These 
different filtering steps led to a list of variant sites that I used in every subsequent stage of 
the study. 
Using SAMtools, I called the aforementioned variant sites in 875 cases from the 1000g, 
thus providing a further list against which to filter results from ToF and NDD cases. 
Variants present in ToF or NDD cases that were also present in the 1000g at least once 
were filtered as part of a more stringent filtering criterion. This left only variants unique 
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to either set of cases. Additionally, this step removed artefacts. The list of variants from 
the 1000g available through ANNOVAR will have had some known artefacts removed 
from it. The variant sites I called from the 1000g will still carry these artefacts and can 
thus be used to remove the artefacts that may exist in my list of variants. It is worth 
pointing out that this filter is particularly stringent and will remove variants that would be 
estimated to have a MAF~0.05% but could be in fact much rarer due to the limited 
amount of alleles used to estimate the MAF. In Section 5.4, I annotated the results I 
obtained following my main filtering pipeline to account for the results of obtained after 
stringent filtering. 
At every stage of the WES study, I divided rare variants into four categories: truncating, 
predicted deleterious, non-synonymous and synonymous. Here I define variants as 
truncating if they are predicted to shorten the coding segment of a gene (Rivas et al., 
2015). This category includes nonsense variants and splice site variants. The following 
category; predicted deleterious, includes variants predicted as deleterious by a consensus 
of pathogenicity predictors, excluding truncating variants. The predictors used are 
MutationTaster, PolyPhen2 and LRT, as in Chapter 4. In order for a variant to be 
considered predicted deleterious, each pathogenicity predictor has to predict the variant to 
be at least possibly deleterious. The non-synonymous category includes all missense 
variants with the exception of those in the previous category. The synonymous category 
includes all variants that are synonymous and therefore does not overlap with any of the 
three other categories. To separate the effects of each category, it was crucial that none of 
the categories overlap. This was particularly crucial for the truncating and predicted 
deleterious categories for which deleteriousness was determined through dissimilar 
approaches.  
The first step of this WES ToF study was to establish the presence of rare truncating 
variants and rare variants predicted deleterious in genes previously implicated in ToF and 
CHD. Mutated genes that influence the risk of ToF will be more common in ToF patients 
than in patients with some unrelated disease, a fact that is expected to be reflected in the 
number of cases with one or more rare variants in known ToF genes. I therefore 
compared genes harbouring rare variants in 824 ToF cases to two sets of genes implicated 
in ToF as summarised in Table 21. 
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Gene set Disease Genes in set  Source 
Known ToF ToF (isolated) 20 Gene sequencing studies (see Table 18) 
IVA  ToF (isolated) 42 Ingenuity Variant Analysis software
™
  
ToF syndrome ToF (syndromic) 80 Winter-Baraitser Dysmorphology Database 
HRC  CHD 312 HeartRepair consortium 
Zaidi  CHD (severe) 276 Study by Zaidi et al. (2013) 
CHD syndrome CHD (syndromic) 674 Winter-Baraitser Dysmorphology Database 
Cilia CHD (cilia) 61 Study by Li et al. (2015) 
Table 21. Summary of gene sets used in the study of variants in genes previously implicated in ToF or CHD. 
The first set contained genes that were causally linked to isolated ToF through gene 
sequencing studies; presented in Table 18, while the second set contained genes identified 
through Ingenuity Variant Analysis software
™ 
(QIAGEN, 2015) as affecting isolated ToF. 
One gene in the set identified through Ingenuity Variant Analysis software
™
, TGFB1, 
was annotated as having a “protective effect” and was therefore excluded. Additionally, I 
looked at variants in genes associated with syndromes that involved ToF, catalogued by 
the Winter-Baraitser Dysmorphology Database (London Medical Databases, 2014). I also 
compared the genes in my study to two sets of genes implicated in various types of CHD, 
also summarised in Table 21. The first set originated from the HeartRepair Consortium 
(HRC) (EU FP7 Consortium). The HRC is a European research group investigating 
cardiac development through various methods. The different consortium members have 
contributed to a set of candidates, each using their own criteria of selection, but with the 
unifying theme that the genes were somehow involved in CHD. The second set was 
compiled for a study on the contribution of de novo variants to severe CHD, including 
ToF (Zaidi et al., 2013). Zaidi et al. (2013) selected genes associated to CHD through 
human and model system studies. As before I compared genes harbouring variants in my 
study to genes associated with syndromes, in this case involving CHD, compiled in the 
Winter-Baraitser Dysmorphology Database (London Medical Databases, 2014). 
Following a study by Li et al. (2015) suggesting that genes involved with cilia 
development and cilia-transduced signalling play a major role in CHD, I decided to 
include these genes into my study. The mutated mouse orthologs of these genes were 
found to cause CHD (Li et al., 2015).  Some overlap between sets is to be expected. The 
overlap between categories pertaining to ToF and CHD in general are shown in Figure 23, 
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where I have grouped ToF lists and CHD lists together. Most of the genes from the 
known ToF gene set are included in the IVA gene set. Comparing all the gene sets 
pertaining to ToF with the cilia gene set shows overlap only in 2 genes. 
For each gene set, I calculated the odds ratio of ToF cases harbouring rare variants; first 
truncating followed by predicted deleterious, in candidate genes for ToF or CHD over 
NDD cases. 
 
Figure 23. The overlap between the gene sets pertaining to ToF (top left) and between those pertaining to CHD 
(top right). Also shown is the overlap between all ToF gene sets and all CHD gene sets with the cilia gene set 
(bottom). 
 121 
 
The next step in the WES ToF case study was to detect clustering in rare variants in the 
four categories delineated above. Variants contributing to disease are expected to cluster 
within specific gene or exons. The different categories provide a gradient of predicted 
effect against which the amount of clustering can be contextualised. For this, I 
implemented the Poisson approximation of The Wd statistic described by Lange (1997). 
Assuming that each position in the coding region of the exome is equally likely to carry a 
rare variant, the statistic estimates the probability of observing more than the expected 
number of rare variants for a given length of coding sequence (CDS) given the total 
number of variants in the exome and the total number of CDS and their lengths. I set the 
threshold for significance as α=0.05. For this study, I define two sets of CDS: The coding 
portion of the gene and the exon. For the gene, coding regions were determined using 
known gene transcripts. The number of protein-coding genes was established to be 19,214, 
while the number of exons 233,785, from records in the Ensembl database (Cunningham 
et al., 2015). These values were used to correct for multiple-testing. The identifiers and 
sizes of known protein-coding transcripts and specific exons were also obtained from the 
Ensembl database using BioMart to shape and download the query (Cunningham et al., 
2015). Ensembl provides transcripts which have different levels of support, signalled by a 
transcript support level (tsl) flag. For this study, I only used gene transcripts marked as 
tsl:1 which signifies the following: “all splice junctions of the transcript are supported by 
at least one non-suspect mRNA” (Cunningham et al., 2015). I counted variants falling 
within a CDS using two different schemes. For the first scheme, if a variant at one 
particular position was seen in several different patients it was still only counted once. I 
refer to this first scheme as clustering by position. This ensured that any remaining non-
rare variants or sequencing artefacts repeating across individuals did not lead to excessive 
clustering, while masking genuine clusters of rare variants. In a second scheme, I counted 
the actual number of rare variants in patients. I refer to this second scheme as clustering 
by variant. For comparison, I also looked at clustering within genes and exons in NDD 
cases. In order to compare clustering in ToF and NDD cases, I sampled variants in ToF 
cases 1000 times in each category, with each new sample containing the same number of 
variants as in NDD cases. This is an important step given the difference in the number of 
cases with ToF and NDD. I looked for any clustering in genes previously implicated in 
CHD using the gene sets described in Table 21. 
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Finally, I performed pathway analysis on the genes identified at different stages of this 
project. As in chapter 4, I started by using STRING v.10 (Jensen et al., 2009), followed 
by EnrichNet (Glaab et al., 2012). Using STRING, I looked at the interaction between the 
protein products of the genes found in each clustering category. I first looked for 
enrichment in interaction, followed by specific enrichment in gene ontology (GO) terms 
(Gene Ontology, 2004) and KEGG interaction pathways (Kanehisa and Goto, 2000). 
Using EnrichNet, I interrogated a number of pathway databases to uncover any over-
representation of genes belonging to a certain pathway or process. The significance of 
overrepresentation is judged using two metrics: the level of overlap between query genes 
and genes in a pathway; given as a q-value, and the distance of query genes to genes in a 
pathway; given as an XD-score. The evidence gathered from different layers of enquiry 
was used to determine which genes could play a role in ToF. 
5.4. Results 
5.4.1. Sequence data presentation 
My study originally focused on 867 ToF cases sequenced by MUGQIC and 500 NDD 
cases, sourced from various UK10K studies that were to be used for comparison. The 
mean depth of coverage for each set and the number of variants per case is given in Table 
22 along with an overall estimation of the sensitivity and specificity using population data 
(Houniet et al., 2015). The mean read depth per ToF case is nearly twice that of NDD 
cases. This likely stems from differences in sequencing protocol between case sets. 
 
 ToF cases (n=867) NDD cases (n=500) 
Read depth per case (mean) 93.9 49.9 
Number of Q30 variants per case (mean) 38589 39668.8 
Estimated sensitivity (%) 95.9 93.3 
Estimated specificity (%) 99.5 99.7 
Table 22. Description of sequence data from ToF and NDD cases in target regions before the selection of cases 
with high specificity. 
As an initial quality filtering step, I excluded cases that were in the lower specificity 
range, with an estimated specificity ≤99%. These are shown in Figure 24. Overall, 824 
ToF cases and 490 NDD cases were estimated to have a specificity >99%. All other cases 
were not used for the remainder of the study. 
Table 22 hints at some systematic difference between sets. This may be the result of 
variations in sequencing protocol which can affect the frequency with which a particular 
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allele is observed in a set of cases. The variability in allele frequencies imputable to 
disease may consequently be masked by the variability introduced by different 
sequencing protocols. To determine whether the two sets are comparable, for each gene I 
compared the number of ToF and NDD cases with at least one high-confidence rare 
synonymous variant. I ended up with an individual count per gene for each set. The 
counts per gene in each set were compared using Fisher’s exact test and the resulting 
distribution was compared to a chi square distribution. If the two sets have comparable 
variant counts, the resulting distribution should approximately follow a chi-square 
distribution. The distribution of my data did not follow the expected chi-square 
distribution, as shown in Figure 25. There was more variance in variant counts between 
the two sets than would be expected by chance alone. This manifests in Figure 25 as an 
upward curve. Figure 26 shows the same experiment over higher-confidence variants 
(Q60). Selecting variants from higher-confidence calls does not lead to a chi-square 
distribution. A comparison of allele frequencies in case sets, following the designs 
described in Section 5.2.2, is therefore likely to be compromised by sequencing bias. 
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Figure 24. Estimates of sensitivity and specificity in 824 ToF cases and 490 NDD cases. The line represents a cut-
off threshold of 99%. Cases below the threshold are excluded from the study. Data visualisation provided by 
Mauro Santibañez-Koref. 
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Figure 25. Distribution for each gene compared with a standard distribution of Fisher’s exact test statistics. The 
distribution does not approximate the chi-square distribution. 
 
 
Figure 26. Distribution for each gene (variants Q60) compared with a standard distribution of Fisher’s exact test 
statistics. Despite quality selection, the distribution does approximate the chi-square distribution. 
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Variant calls for each case were filtered to contain only high-quality rare variants. The 
mean count of these rare variants and the category they belong to are summarised in 
Table 23. There appears to be more rare SNVs of all categories per ToF case than per 
NDD case. The largest difference concerns truncating SNVs with around 1.5 times more 
variants per ToF case than per NDD case. In the categories that contain indels, the 
differences between ToF and NDD cases were more pronounced. There were around 3.8 
more indels predicted deleterious per ToF case than per NDD case. The differences are 
not necessarily biologically meaningful and could also be the result of differences in 
sequencing protocols. Alternatively, it can be the result of different set sizes, with the 
rarer variants having a lower probability of being represented in a set of 490 cases over a 
set of 824 cases. 
Category ToF cases (n=824) NDD cases (n=490) 
 SNVs Indels SNVs Indels 
Truncating 8.9 6.4 6 3.6 
Predicted deleterious 47.1 7.5 39 2 
Non-synonymous 105.9 0 81.1 0 
Synonymous 79.1 0 56 0 
Table 23. Mean count per patient of rare variants in each variant category. Categories are mutually exclusive. 
 
5.4.2. Variants in genes implicated in congenital heart disease 
Given known issues with indel calling using SAMtools, I decided to primarily focus on 
SNVs. I started by focusing on those rare SNVs categorised as truncating and therefore 
with the highest potential to be damaging. Do any of these rare truncating SNVs occur 
within genes previously associated with ToF or CHD? How many ToF cases are these 
rare SNVs found in? To answer these questions, I used the seven sets of genes previously 
associated with either ToF or a range of CHDs, described in Section 5.3. Answers are 
provided by the data presented in Table 24.
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Gene set Carrier frequency in 
ToF cohort (%) 
Number of genes Number of SNVs Carrier frequency in 
NDD cases (%) 
Number of genes Number of SNVs 
Known ToF  0.8 5 7 0 0 0 
IVA  2.2 10 19 0.4 2 2 
ToF syndrome 3.3 23 35 2.4 10 12 
HRC  11 91 139 9.6 41 48 
Zaidi  10.4 88 139 10.2 36 54 
CHD syndrome 21.8 227 376 23.7 104 139 
Cilia 5.9 30 67 4.7 15 23 
Table 24. Rare truncating SNVs in ToF and NDD cases present in genes from CHD gene sets. For results with indels see Appendix, Table S3.
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Of particular note is the fraction of ToF cases with truncating rare SNVs in known ToF 
genes. Rare truncating SNVs in known ToF genes were found in 0.8% of ToF cases. The 
truncating SNVs occurred across 5 ToF genes: GATA6, JAG1, NKX2-6, NODAL and 
TBX1. NKX2-6 and NODAL both harboured two variants each. Allowing for genes more 
loosely implicated in ToF by using the set provided from IVA’s data mining increased the 
fraction of ToF cases in which genes were found to 2.2%. Considering genes implicated 
in syndromes in which ToF has been observed instead of the isolated ToF genes from the 
previous two sets resulted in a carrier frequency in ToF patients of 3.3%. A little over 10% 
of ToF patients had at least one truncating variant in genes that belonged to the Zaidi or 
HRC gene sets. Rare truncating SNVs in genes implicated in syndromes with any CHD 
phenotype were found in 21.8% of cases. All three sets cover a larger array of genes than 
previous sets, particularly the latter. It is therefore to be expected that a higher fraction of 
ToF cases have truncating variants in genes that appear in these sets. Variants in genes 
belonging to the Cilia gene set were found in 5.9% of ToF patients. To establish whether 
the genes in each set are more prevalent in ToF cases than in some unrelated disease 
requires a point of comparison. I performed the same analysis on NDD cases, the results 
of which are shown in Table 24. 
The most interesting result was that, in 490 individuals with NDD, not a single rare 
truncating SNV was found in a known ToF gene. Two individuals with NDD did have 
truncating variants in genes associated with ToF according to IVA. The two genes in 
question, MYOM2 and TCEB3, originated from a single study by Grunert et al. (2014). 
MYOM2 was found both in ToF cases and NDD cases. The differences between ToF and 
NDD patients for other gene sets were less striking. For example, a total of 2.4% NDD 
patients had at least one truncating variant in a gene previously implicated in syndromes 
that include ToF, compared to 3.3% in ToF patients. This result is altogether not 
unexpected given that some syndromes will involve both CHD and neurodevelopmental 
disorders. Patients with CHARGE syndrome for example; caused by mutations in CHD7, 
can present both ToF and mental retardation (Michelucci et al., 2010). To establish 
whether genes in a particular gene set were significantly more prevalent in ToF cases than 
in NDD cases, I calculated an odds ratio for each set. The odds ratios are given in Table 
25. The odds of truncating variants being found in genes associated with ToF; whether in 
the Known ToF or IVA gene set, were substantially higher in ToF cases than in NDD 
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cases. However, this did not extend to genes implicated in syndromes of which ToF is a 
part. For other gene sets, Fisher’s test did not reach statistical significance and the odds 
gravitated towards 1. Lower odds are to be expected when looking at CHD genes, many 
of which have yet to be shown to influence the risk of ToF. Conversely, many of them 
could be associated with neurodevelopmental disorders. This conclusion is particularly 
applicable to the CHD syndrome gene set. Additionally, the HRC gene set contains a 
subjective selection of CHD genes some of which could be only tenuously linked to CHD. 
Given that the two sets of cases were not well-matched, one must exercise great care in 
interpreting these results. 
Gene set Odds ratio (p-value) 
Known ToF  ∞ (3.79E-2) 
IVA  5.44 (6.76E-3)  
ToF syndrome 1.35 (2.49E-1) 
HRC  1.17 (2.32E-1) 
Zaidi  1.03 (4.86E-1)  
CHD syndrome 0.9 (7.99E-1) 
Cilia 1.28 (2.01E-1) 
Table 25. The odds of ToF cases having truncating variants in relevant genes over NDD cases. 
For both ToF and NDD patients, I looked at the distribution of truncating SNVs in genes 
from the HRC set. 80 of 91 genes harboured less than 3 variants in ToF cases. All 41 
genes with SNVs in the NDD cases had less than 3 variants. Both ToF and NDD cases 
had truncating SNVs for 16 of these genes. Table 26 lists the few genes for which 
variants were found only in ToF patients and for which there were more than 3 truncating 
SNVs. For this gene set, NOTCH1 was revealed to be the gene with the largest number of 
variants. IGF2 presented an equal number of truncating variants, but these are all filtered 
out if stringent filtering is applied. 
HRC genes Number of truncating variants 
IGF2*, NOTCH1  5 
EDN* 4 
CHFR, CLTC, MESP1, PRKG1, SCN5A,VCL 3 
Table 26. HRC set of genes for which there are at least 3 truncating SNVs in 824 ToF cases, but not in 490 NDD 
cases. *SNVs in gene completely removed by stringent filtering. 
Having looked at rare truncating SNVs, I then turned to variants predicted as deleterious. 
It is worth reiterating at this stage that truncating SNVs were not included in this category. 
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The results for ToF and NDD cases are shown in Table 28. SNVs predicted to be 
deleterious in known ToF genes were found in 3.6% of ToF patients. It is important to 
note at this stage that a number of missense variants were found in known ToF genes in 
two gene sequencing studies carried out on a subset of the ToF cases being studied here 
(Griffin et al., 2010; Topf et al., 2014). TBX1 and HAND2 were among the genes 
sequenced in these two studies. In order to avoid bias from variant rediscovery, I carefully 
surveyed the variants found in my analysis and compared them to those found in the two 
gene sequencing studies. There was no overlap in the variants that were found. As shown 
in Table 23, per individual, the number of rare SNVs predicted to be deleterious is an 
order of magnitude larger than the number of rare truncating SNVs. This translated to a 
high carrier frequency for each gene set, whether ToF or NDD patients were being 
studied. 
Table 27 provides the list of known ToF genes observed in ToF cases. Genes for which 
truncating SNVs were found all also harbour at least one SNV predicted to be deleterious 
in ToF cases. Notably, there were six SNVs fitting that description in JAG1. 
Known ToF genes Number of variants predicted deleterious 
JAG1  6 
GATA4 5 
BVES, TBX5, ZFPM2 3 
FOXH1, GATA5, GATA6, NODAL 2 
GJA5, HAND2, NKX2-6, TBX1, TDGF1  1 
Table 27. Known ToF genes for which there are variants predicted deleterious in 824 ToF cases. 
NDD patients also presented variants in known ToF genes. Given that the damaging 
potential of these variants is more uncertain; as it relies on pathogenicity prediction tools, 
this result was not entirely surprising. Five genes for which SNVs were found in ToF 
patients also harboured SNVs in NDD patients: BVES, FOXH1, JAG1, NKX2-6 and TBX5. 
Three variants were found in JAG1 in NDD patients for example. The contrasts between 
ToF and NDD patients observed when studying rare truncating variants in known ToF 
genes did not carry over to rare variants predicted as deleterious. However, the odds ratios 
did reveal some differences, as shown in Table 29.
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Gene sets Carrier frequency 
in ToF cases (%) 
Number of genes Number of SNVs Carrier frequency in 
NDD cases (%) 
Number of genes Number of SNVs 
Known ToF  3.6 14 33 1.8 5 9 
IVA 9.2 32  85 8.2 16 42 
ToF syndrome 27.8 54 289 17.6 42 93 
HRC  65 229   995 58.6 172 449 
Zaidi  59.5 184  877 54.7 143 396 
CHD syndrome 89.2 469 2255 87.6 391 1106 
Cilia 30.1 44 312 33.5 43 205 
Table 28. Rare SNVs predicted to be deleterious in ToF and NDD cases that are present in genes from CHD gene sets. For results with indels see Appendix, Table S4. 
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ToF patient presented more than twice the odds of having a variant predicted to be 
deleterious in a known ToF gene as an NDD patient. Given the increased number of 
SNVs included in this category, statistical significance was reached for several gene sets. 
This was the case for the HRC and the ToF syndrome gene sets. The latter gene set 
presented an odds ratio of 1.8 in favour of ToF patients. Whether statistically significant 
or otherwise, other gene sets had odds ratios close to 1. 
Gene sets Odds ratio (p-value) 
Known ToF  2.02 (4.18E-2) 
IVA  1.14 (2.91E-1)  
ToF syndrome 1.8 (1.33E-5) 
HRC  1.32 (1.12E-2) 
Zaidi 1.22 (5.11E-2)  
CHD syndrome 1.17(2.06E-1) 
Cilia 0.86 (9.09E-1) 
Table 29. The odds of ToF cases having variants predicted as deleterious in relevant genes over NDD cases. 
To determine if SNVs in specific genes of the ToF syndrome set might be responsible for 
the observed odds ratio, I looked at gene-specific odds ratios and their distribution in ToF 
and NDD cases. Genes for which variants predicted to be deleterious were found largely 
overlapped in ToF and NDD cases. Among the 10 genes with the most SNVs in ToF 
cases, only PDX1 was not represented in NDD cases. However, on further inspection, 
many of the 13 individuals with variants in PDX1 were found to share one of two 
recurring variants, leaving only two unique variants. To compare variants in ToF and 
NDD cases, I therefore chose to focus only on the proportion of individuals with unique 
variants. Furthermore, for each gene only one variant was counted per individual. The 
results of this analysis are shown in Table 30. The odds of a variant being observed in 
NOTCH1 in a ToF patient were 5 time higher than in an NDD patients. Results for other 
genes did not reach statistical significance. 
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ToF syndrome 
genes 
SNVs pred. deleterious in 
ToF patients 
SNVs pred. deleterious in 
NDD patients 
Odds ratio (p-value) 
NOTCH1 25 3 5.07 (1.63E-3) 
DOCK6 15 3 3.01 (5.22E-2) 
ATP7A 9 1 5.39 (6.46E-2) 
CHD7 9 3 1.79 (2.86E-1) 
ACE 9 7 0.76 (7.89E-1) 
GLI3 6 3 1.19 (5.51E-1) 
EHMT1 8 1 4.79 (9.45E-2) 
BOC 8 3 1.59 (3.63E-1) 
Table 30. Genes from the ToF syndrome set with the most SNVs predicted to be deleterious after recurring 
variants have been excluded. 
Whether the focus is on truncating variants or variants predicted to be deleterious the 
odds of finding rare variants in known ToF genes in ToF cases rather than NDD cases 
were consistently higher. Additionally, there were slightly higher odds of finding variants 
predicted as deleterious in genes from the ToF syndrome gene set in ToF patients than in 
NDD patients. The overabundance of NOTCH1 carried part of that trend. 
5.4.3. Identification of variants clustering in genes and exons 
Results like those shown for NOTCH1 in Table 30 suggest that rare variants are clustered 
within certain genes in ToF patients. Following the assumption that each position in the 
coding sequence (CDS) of the exome is equally likely to carry a variant, clustering then 
refers to a higher concentration of variants than expected by chance within a stretch of 
CDS given the overall variant rate. If ToF patients harbour variants that are disease-
causative, some level of clustering across corresponding genes should be discernible in 
the disease-specific population. The second step in this WES study consisted in 
identifying such clusters in ToF cases and sorting them by gene. Genes for which clusters 
were found in ToF and NDD cases were excluded as not disease-specific. It is important 
to stress that this does not constitute a comparison between ToF and NDD cases, as the 
two sets were not well-matched, as shown in Section 5.4.1. The NDD cases here provided 
a filter for clusters that were not specific to ToF cases. Genes were also excluded if 
clustering was also found in the Synonymous category in ToF cases given that 
synonymous variants are unlikely to lead to be disease-causative. 
As outlined in Section 5.3, I started by looking at clustering of SNVs by position. These 
results are shown in Table 31 for every category of rare variant at gene and exon level. 
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The number of genes in which clusters occur at both levels was also determined. Clusters 
were identified in a total of 144 genes. Among these genes, 13 were identified both in 
ToF and NDD cases. Crucially, none of these overlapping genes were found in the 
Truncating category. This is significant given that the category concentrates the most 
likely highly-deleterious variants. Looking at the overlap between the categories in ToF 
cases showed 15 genes present in at least two categories. 7 of the 15 genes overlapping 
categories in ToF cases were also present in NDD cases. The recurrence of these genes is 
likely to be the product of their high tolerance to mutation, leading to false cluster 
detections. Both the Non-synonymous and Synonymous categories, which are expected 
not to concentrate disease-causing variants presented many clusters. 
CDS type ToF cases (n=824) NDD cases (n=490) 
Truncating 6,802 2,623 
Gene 3 1 
Exon 7 6 
Both 1 0 
Predicted deleterious 34,065 16,454 
Gene 30 11 
Exon 19 8 
Both 4 0 
Non-synonymous 73,043 34,627 
Gene 37 9 
Exon 19 9 
Both 7 0 
Synonymous 53,767 24,159 
Gene 18 4 
Exon 8 6 
Both 2 0 
Table 31. Number of genes that showed evidence of clustering (by position) at gene and exon levels. The total 
number of positions in each category in ToF and NDD cases is given in the header of each section. Only SNVs 
were considered here. 
Despite not being able to compared ToF and NDD cases directly, I was able to compare 
their rates of clustering. To do this, the same number of positions had to be studied in 
both. As shown in Table 31, the number of positions studied for ToF cases is at least 
twice that of NDD cases, due not only to the higher number of ToF cases, but also 
differences in sequencing. In order to get an approximation of the number of clusters that 
would be observed in ToF cases given the same number of positions as in NDD cases, I 
sampled the positions in ToF cases 1000 times to match the number of positions in NDD 
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cases. For example, for the truncating category, I created 1000 samples from ToF cases 
covering 2,623 positions randomly selected from the original 6,802. For each of these 
lists, I uncovered clusters around gene and exons and produced an average number of 
clusters. The results of this process are shown in Table 32. With some exceptions, ToF 
and NDD cases showed similar numbers of clusters. If disease-causative variants were 
responsible for most ToF cases, more clustering in ToF cases should have been observed 
in the Truncating and Predicted Deleterious category. No clear indication of this was 
found. 
CDS type NDD cases (n=490) 1000 ToF cases samples (from n=824) 
  
Average 
Fraction with more clusters 
than NDD cases 
Truncating 2,623  
Gene 1 1.7 0.51 
Exon 6 7.5 0.64 
Predicted deleterious 16,454  
Gene 11 9.4 0.23 
Exon 8 8.8 0.53 
Non-synonymous 34,627  
Gene 9 11.4 0.76 
Exon 9 6.5 0.07 
Synonymous 24,159  
Gene 4 4.9 0.57 
Exon 6 4.1 0.04 
Table 32. Average number of genes which showed evidence of clustering (by position) at gene and exon levels 
after sampling of positions in ToF cases (NDD cases are shown for comparison). The fraction of samples that 
produced a higher number of clusters than observed in NDD cases is also indicated. Only SNVs were considered. 
Clusters of truncating SNVs were found across 9 genes, most of these identified within a 
single exon. Most clusters were found to include no more than 3 truncating SNVs. The 
exceptions were clusters in genes CCDC102B and FLT4, with cluster sizes in the gene of 
5 and 8 SNVs respectively; where cluster size refers to the number of SNVs in the cluster. 
The clusters were specific to the Truncating category, the only exception being a cluster 
of 8 SNVs in the non-synonymous category across CCDC102B. Table 33 describes those 
genes in which clusters were found. The clusters are not affected if stringent filtering is 
applied. 
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Gene Clustering level Cluster size (p-value) 
A2M Exon 2 (3.72E-2)  
CCDC102B Gene/ Exon 5 (3.57E-2) / 3 (2.65E-2)  
CTPS2 Exon 3 (2.74E-3)  
FLT4 Gene 8 (1.28E-2) 
PHF10 Exon 3 (9.16E-3)  
RAD9B Exon 3 (4.07E-3)  
SHPK Exon 3 (2.98E-2)  
TAC3 Gene 3 (4.36E-2) 
TNPO1 Exon 3 (2.98E-3)  
Table 33. Size and p-value of clusters (by position) of truncating SNVs in ToF patients. The clusters of truncating 
variant in NDD patients do not occur in the same genes. 
There were considerably more clusters in the Predicted Deleterious category. In total, 
clusters were found in 48 genes. Among these, 4 genes were also the site of clustering in 
NDD cases: ATG2A, PCDH9, PRRC2C and ZNF423. SNVs in the Synonymous category 
in ToF cases were also found to cluster in PRRC2C and ZNF423 and APC2. The same 
genes were found in the Non-synonymous category as well, with the addition of ATG2A. 
The abundance of SNVs in these genes across multiple categories and, more importantly, 
across cohorts suggested a high gene mutation rate independent of ToF. Applying 
stringent filtering to the list leads to the further exclusion of 5 genes: ADAMTS17, 
MEF2D, SLC26A1, STX6 and VCL. Table 34 lists the 10 genes with the most significant 
clustering relative to gene or exon size; excluding the 9 genes just mentioned. The full list 
can be found in the Appendix as Table S6. The list includes NOTCH1 which was 
identified in Section 5.4.2 as having an overabundance of variants in ToF patients 
compared to NDD patients. The presence of a cluster in NOTCH1 in ToF cases, but not in 
NDD cases thus consolidates previous results. The largest clusters were found in NEB and 
HMCN1 with a variant count larger than 50. Unlike clusters in the previous category, a 
majority of clusters were found spanning several exons rather than being concentrated 
within a single one. 
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Gene Clustering level Cluster size (p-value) 
HMCN1 Gene 56 (4.37E-7) 
SERBP1 Gene/ Exon 14 (6.18E-7) / 9 (1.92E-5) 
MYO7A Gene 30 (6.36E-6) 
NAV2 Gene 32 (6.38E-6) 
GLDC Gene 20 (9.11E-6) 
NEB Gene 58 (2.83E-5) 
NELL1 Gene 17 (4.80E-5) 
NOTCH1 Gene 31 (7.89E-5) 
SNCAIP Gene 6 (8.95E-5) / 4 (2.99E-2) 
PTPN5 Exon 6  (1.35E-4) 
Table 34. Size and p-value of the 10 most significant clusters (by position) of SNVs predicted to be deleterious in 
ToF patients, excluding those with an equivalent in NDD cases and the Synonymous SNV category. The full list 
is in the appendix in Table S6.  
After looking at clusters by position, I looked at clusters formed by variants counted for 
each occurrence; which I refer to here as by variant. The number of clusters in each 
category for ToF and NDD cases is shown in Table 35. Here again I considered only 
SNVs. This approach to clustering led to a sharp increase in each category both in ToF 
and NDD cases when compared to results from clustering by position. This suggests, 
despite filtering for rare variants, that many variants shared by multiple unrelated 
individuals remained in the data. The application of stringent filtering supports this view 
as large numbers of clusters from the first three categories were discarded as a result. This 
was particularly true of clusters in exons for both the Predicted Deleterious and Non-
synonymous categories with 79 and 126 clusters removed after stringent filtering. The 
results after stringent filtering are shown in the Appendix in Table S5. A total of 51 genes 
were found in at least two categories, 14 of which were also found in NDD cases. 
However, there was once more little overlap between the Truncating category and other 
categories. CCDC102B was once again shared by Truncating and Non-synonymous 
categories. GCKR and TPO were shared with the Synonymous category. FLT4, 
previously found to harbour significant clustering in the Truncating category for ToF 
cases, was also found in the same category for NDD cases. Crucially however, the 
clustering was limited to exon 2 and involved the same exact variant in 4 different NDD 
patients. By contrast, the cluster in ToF cases involved 8 distinct rare variants. Therefore, 
the presence of a cluster in FLT4 in NDD patients does not affect the importance 
attributed to the cluster in ToF patients. 
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CDS type TOF cases (n=824) NDD case (n=490) 
Truncating 7,326 2,964 
Gene 34 34 
Exon 60 81 
Both 24 25 
Predicted deleterious 38,826 19,105 
Gene 80 31 
Exon 186 159 
Both 43 18 
Non-synonymous 87,247 39,763 
Gene 126 29 
Exon 222 54 
Both 67 9 
Synonymous 65,177 27,453 
Gene 83 13 
Exon 255 58 
Both 50 7 
Table 35. Number of genes that showed evidence of clustering (by variant) at gene and exon levels. The total 
number of variants in ToF and NDD cases is given for each category. Only SNVs were considered. 
I once again compared ToF and NDD cases through sampling. The results are shown in 
Table 36. The numbers of genes with clusters in each category varies widely between 
ToF and NDD cases. This is true of categories where little variation was expected such as 
the Synonymous category. There were almost systematically less clusters in the samples 
of ToF cases for the Truncating and Predicted Deleterious categories compared to NDD 
cases. The opposite tendency was observed in the remaining two categories. One possible 
explanation for this observation is that it represents disease-specific clustering in the 
NDD cases. However, it is difficult to for a conclusion in this case given that ToF and 
NDD cases were not well-matched. The excess clustering in NDD cases could also be due 
to a higher number of artefacts in that set of cases over ToF cases. 
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CDS type NDD cases (n=490) 1000 TOF cases samples (from n=824) 
  
Average 
Fraction with more clusters 
than NDD cases 
Truncating 2,964  
Gene 34 11.1 0 
Exon 81 24.4 0 
Predicted deleterious 19,105  
Gene 31 25.5 0.07 
Exon 159 68.2 0 
Non-synonymous 39,763  
Gene 29 38.8 0.99 
Exon 54 74.1 1 
Synonymous 27,453  
Gene 13 20.8 0.97 
Exon 58 66.4 0.87 
Table 36. Average number of genes which showed evidence of clustering (by variant) at gene and exon levels 
after sampling of positions in ToF cases (NDD cases are shown for comparison). The fraction of samples that 
produced a higher number of clusters than observed in NDD cases is also indicated. Only SNVs were considered. 
In the following sections, I have therefore decided to focus on results obtained from the 
study of clustering when SNVs were counted by position rather than by variant. 
5.4.4. Clustering in genes implicated in CHD 
Having identified clusters in genes and exons, some fraction of which could be 
hypothetically explained by genes influencing the risk of ToF, I then compared the sets of 
CHD genes to all clusters for ToF case. Were any of the genes in which clusters were 
found already implicated in ToF or CHD more generally? The results are given in Table 
37, with a gene by gene break down for each category in the Appendix, Table S7. Table 
38 provides the list of genes for which clusters were found in the Predicted Deleterious 
category for ToF cases, but not in the Synonymous category or in NDD cases. 
Gene sets Truncating Predicted Deleterious Non-Synonymous Synonymous 
Known ToF  0 0 0 0 
IVA  0 0 0 0 
ToF syndrome 0 2 0 0 
HRC  0 4 2 1 
Zaidi  0 2 1 0 
CHD syndrome 0 6 4 4 
Cilia 0 1 0 0 
Table 37. Number of genes from CHD gene sets that harbour clusters (by position) for ToF cases. There is some 
overlap between genes found in each gene set. For list of genes see appendix, Table S7. 
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None of the genes included in ToF and IVA sets presented clustering. Clusters in two 
genes of the ToF syndrome set were found in the Predicted Deleterious category, 
NOTCH1 and PORCN; NOTCH1 is also shared by the HRC, Zaidi and CHD syndrome 
sets. As in sections above, the cluster in NOTCH1 stood out with 31 SNVs. 
Gene Gene set Clustering level Cluster size (p-value) 
ADAMTS17* CHD syndrome Gene 17 (4.15E-3) 
CC2D2A CHD syndrome, Cilia Exon 4 (4.07E-2) 
COL3A1 CHD syndrome Gene 19 (1.62E-2) 
MEF2D* HRC Gene 6 (2.00E-2) 
MYOM1 HRC Exon 5 (3.19E-3) 
NEK2 Zaidi Gene 10 (2.09E-2) 
NOTCH1 ToF/CHD syndrome, HRC, Zaidi  Gene 31 (7.89E-5) 
PORCN ToF/CHD syndrome Exon 4 (4.72E-2) 
VCL* HRC Gene 13  (4.74E-2) 
Table 38. Genes present in CHD gene sets for which there are clusters (by position) in the Predicted Deleterious 
category only for ToF cases. Also excluded are genes in the Synonymous category. *Gene no longer in list if 
stringent filtering is applied. 
 
5.4.5. Pathway analysis. 
I started by submitting genes in which SNVs cluster to STRING v.10 (Jensen et al., 2009). 
I then ran these same genes through EnrichNet (Glaab et al., 2012). STRING required at 
least 10 genes in order to calculate interaction enrichment. I therefore combined the 
Truncating and Predicted Deleterious categories for this step, producing a total list of 54 
genes. The potential protein-protein interactions identified by STRING are shown in 
Figure 27. STRING determined the set of genes not to be enriched in interactions (p-
value=6.60E-1). A total of 4 interaction networks were found, including one with 4 
interacting proteins. The networks included genes found in the HRC gene set MEF2D, 
NOTCH1 and VCL. On closer inspection, not all protein-protein interactions appeared 
convincing. Evidence of protein-protein interactions for the protein products in the 
network containing 4 proteins; NMNAT1, LARS, CTPS2, PUS7, relied entirely on 
evidence from homologous genes in other species. As a result, the highest combined 
score (CS) for that network was 0.479, between NMNAT1 and LARS. The predicted 
interactions between NEB and VCL (CS=0.472) and between COL3A1 and ZNF423 
(CS=0.437) relied solely on the co-mention of proteins and genes in publications, a fairly 
vague criterion to base interaction on. By contrast, the putative interactions between 
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MEF2D and NOTCH1 (CS=0.764) and between NOTCH1 and FLT4 (CS=0.946) showed 
stronger interactions, with varied types of evidence. In addition to co-mention of 
NOTCH1 and FLT4 in 50 publications, homologs in other species were found to interact 
in experimental and biochemical interactions. This result is particularly interesting given 
that the network included both NOTCH1 and FLT4, genes singled out in previous sections. 
 For comparison, I performed the same step for NDD cases. This produced a list of 26 
genes. STRING determined that there was no enrichment in interactions in this list either 
(p-value=1.16E-1). A single interaction network was found, including the proteins of 
genes GRIK, DLG3 and TANC1. Interestingly, GRIK is associated with depersonalisation 
disorder; a type of psychosis, and DLG3 with mental retardation, suggesting this network 
could be of biological significance for NDD cases. However, the combined score for their 
predicted interaction was only 0.476. Running either of these lists of genes through 
EnrichNet did not return any significant enrichment for known pathways or processes. 
The genes GRIK and DLG3 were found to belong to a group of ionotropic activity of 
kainite receptors, but this was only significant in terms of network distance distribution 
(XD-score=1.8) and not overlap (q-value=6.7E-2).  
As an additional test, I submitted all genes with at least one unique rare truncating SNV 
in ToF cases, and then in NDD cases, to EnrichNet. This resulting in a gene set of 4,971 
genes in ToF cases and 2,309 genes in NDD cases, a large fraction of the total of human 
genes. Both resulting gene sets were enriched for ABC transporters (ToF cases: XD-
score=3.2 and q-value=2.2E-4; NDD cases: 2.7 and q-value=2.2E-5) according to KEGG, 
while the gene set for ToF cases was also enriched for genes involved in 
glycosaminoglycan degradation (XD-score=3.169 and q-value=4E-2). 
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Figure 27. Protein-protein interactions for genes in which clusters of SNVs in Truncating and Predicted 
Deleterious categories were found. 
While the functional link found between NOTCH1 and FLT4 could prove to be 
significant if FLT4 is confirmed to play a role in ToF, the STRING analysis did not lead 
to any new conclusions regarding potential pathways involved in ToF. The results from 
EnrichNet pathway analyses were similarly inconclusive. 
5.5. Discussion 
The work presented in this chapter provides both evidence of overrepresentation of 
known and potential ToF genes in ToF patients compared with NDD patients. In this 
Section I will review the evidence gathered for different genes. 
5.5.1. Re-discovery of known ToF genes 
In Section 5.4.2, I reported that rare truncating SNVs in known ToF genes; genes 
previously implicated in ToF via gene sequencing studies (Table 18), were found in 0.8% 
of ToF patients while being completely absent from NDD patients. This involved 5 of 20 
known ToF genes with NKX2-5 and NODAL each harbouring two SNVs each. 3.6% of 
ToF patients were found to harbour SNVs predicted as deleterious in 14 of 20 known ToF 
genes. Many of these SNVs were found in JAG1 and GATA4. However, rare SNVs were 
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also found in 1.8% of NDD patients. Both sets of patients had variants in the same set of 
5 genes. One particular striking example is JAG1, for which 6 SNVs were found in ToF 
patients and 3 in NDD patients. On the other hand, there were also genes with rare SNVs 
only in ToF patients, such as GATA4 with a total of 5 SNVs. ToF patients were shown to 
have twice the odds of having a rare variant predicted deleterious in a known ToF gene 
than NDD patients. But what can explain the 1.8% of NDD patients with SNVs predicted 
to be deleterious in known ToF genes?  
There are two main reasons such results should be expected. The first reason is that a 
number of the variants detected in either set of patients may have been determined as 
deleterious when they are in fact benign. Inferring disease-causing potential for a 
missense variant requires the use of in-silico functional prediction tools with limited 
accuracy (Schwarz et al., 2010). Given that these SNVs would have no influence on the 
incidence of ToF they would be unlikely to be found concentrated in either cohort. 
However, we would still expect to be able to detect the effect of those SNVs correctly 
predicted as deleterious as is likely to be the case in my data. It is also worth noting that 
other deleterious variants might be predicted as benign by at least one functional 
prediction tool, in which case they would fall in the Non-synonymous category and not be 
counted. The second reason we should expect such results is that, among the truly 
deleterious SNVs, there might be some that can contribute to neurodevelopmental 
disorders as well as ToF. Rare SNVs found in JAG1 and predicted as deleterious were 
found in both ToF and NDD patients. Mutations in JAG1 have been implicated in 
Allagille Syndrome which in turn have been known to include neurodevelopmental 
defects such as mental retardation in some rare cases (Rauch et al., 2006). It could 
therefore be hypothesised that SNVs in a gene like JAG1 would contribute to ToF in one 
set of patients and neurodevelopmental disorders in others. Despite this potential overlap, 
rare deleterious SNVs in ToF genes should be more consistently implicated in isolated 
ToF and therefore present in larger proportions among ToF patients over NDD patients.  
This final observation is more difficult to apply to genes in which ToF is part of a 
syndrome. Not only do these syndromes not always involve ToF, they can involve many 
types of neurodevelopmental disorders. As was discussed in Section 5.2.1, 22q11.2 
deletion syndrome is a recurrent cause for ToF. It has also been associated to psychosis 
and ASD, disorders represented in the NDD cases in this study (Wu et al., 2014). Despite 
this, the data appears to indicate higher odds of ToF patients having rare variants 
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predicted deleterious in genes for syndromes involving ToF (see Table 29). A gene by 
gene analysis revealed several genes to be more frequent in ToF cases rather than NDD 
cases although only the overabundance of SNVs in NOTCH1 produced statistically 
significant results. Given that the ToF and NDD cases are not well-matched set, these 
results can only be interpreted as indicative of a potential role for NOTCH1 in ToF, with 
additional evidence needed to complement this finding. It is worth noting that truncating 
SNVs in NOTCH1 were also found in 5 ToF patients and not in NDD patients. NOTCH1 
is catalogued as a cause of Adams-Oliver syndrome; the main feature of which are skin 
and limb abnormalities,  in the Winter-Baraister Dysmorphology Database  (London 
Medical Databases, 2014). CHD is observed in 20% of cases of Adams-Oliver syndrome 
and one possible CHD subtype is ToF (Stittrich et al., 2014). Incidentally, NOTCH1 is 
not the only gene from this set to be involved in Adams-Oliver syndrome. DOCK6, with 
an odds ratio near statistical significance, has also been implicated in the syndrome. One 
paper by Wessels and Willems (2010) claims that NOTCH1 has been implicated in non-
syndromic ToF. This appears to be based the identification of a NOTCH1 mutation in a 
family with aortic valve disease (Garg et al., 2005). The only individual in the pedigree 
with ToF was not evaluated as deceased at the time, but the presence of a NOTCH1 
mutation in other individuals with CHD in the same pedigree does provide some evidence 
that NOTCH1 is implicated in isolated ToF. There is also additional evidence for a role 
for NOTCH1 in ToF from the study of CNVs. A study of 34 infants with isolated ToF; 
which do not include cases of 22q11 deletion syndrome, by Bittel et al. (2014) revealed 
two patients with CNVs encompassing the NOTCH1 gene. In another study of CNVs in 
114 ToF patients, Greenway et al. (2009) identified a single individual with 6 CNVs 
coinciding with NOTCH1 and JAG1 gene regions. Rare truncating SNVs in NOTCH1 
were found in 0.6% of ToF patients, while SNVs predicted as deleterious were found in 
4.1%, a proportion larger than for the list of 20 known ToF genes. Additionally, in 
Section 5.4.5, NOTCH1 was found to have 10 possible functional links with known TOF 
genes, particularly JAG1, another gene from the Notch-signalling pathway. 
Results from the IVA gene set indicate that the odds of observing a rare truncating SNV 
in a gene of the IVA set were more than five times higher for ToF patients than NDD 
patients. However, this difference between ToF and NDD patients disappeared when 
SNVs predicted as deleterious were considered instead. What could explain such a strong 
disparity between the results from the set of known ToF genes and IVA genes? As shown 
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in Figure 23, most genes from the known ToF set are accounted for in the IVA gene set. 
Of the remaining 25 genes identified by IVA, a total of 16 were selected for inclusion 
based on a single paper by Grunert et al. (2014). This implies that any shortcomings with 
the methodology of that particular study could have a large effect on the observed results 
for that particular gene set. The fact that the odds did not favour either ToF or NDD 
patients when rare variants predicted to be deleterious were considered suggests that the 
odds ratio observed for truncating SNVs could be largely led by known ToF genes rather 
than a feature of the IVA gene set. 
What results obtained using ToF-oriented gene sets broadly suggest is that the genes 
previously implicated in ToF; whether by gene sequencing studies or through other 
methods, can only account for a small fraction of ToF cases. It cannot be determined 
which fraction of patients have truly deleterious variants in known ToF genes, but it 
cannot exceed 4.4% of patients.  
The final results to consider are those that arise from the CHD gene sets, mainly the HRC 
and Zaidi sets. The genes in these sets do not appear to be harbouring proportionally more 
variants in either ToF or NDD patients. In Section 5.4.2, I pointed to the size of these sets 
compared with ToF specific gene sets and problems with the methodology of selection as 
potential reasons for these results. A case can be made that this provides further evidence 
that distinct CHD subtypes should be studied separately. Many deleterious gene variants 
will be specific to particular types of CHD. Selecting rare variants in ToF patients 
previously associated with CHD in general might therefore not yield meaningful results. 
In the case of genes from the study by Zaidi et al. (2013), this could be indicative of 
histone-modifying genes playing very little role in ToF specifically. This was the case for 
this study. The combination of ciliopathies and CHD in the Cilia gene set did not produce 
any distinct signal either in ToF patients either. This suggests that if cilia genes do 
influence the risk of CHD, this is not particularly applicable to ToF. Admittedly, many of 
these genes, when mutated, were accompanied by heterotaxy, a phenotype not commonly 
associated with ToF (Li et al., 2015) . 
In Section 5.4.2, I presented the identification of a number of new SNVs in known ToF 
genes as well as SNVs in NOTCH1 which is occasionally described in the literature as a 
cause for ToF, although not systematically. The existence of these SNVs remains to be 
validated by Sanger sequencing in future work. Several genes not previously implicated 
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ToF, but involved in CHD which have appeared to be more abundant in ToF patients 
could play a role in the disease. However, it is not possible to reach a conclusion for these 
genes without an adequate comparator set. Additional comparisons of ToF cases with a 
well-matched reference set should provide additional evidence for some of these gene 
candidates.  
5.5.2. Genes potentially involved in isolated ToF from clustering 
The number of clusters varied significantly depending on the approach taken. The number 
of clusters varied strongly depending on whether clusters were determined by position or 
by variant. Determining clusters by counting each variant regardless of whether it had 
appeared in other individuals already led to a sharp increase in the number of clusters. 
Through sampling of variants in ToF patients, I was able to compare the proportional 
number of clusters in ToF and NDD cases (see Table 36). Where clusters had been 
obtained by counting each occurrence of a variant instead of each variant position once, 
NDD cases had more clusters of the Truncating and Predicted Deleterious category while 
ToF cases had more clusters of the Non-synonymous and Synonymous category. By 
comparison, counting variants by position led to ToF and NDD cases with similar 
numbers of clusters as evidenced in sampling results (see Table 32). This suggested that 
there was no excess of clustering in ToF cases compared to NDD cases. Assuming that 
ToF is largely brought on by single highly-penetrant rare variants while NDDs are the 
product of several interacting common and rare variants, one would expect to see more 
clustering in ToF patients than in NDD patients. This in turn suggests that highly-
penetrant rare variants do not play a major role in ToF. 
The first observation that can be made about genes for which there is evidence of 
truncating SNV clustering in ToF cases is that many of these clusters were extremely 
small and many resided near the threshold of statistical significance (see Table 33). One 
example was the cluster detected in A2M in exon 35. It is unlikely that a cluster that 
includes only 2 SNVs will truly be significant. This finding most likely reflects the small 
size of exon 35. Only two genes were the site of clustering involving more than 3 variants, 
CCDC102B and FLT4, with clusters of 5 and 8 respectively. Clustering was also found in 
CCDC102B in the Non-synonymous category. Both of these genes thus appeared to have 
a genuine overabundance of truncating SNVs in ToF patients. In the case of FLT4, this 
fact must be balanced with the discovery of a cluster in NDD cases as well when clusters 
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were counted by variant. However as described in Section 5.4.3, this was the result of a 
single variant identical in four NDD patients and thus not the product of a very rare 
variant. 
A number of other details about the gene suggest a potential role. FLT4; also previously 
described as VEGFR-3, encodes a tyrosine kinase receptor for vascular endothelial 
growth factors C and D. In humans, mutations in the gene cause Milroy disease 
(lymphedema) with the causative variants identified in patients with the disease occuring 
within the kinase domains (Connell et al., 2009). However, Dumont et al. (1998) showed 
that the early inactivation of Flt4 in mice leads to the abnormal development of large 
blood vessels, including the dorsal aorta. They concluded that “VEGFR-3 has an essential 
role in the development of the embryonic cardiovascular system before the emergence of 
the lymphatic vessels” (Dumont et al., 1998).  These results were corroborated by later 
studies in mice (Haiko et al., 2008). Further mining the literature using IVA (QIAGEN, 
2015) revealed that FLT4 directly interacts with 3 genes that are all associated with 
cardiac defects found in ToF patients: VEGF, NOS3 and STAT3. The VEGFR3 protein 
binds with the VEGFA protein (Kukk et al., 1996). Vegfa, when knocked out in mice can 
lead to an overriding aorta, VSD and persistent truncus arteriosus (Stalmans et al., 2003). 
In fact, Stalmans et al. (2003) explicitly describe cardiac defects in some of these mice as 
ToF. The VEGFR3 protein also increases activation of the eNOS protein (Lahdenranta et 
al., 2009). Nos3 knockout in mice has been known to lead to VSD (Feng et al., 2002). 
Finally, the VEGFR3 protein increases activation of STAT3 protein (Korpelainen et al., 
1999). Stat3 knockout in mice cardiac cells can lead to pulmonary stenosis (Zhang et al., 
2009). The different pathways from FLT4 to CHD are represented in Figure 28. 
CCDC102B by comparison, is not well characterized. 
In addition to rare truncating SNVs having been found in FLT4 in ToF patients, a single 
CNV encompassing the gene FLT4 was also found in a study by Soemedi et al. (2012b) 
of 283 ToF trios; including probands analysed in this study. Soemedi et al. (2012b) found 
that 3 of the 5 genes covered by the duplication in 5q35.3 are expressed in fetal heart. The 
results of my study would suggest that it is the disruption of FLT4 that leads to ToF in 
this patient. 
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Figure 28. Pathway from FLT4 to CHDs relevant to ToF as seen in IVA (QIAGEN, 2015). 
A large number of clusters were found for rare SNVs predicted deleterious. This included 
a cluster in NOTCH1, one of the genes in which we have previously established an 
overabundance of SNVs in ToF cases. Some of the top clustering results involved long 
genes with SNVs spread across many exons with no particular region showing a 
concentration of SNVs. This was the case for HMCN1, MYO7A, NAV2 and NEB. None of 
these genes have been reported as involved in cardiogenesis. HMCN1 mutations have so 
far been identified as the cause of age-related macular degeneration (Schultz et al., 2003). 
NEB has been determined as the leading cause of nemaline myopathy (Lehtokari et al., 
2006). Mutations in MYO7A have led to cases of deafness and Usher syndrome; which 
leads to visual impairments in addition to deafness (NCBI, 2015). None of those genes 
appear to present links with cardiogenesis. On the other hand, 9 of 14 SNVs in SERBP1 
were found in the first exons, forming a cluster at both exon and gene level. Variants in 
SERBP1 have not been linked to disease, but the protein product of the gene binds with 
the mRNA product of SERPINE1; a serine proteinase inhibitor, which has been 
implicated in thrombophilia; an increase in the risk of blood clotting (Rebhan et al., 1998).  
The only indication of a large cardiac defect being associated with the mutated gene was 
in a patient presenting an inferior vena cava interruption; in addition to a deep vein 
thrombosis, who also had a variant in SERPINE1 (Galati et al., 2011). The patients also 
had several other variants in genes associated with thrombophilia (Galati et al., 2011). 
NELL1 mutations lead to congenital skeletal defects (Desai et al., 2006). Cases of 
syndromic ToF have been accompanied by skeletal defects; as in Alagille syndrome 
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(Bauer et al., 2010). However, no link between NELL1 and congenital heart disease has 
been established yet. 6 SNVs were found in SNCAIP including 4 in a single exon. 
However, this exon is non-coding in the particular transcript for which clustering was 
detected (Cunningham et al., 2015). PTPN5 presents an interesting case as 6 SNVs were 
identified specifically in one of 15 exons. It has been suggested that another protein 
tyrosine phosphatase, PTPN11, influences the susceptibility of an individual to ToF; in 
this case through the action of a common variant (Goodship et al., 2012).  
One of the limitations of this study was the absence of a well-matched reference set 
which could act as a control, that is, individuals not selected for the presence of any 
specific condition, who had been sequenced using identical methodology. A study of the 
ToF patients which uses controls from the 1000 genomes project is currently underway. 
This study will follow some of the methodologies outlined in Section 5.2.2, which could 
not be applied to this current study. The results of these future studies will complement 
the study presented in this chapter. Further work will also involve the refinement of 
cluster detection strategies. The rate of variation differs for each gene and could have an 
impact on cluster detection. This should be taken into account for better cluster 
identification. The recent release of the repository ExAC offers one possible resource that 
could provide per gene estimates of variation rate. 
5.6. Conclusion 
At the time of writing, this study is the largest WES study of ToF yet reported. It involved 
the study of 824 ToF patients against 490 patients with various neurodevelopmental 
disorders. Despite the inherent limitations of the comparator set, I was able to uncover an 
overabundance of genes previously implicated in ToF in ToF patients compared to NDD 
patients. For one specific category, this extended to genes previous implicated in 
syndromes that involved ToF. However, these genes only accounted for a small fraction 
of ToF patients. I used clustering to uncover genes that may also be implicated in ToF. 
With support from pathway analysis and the existing literature on the genes found, I was 
able to uncover a promising candidate, FLT4. My study also strongly suggests that 
NOTCH1 in involved in the manifestation of sporadic non-syndromic. This study also 
suggests that highly-penetrant variants can only explain a small fraction of ToF cases, 
leading to the conclusion that a more complex genetic etiology might be at work in many 
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ToF cases. Further refinements in methodology and in the choice of comparator set 
should provide more insight. 
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Chapter 6. General Discussion
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6.2. Summary 
The overarching aim of this PhD was to uncover potential causal rare variants in patients 
with congenital heart disease (CHD). My work had three aspects: the study of families in 
which a disease trait was segregating, the study of de novo mutation in sporadic cases of 
transposition of the great arteries (TGA) and the study of a large series of cases of 
tetralogy of Fallot (ToF). Each of these studies was conducted using WES and focused on 
variants found in protein-coding regions. 
The study of CHD was initiated with the analysis of 8 families. 7 of these families 
exhibited cardiovascular disease, 5 with a CHD phenotype; the other two displaying 
relapsing cardiomyopathy and atypical Brugada syndrome (BrS) respectively. The 8 
families had been analysed over the course of a few years and remained unresolved. 
There can be many possible reasons for the absence of suitable candidates in such 
projects, starting with the genuine absence of causal rare variants. For example, the 
disease could have been triggered by a rare copy number variant (CNV) or represented an 
aggregation of sporadic cases. Another reason could be the poor quality of sequencing at 
particular loci, leading the causal variant to be missed in one or more carriers. The design 
and implementation of BAMily was an attempt to address this second issue. I analysed all 
8 families using BAMily and SAMtools. This was followed by the analysis of de novo 
mutation in sporadic cases of TGA. 32 probands were sequenced with their unaffected 
parent; and in one family an unaffected sibling. The cohort only included non-syndromic 
cases of TGA; cases that did not exhibit additional cardiac or extracardiac defects. The 
third analysis was based on a large series of 867 non-syndromic ToF cases. This study 
was originally envisioned as a case-control comparison. However, we were unable to 
obtain a control set sequenced at the same site as the non-syndromic ToF cases and with 
the same technology. I concentrated on finding clusters of variants within our cases and 
used as a reference set 500 cases from multiple studies of neurodevelopmental disorders 
(NDD) from the UK10K study (Wellcome Trust Sanger Institute, 2010). This was the 
closest dataset in terms of sequencing approach available to me at the time. I found the 
sets not to be suitably matched, but was nonetheless able to gain insights into the genetic 
etiology of ToF.  
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In this chapter, I review each of the three studies, including limitations and possible 
improvements, and integrate the main findings and discuss them in relation to the primary 
objective of my thesis. 
6.3.  Limitations. 
6.3.1. Limitations working with WES data 
In Chapter 3, I presented some of the limitations intrinsic to WES data. Specifically, I 
described how a new approach to variant calling could address issues arising from 
imperfect sequence coverage. I implemented and tested the variant caller BAMily which I 
subsequently applied to the 8 families in which a disease was segregating. These 
limitations also informed the design of the study of non-syndromic TGA. In this study, I 
obtained variants from the consensus of two variant callers, SAMtools (Li et al., 2009a) 
and GATK UnifiedGenotyper (DePristo et al., 2011) in order to limit the number of false 
positives. In each study, calling indels proved to be problematic. Many indels were picked 
out as false positives in IGV (Robinson et al., 2011). I excluded indels from the core of 
the study of non-syndromic ToF patients. Indels were judged on a case by case basis in 
other studies.  
6.3.2. Limitations due to study assumptions 
Each WES analysis presented in this thesis was built on the assumption of single rare 
variants causing disease. The analysis of non-syndromic TGA and ToF patients was also 
based on the assumption that these variants were highly penetrant. Each assumption 
implies limitations on what results can be found.  
In two families, no potential causal variants were identified. For these families, a more 
complex genetic etiology could be at work. Overall, likely causative SNVs and indels 
were found in 5 out of 8 families; or 62.5% of families. This rate of success is comparable 
to the 60% reported by Gilissen et al. (2012) for their WES projects centred on Mendelian 
disease. Extending the search for rare variants to CNVs led to the discovery of a causative 
CNV in one of the families. 
The study of 32 TGA patients and their parents yielded 24 de novo variants across 14 
probands, with 16 variants in 11 probands predicted as deleterious by at least one 
pathogenicity predictor. The rate of de novo variants per proband was 0.75, comparable to 
the estimated rate of de novo variants in the protein-coding exome on average per 
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newborn of 0.74; determined from the rate for whole-genome (Veltman and Brunner, 
2012b). If most TGA cases in this study arose through highly-deleterious de novo 
mutations, this would be reflected by the rate of de novo variants per proband due to 
effect of selection bias (Girard et al., 2011). Instead, what the rate found suggests is that 
highly-deleterious de novo do not account for most TGA cases. This was the general 
conclusion put forward by Zaidi et al. (2013) for severe CHD. Specifically, Zaidi et al. 
(2013) estimated that de novo mutation could contribute 10% of severe CHD. In their 
study, Zaidi et al. (2013) compared the rate of de novo variants per individual in genes 
selected for their expression in the embryonic mouse heart cases and controls. With rates 
of 0.88 and 0.85 de novo variants per individual in cases and controls, Zaidi et al. (2013) 
determined that the difference between patients with severe CHD and controls was not 
statistically significant. The study also reported few de novo variants to which TGA could 
be attributed. For 65 TGA patients, no more than 3 potentially causative de novo 
mutations were found. In my own study I have concluded that de novo variants are not the 
major factor in the development of TGA. The current approach can be used to elucidate 
the few cases that are due to disease-causing de novo variants. Prospective disease-
causative de novo variants that have been validated have been identified in 3 TGA 
patients; or around 10% of cases. However, a different approach will be needed to 
complement the genetic etiology of TGA. 
The principal limiting factor in the study of non-syndromic ToF patients was the lack of a 
well-matched reference set, as discussed in Chapter 5. The rate of clustering in each 
cohort of patients nonetheless strongly suggested that my starting assumption did not 
apply to non-syndromic ToF either. The rates of clustering, when variants were only 
counted once per position, in truncating SNVs and SNVs predicted as deleterious were 
equivalent for ToF and NDD patients. This suggested one of two possibilities: either 
highly-deleterious rare SNVs influence the risk of disease to a high degree in both sets of 
patients or it does so in neither. There are at least two reasons to suspect the latter is true. 
One reason is that NDD have already been identified as polygenic disorders, arising from 
the combined action of several common and rare variants (Clarke et al., 2015). 
Incidentally, this could explain the higher rate of clustering in NDD patients when each 
variant was counted for both truncating SNVs and SNVs predicted as deleterious with 
this approach favouring variants that are near the limit between common and rare variants. 
A second reason is the small role that SNVs in genes previously implicated in ToF play in 
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this cohort. Genes previously implicated in ToF through gene sequencing studies showed 
no sign of clustering. Only 0.8% of ToF patients had truncating SNVs in these genes, 3.6% 
of ToF patients if variants predicted as deleterious were considered instead. In this latter 
case, only a fraction of the SNVs uncovered will truly be disease-causative. The relative 
absence of clusters in genes that can be associated with a CHD phenotype also suggests 
highly-deleterious rare SNVs cannot account for the majority of ToF cases. Clusters in 
FLT4 and NOTCH1 are the exception and as such, their finding is the main result of the 
study.  
The assumptions made for cluster detection also place limits on this last study. It was 
assumed that the number of rare variants found in any segment of the exome of a set size 
would be the same regardless of locus. This leads to false clustering in genes that tolerate 
high mutation rates. In this study, I tackled this issue by excluding genes in which 
synonymous variants cluster. I also excluded genes with any type of clustering found in 
NDD patients. However, an approach that can avoid these false clusters in the first place 
is needed. I make suggestions of improvement in the following section. 
6.3.3.   Potential disease-causing variants. 
The WES studies centred around cardiovascular disease have led to several outcomes. 
With the large series of non-syndromic ToF cases, the influence of genes implicated in 
ToF through gene-sequencing studies was reaffirmed, albeit with a smaller contribution to 
disease etiology than suggested by the original studies (see Table 1, Chapter 5). The role 
of mutation in NOTCH1 in the development of ToF phenotypes was also reaffirmed 
(Wessels and Willems, 2010). While SCN5A and SCN10A have both been implicated in 
Brugada syndrome previously, the identification of a CNV spanning both genes 
constitutes a new finding (Hu et al., 2014). For 7 genes in particular, evidence from the 
literature supports a role in cardiovascular disease: CLTCL1, FLT4, GREB1, HES1, 
POPDC3, RBP5 and SLC5A6. There is some evidence to suggest that a rare de novo 
variant in SNX13 in a patient with non-syndromic TGA could also be disease-causing 
although this is still a speculative conclusion. The discovery of disease-causing variants 
in families in which disease is segregating involved the design and implementation of a 
new variant caller: BAMily.  
Variants in NOTCH1 were found in multiple studies. A missense variant in NOTCH1 was 
detected; and subsequently validated, in a family in which two siblings were diagnosed as 
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having pulmonary atresia (PA) and ventricular septal defect (VSD) accompanied by 
major aortopulmonary collateral arteries (MAPCA). Interestingly, the combination of PA 
and VSD; occasionally with MAPCA, is typically interpreted as a variation of the ToF 
phenotype (Prieto, 2005). Additionally, 5 nonsense variants were found in NOTCH1 
among non-syndromic ToF patients that were not found in NDD patients. NOTCH1 was 
also found to harbour a cluster of single nucleotide variants (SNV) predicted as 
deleterious in ToF patient. No cluster was found among synonymous variants or in any 
category of SNV for NDD patients. While it is not possible to ascertain which specific 
SNVs predicted as deleterious are disease-causative, the truncating SNVs are likely to be 
disease-causative. NOTCH1 has been implicated in ToF, in a single individual in a family 
case study and a in a single CNV in a study of ToF patients (Garg et al., 2005; Greenway 
et al., 2009). My results demonstrate that disease-causative variants for NOTCH1 are 
found in non-syndromic ToF patients as well. Interestingly, the variant in the family I 
studied is assumed to have reduced penetrance as neither parents present the disease 
phenotype (see Chapter 3, Figure 6). It is therefore possible that some NOTCH1 variants 
could also have reduced penetrance in non-syndromic ToF patients. 
Another strong gene candidate in the development of ToF is FLT4. 8 nonsense variants 
were found to cluster within FLT4 in ToF patients. The protein product of FLT4 interacts 
with the protein from 3 genes; VEGF, NOS3 and STAT3, through binding and increased 
activation (Feng et al., 2002; Stalmans et al., 2003; Zhang et al., 2009). These genes have 
been implicated in cardiac defects found in ToF. Also of interest is the fact that the 
expression of STAT3 is also regulated by another gene previously implicated in ToF, 
PTPN11 (Zhang et al., 2009; Goodship et al., 2012). A common variant in PTPN11 was 
shown to influence the risk of developing ToF (Goodship et al., 2012). FLT4 and 
PTPN11 could be influencing disease risk through STAT3. 
A de novo missense variant in RBP5 was found in a patient with non-syndromic TGA. A 
variant in that gene had previously been implicated in a case of total anomalous venous 
return (Nash et al., 2015). Investigating this result, Nash et al. (2015) created Zebrafish 
mutants in rbp7a, the closest homolog to RBP5. In almost half of fish, the mutation led to 
abnormal looping of the heart (Nash et al., 2015). The fact that the gene encodes a 
retinol-binding protein is also particularly significant given that the intake of retinol 
supplements during pregnancy or the injection of retinoic acid in a pregnant mouse 
triggers TGA in offspring (Loffredo et al., 2001). 
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Two missense variants, in HES1 and PODC3, were found in a pair of siblings with 
double-outlet right ventricle (DORV). The most promising candidate was the variant in 
HES1. Like NOTCH1 and JAG1, HES1 is a component of the Notch signalling pathway 
(Rochais et al., 2009). The homolog Hes1 is expressed in the second heart field during 
cardiogenesis in mice, playing an essential role in outflow tract development (Rochais et 
al., 2009). POPDC3 shares sequence similarity with BVES, a gene implicated in ToF 
through gene sequencing studies (Wu et al., 2013). My own study of non-syndromic ToF 
cases does not support the notion that BVES plays a substantial role in ToF which casts 
some doubt on the role of POPDC3 on DORV. 
For two missense variants, in genes CLTCL1 and GREB1, evidence of a potential role in 
cardiac malformation was obtained from CNV studies. A variant in CLTCL1 was found in 
a mother and daughter presenting complex CHD profiles which included extracardiac 
features; such as lymphoedema in the mother. CLTCL1 is one of the genes lost as a result 
of a 22q11.2 deletion (Michaelovsky et al., 2012). Crucially, the daughter had an 
interrupted aortic arch (IAA). Half of IAA cases are attributable to a 22q11.2 deletion 
syndrome (Kobrynski and Sullivan, 2007). Although the deletion of TBX1 has been 
typically designated as the main contributor of cardiac defects in 22q11.2 deletion 
syndrome, a role for CLTCL1 cannot be excluded. A de novo missense variant in GREB1 
was found in a non-syndromic TGA patient. In a study conducted by Fakhro et al. (2011), 
GREB1 was lost as a result of a rare CNV in a case of malposition of the great arteries 
(Fakhro et al., 2011). Expression patterns in Xenopus Tropicalis suggested a role in 
cardiogenesis, specifically left-right patterning (Fakhro et al., 2011).  
One non-syndromic TGA patient has a de novo missense variant in SNX13. Knockouts of 
the mouse homolog SNX13 lead to abnormal blood vessel morphology and embryonic 
lethality (Zheng et al., 2006). There is potentially a link between sorting nexins and 
heterotaxy; a feature of syndromic TGA cases, via ciliopathies (Ware et al., 2011; Chen 
et al., 2012). However, this line of reasoning remains highly speculative at this stage. 
Two of the three WES study designs used to uncover disease-causing variants made use 
of BAMily. The design, implementation and testing of the variant caller are covered at 
length in Chapter 3. In addition to laying the foundation for a new approach to variant 
calling, BAMily has contributed to the discovery of potentially disease-causative rare 
variants in families with a disease that is segregating and in non-syndromic TGA patients. 
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6.3.4.   Outlook 
The WES analysis of patients with various cardiac defects throughout this PhD has led to 
the discovery of likely disease-causing variants. In due course, these will be studied in 
biological experiments investigating the mechanisms that lead to heart disease. The 
necessity for a new approach to variant calling has also led to the design and 
implementation of the variant caller BAMily, which has contributed to variant discovery 
in two analyses. However, what these analyses have also revealed is that only a small 
fraction of non-syndromic TGA and ToF cases can be attributed to highly-penetrant rare 
variant. This is consistent with what the literature already suggests for severe CHD, 
whether SNVs or CNVs are considered (Greenway et al., 2009; Soemedi et al., 2012b; 
Zaidi et al., 2013). Elucidating the genetic etiology of sporadic CHD will therefore 
require the study of rare variants that influence the risk of disease with varying effect 
sizes. Methods for collapsing rare variants might provide some insight in the short-term 
(Lee et al., 2014b). However, detecting the effect of single rare variants that are not fully 
penetrant will require large case-controls studies with a number of patients vastly 
exceeding what has been done for CHD in terms of WES studies to date (Zuk et al., 
2014). 
6.4.  Conclusion 
The overarching aim of this PhD was to discover likely causal rare variants in patients 
with CHD as well as a few other congenital defects. The work I carried out towards 
fulfilling this aim revealed promising candidates across 9 genes: CLTCL1, HES1, 
POPDC3, NOTCH1, FLT4, SLC5A6, GREB1, RBP5 and SNX13. With the exception of 
NOTCH1, these genes have not previously been implicated in the diseases of the patients 
in which candidates were found. NOTCH1 harbours likely disease-causing variants in two 
distinct studies, a familial case of PA/VSD/MAPCA and patients with sporadic non-
syndromic ToF. Many of the genes in which likely causative variants were uncovered for 
this thesis will be the subject of biological experiments. In the process of identifying 
potential causal rare variants, I have established that highly-deleterious mutations do not 
contribute to the majority of non-syndromic ToF and TGA cases, suggesting a more 
complex genetic etiology. Future studies of CHD will undoubtedly focus on elucidating 
the genetic contribution of variants with reduced penetrance on severe CHD phenotypes 
such as ToF and TGA.
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Full results of variant caller comparisons 
The following tables contain supplementary data relevant to Section 3.4.4. 
 SAMtools GATK FamSeq PolyMutt BAMily 
Variants present in cousin-uncle pair, absent in unrelated individual (3 trios) 
SNVs (avg.) 6885 7313 7792 7159 7386 
Position in calls 1181 1186 1203 1183 1186 
True positive 1168 1179 1182 1176 1179 
Sensitivity % 96.88 97.79 97.98 97.51 97.73 
Specificity % 99.9 99.95 99.83 99.94 99.94 
False discovery % 1.05 0.53 1.8 0.62 0.62 
…in cousin-cousin pair, absent in unrelated individual (3 trios) 
SNVs (avg.) 6051 6459 6954 6301 6533 
Position in calls 1100 1104 1124 1101 1105 
True positive 1087 1098 1100 1096 1098 
Sensitivity % 96.74 97.72 97.86 97.51 97.72 
Specificity % 99.9 99.95 99.81 99.96 99.95 
False discovery % 1.12 0.54 2.14 0.45 0.6 
…in uncle-cousins trio, absent in unrelated individual (3 quartets) 
SNVs (avg.) 4261 4484 5035 4432 4476 
Position in calls 780 778 799 778 782 
True positive 769 774 776 773 774 
Sensitivity % 96.85 97.48 97.82 97.35 97.52 
Specificity % 99.91 99.96 99.83 99.96 99.94 
False discovery % 1.5 0.6 2.8 0.69 0.98 
…in cousins trio, absent in unrelated individual (1 quartet) 
SNVs 3731 3950 4309 3901 3971 
Position in calls 716 710 724 709 714 
True positive 703 706 707 705 706 
Sensitivity % 96.7 97.11 97.25 96.97 97.11 
Specificity % 99.9 99.97 99.87 99.97 99.94 
False discovery % 1.82 0.56 2.35 0.56 1.12 
…in uncle-cousins quartet, absent in unrelated individual (1 quintet) 
SNVs 2989 3113 3515 3094 3609 
Position in calls 561 556 570 556 558 
True positive 550 552 554 551 552 
Sensitivity % 96.66 97.01 97.36 96.84 97.01 
Specificity % 99.92 99.97 99.88 99.96 99.96 
False discovery % 1.96 0.72 2.81 0.9 1.08 
Table S1. Sequence data and microarray data comparison for various sample sizes with cousin-cousin and uncle-
cousins arrangements shown separately. In this table, positions refer to the positions covered by the microarray 
data.  
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 SAMtools GATK FamSeq PolyMutt BAMily 
Variants in cousins, absent in uncle and unrelated individual (1 quintet) 
SNVs 752 833 828 818 829 
Position in calls 156 154 154 154 155 
True positive 152 152 152 152 152 
Sensitivity % 96.2 96.2 96.2 96.2 96.2 
Specificity % 99.97 99.99 99.99 99.99 99.98 
False discovery % 2.56 1.3 1.3 1.3 1.94 
…in uncle-cousins trio, absent in one cousin and unrelated (3 quintets) 
SNVs (avg.) 1278 1360 1549 1360 1354 
Position in calls 219 221 229 221 223 
True positive 216 219 220 219 220 
Sensitivity % 95.99 97.18 97.92 97.18 97.77 
Specificity % 99.98 99.99 99.94 99.99 99.98 
False discovery % 1.37 0.91 3.64 0.91 1.33 
…in cousin pair, absent in uncle-cousin-unrelated trio (3 quintets) 
SNVs (avg.) 1095 1152 1165 1153 1186 
Position in calls 169 170 170 170 171 
True positive 166 169 168 169 169 
Sensitivity % 96.52 97.85 97.47 97.85 97.85 
Specificity % 99.98 99.99 99.98 99.99 99.99 
False discovery % 1.38 0.6 1.38 0.6 1.17 
…in uncle-cousin pair, absent in cousins-unrelated trio (3 quintets) 
SNVs (avg.) 1410 1506 1586 1512 1529 
Position in calls 183 184 188 184 184 
True positive 180 183 183 183 182 
Sensitivity % 95.38 97.03 97.38 97.18 96.84 
Specificity % 99.98 99.99 99.96 99.99 99.99 
False discovery % 1.83 0.5 2.65 0.69 0.69 
Table S2. Sequence data and microarray data comparison for a fixed sample size of five, assuming different 
pairs and trios of individuals to be non-carriers. In this table, positions refer to the positions covered by 
microarray data. 
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Analysis of protein-protein functional links 
The following table contain supplementary data relevant to Section 4.4.1. 
 
Figure S1. Number of functional interactions separating protein products of genes from the final list of 24.  
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PHLPP2 1 2 2 1 2 2 2 2 2 2 3 2 2 2 2 2 2 3 3 3 3 3 4
PDE4D 1 2 2 2 2 2 2 2 2 2 2 2 2 3 3 3 3 3 3 2 2 3 4
ENTPD2 2 2 3 3 2 2 3 3 3 3 3 2 3 3 3 3 3 2 2 3 3 3 4
ZNF419 2 2 3 2 3 3 3 2 3 2 3 3 3 2 3 3 2 3 3 3 4 3 4
ZNF227 1 2 3 2 3 2 3 3 3 3 3 3 3 2 3 3 2 3 3 3 4 4 4
GPR17 2 2 2 3 3 3 3 3 2 3 3 1 3 3 3 3 3 3 3 3 3 4 4
RAD52 2 2 2 3 2 3 3 2 3 3 3 3 3 3 3 3 3 3 3 3 3 3 5
CREB3L3 2 2 3 3 3 3 3 3 2 3 2 3 2 3 2 3 3 3 3 3 3 4 5
ZFHX3 2 2 3 2 3 3 2 3 3 2 3 3 3 3 3 3 3 3 3 3 4 3 4
KCNJ12 2 2 3 3 3 2 3 2 3 3 3 3 3 3 3 3 3 3 3 3 3 4 4
FAM208B 2 2 3 2 3 3 3 3 2 3 3 3 3 3 3 3 3 3 3 3 4 3 4
CPT2 3 2 3 3 3 3 3 2 3 3 3 3 3 3 2 2 3 3 3 3 4 3 5
PROK1 2 2 2 3 3 1 3 3 3 3 3 3 3 3 3 3 4 3 3 3 3 4 5
GREB1 2 2 3 3 3 3 3 2 3 3 3 3 3 3 3 3 3 3 3 3 3 4 5
HECTD4 2 3 3 2 2 3 3 3 3 3 3 3 3 3 3 3 2 3 3 3 4 4 5
ANGPTL2 2 3 3 3 3 3 3 2 3 3 3 2 3 3 3 3 4 3 3 3 3 4 5
COL11A2 2 3 3 3 3 3 3 3 3 3 3 2 3 3 3 3 3 3 3 4 3 4 4
ZNF577 2 3 3 2 2 3 3 3 3 3 3 3 4 3 2 4 3 3 4 3 4 4 5
DCDC1 3 3 2 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 4 4 4 5
RBP5 3 3 2 3 3 3 3 3 3 3 3 3 3 3 3 3 3 4 3 4 4 4 5
SNX13 3 2 3 3 3 3 3 3 3 3 3 3 3 3 3 3 4 3 4 4 4 4 5
LMOD3 3 2 3 4 4 3 3 3 4 3 4 4 3 3 4 3 3 4 4 4 4 5 5
GDPGP1 3 3 3 3 4 4 3 4 3 4 3 3 4 4 4 4 4 4 4 4 4 5 5
KRTAP4-6 4 4 4 4 4 4 5 5 4 4 4 5 5 5 5 5 4 5 5 5 5 5 5
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Tables that include both SNVs and indels. 
The following tables contain supplementary data relevant to Section 5.4.2. 
Gene set Carrier frequency in 
ToF cohort (%) 
Number of genes Number of variants Carrier frequency in 
NDD cases (%) 
Number of genes Number of variants 
Known ToF  1.8  6  15  0  0  0  
IVA  5 17  42 0.6  3  3  
ToF syndrome 6.7 32 64 3.1 13 15 
HRC  19  127  221 13.9  53  71  
Zaidi  18 116  224  16.1 56  88  
CHD syndrome 38.5 284 587 33.5 145 213 
Cilia 10 36 104 6.3 21 31 
Table S3. Rare truncating variants in ToF and NDD cases present in genes from CHD gene sets.  
 
Gene sets Carrier frequency in 
ToF cases (%) 
Number of genes Number of variants Carrier frequency in 
NDD cases (%) 
Number of genes Number of variants 
Known ToF  5.3  16  47  2.2  7  11  
IVA 11   35  102  8.2  16  42  
ToF syndrome 33.1 59 378 19.4 44 106 
HRC  69.4 239   1113   61  178  474  
Zaidi  64.6  194  984  56.7  149  420  
CHD syndrome 92.5 490 2601 90 404 1191 
Cilia 31.9 45 334 33.9 43 208 
Table S4. Rare variants predicted to be deleterious in ToF and NDD cases present in genes from CHD gene sets.
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Updated tables following additional filtering against 875 controls from the 1000g 
project 
The following tables contain supplementary data relevant to Section 5.4.3. 
CDS type TOF cases (n=824) NDD case (n=490) 
Truncating 6,830 2,680 
Gene 24 28 
Exon 42 60 
Both 18 17 
Predicted deleterious 33,998 17,131 
Gene 45 25 
Exon 107 60 
Both 19 17 
Non-synonymous 71,541 34,844 
Gene 62 21 
Exon 96 49 
Both 28 5 
Synonymous 65,154 27,442 
Gene 83 13 
Exon 255 57 
Both 50 7 
Table S5. The number of genes with significant clustering (by variant) at gene and exon levels following 
additional filtering against 875 controls from the 1000g project. The total number of positions in each category 
in ToF and NDD cases is given in the header of each section. Only SNVs are considered here 
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Complete tables for Predicted Deleterious 
Gene Clustering level Cluster size (p-value) 
ADAMTS17* Gene 17 (4.15E-3) 
APC2* Exon 5 (6.24E-3) 
ATG2A Gene 10 (1.17E-3) 
CC2D2A Exon 4 (4.07E-2) 
CCDC101 Gene 8 (3.46E-2) 
COL3A1 Gene 19 (1.62E-2) 
CPXM2 Gene 14 (4.11E-3) 
CSMD3 Gene 30 (7.33E-3) 
FLNB Gene/ Exon 29 (2.66E-4) / 5 (2.48E-2) 
GLDC Gene 20 (9.11E-6) 
H6PD Gene 15 (1.27E-3) 
HMCN1 Gene 56 (4.37E-7) 
HOOK1 Gene 13 (1.48E-2) 
INSC Gene 11 (1.40E-2) 
KIF16B Gene 8 (1.57E-3) 
LARS Gene 11 (6.82E-3) 
MCM3AP Exon 5 (4.76E-2) 
MEF2D* Gene 6 (2.00E-2) 
MYO7A Gene 30 (6.36E-6) 
MYOM1 Exon 5 (3.19E-3) 
NAV2 Gene 32 (6.38E-6) 
NEB Gene 58 (2.83E-5) 
NECAB2 Gene 8 (4.54E-2) 
NEK2 Gene 10 (2.09E-2) 
NELL1 Gene 17 (4.80E-5) 
NMNAT1 Gene/ Exon 8 (2.33E-2)/ 6 (5.90E-4) 
NOTCH1 Gene 31 (7.89E-5) 
PCDH9 Exon 4 (3.79E-4) 
POLRMT Exon 9 (1.64E-2) 
PORCN Exon 4 (4.72E-2) 
PRRC2C Gene 9 (4.36E-3) 
PTPN5 Exon 6  (1.35E-4) 
PUS7 Exon 4  (1.24E-2) 
RANBP9 Exon 6  (1.01E-3) 
RYR3 Gene 40 (2.65E-2) 
SERBP1 Gene/ Exon 14 (6.18E-7)/ 9 (1.92E-5) 
SLC26A1* Gene 14 (1.59E-3) 
SNCAIP Gene 6 (8.95E-5)/ 4 (2.99E-2) 
ST13 Exon 4 (4.95E-2) 
STX6* Gene 8  (1.12E-2) 
TARBP1 Exon 4  (1.60E-2) 
VCL* Gene 13  (4.74E-2) 
ZFR Exon 5  (7.68E-3) 
ZNF385D Exon 5  (7.07E-3) 
ZNF423 Exon 8  (6.61E-10) 
Table S6. Size and p-value (by position) of SNVs predicted to be deleterious in ToF patients. Underlined are 
genes that are also present in NDD cases or the Synonymous category. *Gene no longer in list after stringent 
filtering against 875 controls from the 1000g project. 
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Tables of genes with clusters and in gene sets. 
The following tables contain supplementary data relevant to Section 5.4.4. 
Gene sets Predicted 
Deleterious 
Non-Synonymous Synonymous In NDD cases 
ToF 
syndrome 
NOTCH1, PORCN    
HRC  MEF2D*, MYOM1, 
NOTCH1, VCL* 
LAMA5, MESP1* LAMA5  
Zaidi  NEK2, NOTCH1 PCNT  VIT 
CHD 
syndrome 
ADAMTS17*, 
CC2D2A, COL3A1, 
NOTCH1, PORCN, 
ZNF423 
HSPG2*, PCNT, 
PLEC, ZNF423 
MECP2, PLEC, 
RYR1, ZNF423 
CENPJ, COL17A1*, 
HSPG2, PLEC*, 
ZNF423 
Cilia CC2D2A    
Table S7. genes from CHD gene sets that harbour clusters (by position) for ToF cases. In bold are genes 
appearing in multiple gene sets (except shared between ToF and CHD syndrome sets as one includes the other).  
Underlined are genes that are also present in NDD cases or the Synonymous category. *Gene no longer in list if 
stringent filtering is applied.  
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